documents incorporated reference portions proxy statement registrants annual meeting stockholders held may incorporated reference part iii annual report table contents part item business general bristolmyers squibb company may referred bristolmyers squibb bms company incorporated laws state delaware august name bristolmyers company successor new york business started bristolmyers company changed name bristolmyers squibb company result merger company divisions subsidiaries engaged discovery development licensing manufacturing marketing distribution sale pharmaceutical nutritional products acquisitions divestitures january company completed divestiture bristolmyers squibb medical imaging medical imaging avista capital partners lp avista gross purchase price approximately million excluding postclosing adjustments result transaction company recorded pretax gain million aftertax loss million included discontinued operations consolidated statements earnings june company acquired kosan biosciences inc developer novel oncology products net purchase price approximately million connection transaction company recorded approximately million acquisitionrelated inprocess research development charges august company completed divestiture convatec business cidron healthcare limited affiliate nordic capital fund vii avista billion result transaction company recorded pretax gain billion billion net tax subject certain postclosing adjustments included discontinued operations consolidated statements earnings december company completed sale mature brand business egypt glaxosmithkline million result transaction company recognized pretax gain million million net tax fourth quarter business segments company reports financial operating information two segmentspharmaceuticals nutritionals nutritionals segment operated companys subsidiary mead johnson nutrition company mead johnson august company completed divestiture convatec business cidron healthcare limited avista results convatec business previously presented former convatec operating segment included discontinued operations periods presented january company completed divestiture medical imaging business avista results included discontinued operations periods presented additional information business segments see item financial statementsnote segment information pharmaceuticals segment pharmaceuticals segment competes worldwide researchbased drug companies smaller research companies generic drug manufacturers products sold worldwide primarily wholesalers retail pharmacies hospitals government entities medical profession company manufactures products us puerto rico foreign countries pharmaceuticals segment comprised global pharmaceutical international consumer medicines businesses pharmaceuticals segment accounted companys net sales us pharmaceutical net sales accounted total pharmaceutical net sales respectively pharmaceutical net sales europe middle east africa accounted total pharmaceutical net sales respectively pharmaceutical net sales japan accounted total pharmaceutical net sales table contents products companys pharmaceutical revenues come products following therapeutic classes cardiovascular virology including human immunodeficiency virus hiv infection oncology affective psychiatric disorders immunoscience pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity market exclusivity based upon patent rights andor certain regulatory forms exclusivity us countries patent rights forms exclusivity expire generic versions medicine approved marketed often substantial rapid declines sales original innovative product companys business focused innovative pharmaceutical products company relies patent rights forms protection maintain market exclusivity products discussion patents rights regulatory forms exclusivity see intellectual property product exclusivity discussion impact generic competition companys business see generic competition increasing portion companys innovative pharmaceutical products biological products biologics currently generic versions biological products approved us law however law could change future even absence new legislation us food drug administration fda taking steps toward allowing generic versions certain biologics competitors seeking approval biological products must file safety efficacy data address challenges biologics manufacturing involve complex processes costly traditional pharmaceutical operations chart shows key products pharmaceuticals segment together year basic exclusivity loss patent rights data exclusivity occurred currently estimated occur us european union eu japan company also sells pharmaceutical products countries however data provided countrybycountry basis individual country sales significant outside us eu japan many instances basic exclusivity loss date listed expiration date patent claims active ingredient drug method using drug approved indication instances basic exclusivity loss date listed chart expiration date data exclusivity period situations data exclusivity without patent protection competitor could seek regulatory approval submitting clinical trial data obtain marketing approval prior expiration data exclusivity company estimates market exclusivity period products casebycase basis purposes business planning length market exclusivity companys products impossible predict certainty complex interaction patent regulatory forms exclusivity inherent uncertainties regarding patent litigation although company provides estimates business planning purposes intended indication companys patents might fare particular patent litigation brought potential infringers assurance particular product enjoy market exclusivity full period time appears estimate exclusivity limited estimate table contents following schedule details sales key products estimated basic exclusivity loss us eu japanese markets years ended december past currently past currently past currently estimated estimated estimated year year year us basic eu basic japanese basic net sales products exclusivity loss exclusivity loss exclusivity loss key pharmaceutical products dollars millions cardiovascular plavix b avaproavalide pravachol virology reyataz c sustiva franchise total revenue baraclude oncology erbitux e j taxol sprycel f ixempra affective psychiatric disorders abilify g h immunoscience orencia e note currently estimated year basic exclusivity loss includes statutory extensions exclusivity earned speculative instances may laterexpiring patents cover particular forms compositions drug well methods manufacturing methods using drug patents may sometimes result favorable market position companys product product exclusivity predicted assured note also products filed biologics license application bla us year exclusivity listed year patent expiration even though currently regulatory pathway approval followon biologic products described detail intellectual property product exclusivity indicates brand names products registered trademarks owned company subsidiaries specific trademark ownership information found company currently market product jurisdiction indicated references eu throughout include member states members european union year ended december basic patent applications filed current member states listed products instances date basic exclusivity loss different various eu member states instances earliest latest dates basic exclusivity loss listed eu countries basic patent obtained may data protection available b data exclusivity eu expired july major markets within europe product national patents expiring specifically claim bisulfate form clopidogrel c data exclusivity eu expires exclusivity period relates sustiva brand e biologic product approved bla us currently regulatory approval path generic biologics f pending application eu patent application filed estonia latvia lithuania malta slovakia slovenia g companys rights commercialize aripiprazole us terminate h companys rights commercialize aripiprazole eu terminate patent protection romania denmark expires data exclusivity eu expires j data exclusivity japan expires table contents summary indication intellectual property position licensing arrangements thirdparty manufacturing arrangements products us applicable eu japan cardiovascular plavix clopidogrel bisulfate platelet aggregation inhibitor approved protection fatal nonfatal heart attack stroke patients history heart attack stroke peripheral arterial disease acute coronary syndrome clopidogrel bisulfate codeveloped jointly marketed sanofiaventis sanofi worldwide alliance operates framework two geographic territories one americas australia companys primary territory europe asia sanofis primary territory composition matter patent us expires includes statutory patent term extension currently subject patent litigation us apotex generic companies well less significant jurisdictions district court upheld validity enforceability composition matter patent circuit court upheld district courts decision sustaining validity patent apotex filed petition circuit court reconsider decision en banc possible time reasonably assess outcome appeal apotex andor timing renewed generic competition apotex potential additional generic competition generic pharmaceutical companies however apotex prevail appeal company would expect renewed generic competition promptly thereafter information litigation matters well generic launch apotex see item financial statementsnote legal proceedings contingencies eu regulatory data exclusivity protection expired july major markets within europe plavix benefits national patents expiring specifically claim bisulfate form clopidogrel remainder eu member countries however composition matter patent covering clopidogrel bisulfate competitors seeking regulatory approval enter markets generic clopidogrel bisulfate addition least one group competitor companies received marketing authorization started market alternative salt form clopidogrel germany competitor companies announced plan seek marketing authorization eu countries addition germany company obtains bulk requirements clopidogrel bisulfate sanofi thirdparty company sanofi finish product facilities information companys arrangements sanofi see strategic alliances item financial statementsnote alliances collaborations avaproavalide irbesartanirbesartanhydrochlorothiazide angiotensin ii receptor antagonist indicated treatment hypertension diabetic nephropathy irbesartan codeveloped jointly marketed sanofi global alliance operates framework two geographic territories one americas australia companys primary territory europe asia sanofis primary territory basic composition matter patent us expires including pediatric extension countries eu data exclusivity eu expired august avapro october avalide irbesartan manufactured company sanofi company manufactures bulk requirements irbesartan finishes avaproavalide facilities avalide company purchases bulk requirements hydrochlorothiazide thirdparty information companys arrangements sanofi see strategic alliances item financial statementsnote alliances collaborations pravachol pravastatin sodium hmg coa reductase inhibitor indicated adjunct diet exercise patients primary hypercholesterolemia lowering risk first heart attack people without clinically evident coronary heart disease elevated cholesterol reducing risk heart attack stroke patients clinically evident coronary heart disease table contents company licensed patent covering pravastatin marketed company us pravachol sankyo company ltd sankyo japan key provisions agreement expiring exclusivity expires marketbymarket basis composition matter patent expired major markets company obtains bulk requirements pravastatin sankyo finishes product facilities virology reyataz atazanavir sulfate protease inhibitor treatment hiv reyataz launched us july company developed atazanavir worldwide license novartis pays royalty based percentage net sales company entitled promote reyataz use combination norvir ritonavir nonexclusive license agreement abbott laboratories company dated july amended pays royalty based percentage net sales market exclusivity reyataz expected expire us major eu member countries japan data exclusivity eu expires company manufactures bulk requirements atazanavir finishes product facilities sustiva franchise efavirenz active ingredient sustiva nonnucleoside reverse transcriptase inhibitor nnrti treatment hiv sustiva franchise includes sustiva antiretroviral drug used treatment hiv well bulk efavirenz included combination therapy atripla sold joint venture gilead sciences inc gilead us company gilead share responsibility commercializing atripla gilead records atripla revenues consolidates results joint venture operating results company records revenue bulk efavirenz component atripla upon sales product gilead joint venture thirdparty customers companys revenue efavirenz component determined applying percentage atripla revenue approximates revenue sustiva brand europe company gilead share responsibility commercializing atripla throughout eu certain european countries gilead records revenues net sales atripla countries europe company records revenues percentage relative contribution represented sustiva december european commission granted marketing authorization atripla information companys arrangement gilead see strategic alliances item financial statementsnote alliances collaborations rights market efavirenz us canada united kingdom uk france germany ireland italy spain licensed merck co inc royalty based percentage net sales composition matter patent efavirenz us expires method use patent treatment hiv infection expires possible six month pediatic extension market exclusivity sustiva expected expire countries eu company another company market efavirenz japan company obtains bulk requirements efavirenz third parties produces finished goods facilities company provides bulk efavirenz gilead responsible producing atripla finished goods baraclude entecavir potent selective inhibitor hepatitis b virus approved fda march treatment chronic hepatitis b infection baraclude discovered developed internally also approved marketed countries outside us including china japan eu company composition matter patent expires us composition matter patent expires eu japan uncertainty chinas exclusivitys laws due uncertainty possible one companies china could receive marketing authorization chinas health authority time company manufactures bulk requirements entecavir finishes product facilities table contents oncology erbitux erbitux cetuximab igg monoclonal antibody designed exclusively target block epidermal growth factor receptor egfr expressed surface certain cancer cells multiple tumor types well normal cells erbitux biological product approved treatment combination irinotecan patients egfrexpressing metastatic colorectal cancer mcrc failed irinotecanbased regimen monotherapy patients intolerant irinotecan march fda approved erbitux use treatment squamous cell carcinoma head neck specifically erbitux approved use combination radiation therapy treatment locally regionally advanced squamous cell carcinoma head neck single agent treatment patients recurrent metastatic squamous cell carcinoma head neck prior platinumbased therapy failed also october company received fda approval supplemental biologics license application sbla filing update erbitux product labeling include overall survival data single agent egfrexpressing mcrc patients failure irinotecanbased oxaliplatinbased regimens erbitux marketed north america company distribution copromotion agreement imclone systems incorporated imclone predecessor company imclone llc whollyowned subsidiary eli lilly company lilly company shares copromotion rights erbitux merck kgaa japan codevelopment cocommercialization agreement signed october among company imclone merck kgaa merck japan erbitux received marketing approval japan july use erbitux treating patients advanced recurrent colorectal cancer description companys alliance imclone see strategic alliances item financial statementsnote alliances collaborations patent specifically claims composition matter cetuximab active molecule erbitux erbitux approved fda health authorities monotherapy use patent use erbitux combination antineoplastic agent approved fda combination use claimed granted us patent expires inventorship use patent challenged three researchers yeda research development company ltd yeda pursuant settlement agreement executed announced december imclone sanofi yeda end worldwide litigation related use patent sanofi yeda granted imclone worldwide license use patent settlement agreement change royalty company pays imclone erbitux sales yeda right license use patent others yedas license patent third parties could result product competition erbitux might otherwise occur early assess whether extent competitive impact occur quantify impact however yeda granted amgen inc amgen license use patent amgen received fda approval market egfrproduct competes erbitux company obtains finished goods requirements cetuximab use north america imclone imclone manufactures bulk requirements cetuximab facilities finishing performed thirdparty imclone description companys supply agreement imclone see manufacturing quality assurance taxol taxol paclitaxel used treatment refractory ovarian cancer firstline treatment ovarian cancer combination cisplatin secondline treatment acquired immunodeficiency syndrome aidsrelated kaposis sarcoma treatment metastatic breast cancer failure combination chemotherapy adjuvant treatment nodepositive breast cancer treatment nonsmall cell lung carcinoma cisplatin market exclusivity taxol expired major markets company manufactures bulk requirements paclitaxel finishes product facilities table contents sprycel dasatinib multitargeted tyrosine kinase inhibitor approved fda june treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy including imatinib treatment adults philadelphia chromosomepositive acute lymphoblastic leukemia resistance intolerance prior therapy dasatinib approved eu november sprycel discovered developed internally market exclusively sprycel expected expire us several eu countries patent pending upon grant would expire april excluding term extensions eu patent application filed cyprus estonia latvia lithuania malta netherlands slovakia slovenia us new chemical entity regulatory exclusivity protection expires orphan drug exclusivity expires protects product generic applications currently approved orphan indications company manufactures bulk requirements dasatinib finishes product facilities ixempra ixempra ixabepilone microtubule inhibitor belonging class antineoplastic agents epothilones analogs october fda approved ixabepilone combination capecitabine treatment patients metastatic locally advanced breast cancer resistant treatment anthracycline taxane whose cancer taxane resistant anthracycline therapy contraindicated monotherapy treatment metastatic locally advanced breast cancer patients whose tumors resistant refractory anthracyclines taxanes capecitabine marketing authorization currently sought eu countries basic composition matter patent protecting ixabepilone us due expire may patent term extension requested upon grant would extend patent term september corresponding patent also granted eu countries due expire june excluding term extensions us new chemical entity regulatory exclusivity protection expires ixabepilone developed company subject license agreement helmholtz zentrum fur infektionsforschung gmbh hzi relating epothilone technologies agreement hzi entitled royalties net sales countries product sold company manufactures bulk requirements ixabepilone facilities including manufacturing active ingredient drug product comprises pharmaceutical kit finished baxter oncology gmbh affective psychiatric disorders abilify aripiprazole atypical antipsychotic agent patients schizophrenia bipolar mania disorder major depressive disorder aripiprazole copromoted us company otsuka pharmaceutical co ltd otsuka companys rights commercialize aripiprazole us terminate thereafter otsuka sole right commercialize aripiprazole us germany spain company copromotes otsuka affiliate uk france company currently acts distributor product copromotes otsuka affiliate european markets company acts exclusive distributor company exclusive licensee product rest world excluding japan certain countries us spain germany company records alliance revenue contractual share net sales records expenses related product alliance revenue recorded company net sales based upon thirdparty customer net sales copromotion countries company recognizes alliance revenue abilify shipped risks rewards ownership transferred thirdparty customers uk france italy company currently records net sales related cost products sold countries company exclusive right sell abilify company also records net sales related cost products sold information companys arrangement otsuka see strategic alliances item financial statementsnote alliances collaborations basic us composition matter patent abilify expires including granted patent term extension otsuka filed us patent trademark office uspto request reexamination us composition matter patent us patent patent covering abilify june uspto issued ex parte reexamination certificate patent confirming patentability original claims approving additional new claims table contents otsuka received formal notices teva pharmaceuticals usa teva barr pharmaceuticals inc barr sandoz inc sandoz synthon laboratories inc synthon sun pharmaceuticals ltd sun apotex stating filed abbreviated new drug application anda fda various dosage forms aripiprazole company otsuka comarket us abilify notices state anda contains piv certification directed patent covers aripiprazole expires october addition notices purport provide otsuka respective piv certification certifications contain various allegations regarding enforceability patent andor validity andor infringement claims therein otsuka filed patent infringement actions based patent teva barr sandoz sun apotex us district court new jersey synthon us district court middle district north carolina otsuka sole rights enforce patent composition matter patent force germany uk france italy netherlands romania sweden switzerland spain denmark original expiration date extended grant supplementary protection certificate countries except romania denmark data exclusivity eu expires composition matter patent austria belgium finland greece ireland luxembourg portugal latvia hungary cyprus czech republic slovenia slovakia poland malta lithuania bulgaria estonia company obtains bulk requirements aripiprazole otsuka otsuka company finish product facilities immunoscience orencia abatacept biological product fusion protein novel immunosuppressive activity targeted initially adult patients moderate severe rheumatoid arthritis inadequate response certain currently available treatments abatacept approved fda december made commercially available us february orencia discovered developed internally company series patents covering abatacept method use patent term extension granted one composition matter patents extending term patent majority eu countries company patent covering abatacept expires majority eu countries company applied supplementary protection certificates would extend term patent granted data exclusivity eu expires company obtains bulk abatacept thirdparty manufacturing facilities company finishes product facilities addition products discussed companys pharmaceuticals segment also includes companys whollyowned upsa consumer medicines business europe includes efferalgan well aspirine upsa dafalgan fervex europe overseas markets strategic alliances arrangements company enters strategic alliances arrangements third parties give company rights develop manufacture market andor sell pharmaceutical products rights owned third parties company also enters strategic alliances arrangements third parties give third parties rights develop manufacture market andor sell pharmaceutical products rights owned company alliances arrangements take many forms including licensing arrangements codevelopment comarketing agreements copromotion arrangements joint ventures general companys strategic alliances arrangements periods coextensive periods market exclusivity protection country bycountry basis alliances arrangements reduce risk incurring research development expenses lead revenuegenerating products however gross margins alliance products generally lower sometimes substantially gross margins companys products partnered profits alliance products shared companys alliance partners assurance new alliances formed company actively pursues arrangements views alliances important complement discovery development activities companys strategic alliances arrangements third parties rights manufacture market andor sell pharmaceutical products contain customary early termination provisions typically found agreements kind generally table contents based partys material breach bankruptcy voluntary involuntary product safety concerns amount notice required early termination generally ranges immediately upon notice days receipt notice termination immediately upon notice generally available party files voluntary bankruptcy petition material safety issue arises product medical riskbenefit incompatible welfare patients continue develop commercialize product termination upon days notice generally available involuntary bankruptcy petition filed dismissed material breach party occurred cured early termination due product safety concerns typically arises product determined create significant risk harm patients due concerns regarding products efficacy level toxicity companys strategic alliances arrangements typically otherwise contain provisions provide party right terminate alliance short notice general party companys strategic alliance arrangement continue exclusivity protection upon expiration termination alliance company retain rights product partys intellectual property loss rights one products marketed sold company pursuant strategic alliance arrangements third parties one countries territories could material companys results operations cash flows case plavix could material financial condition liquidity customary pharmaceutical industry terms companys strategic alliances arrangements generally coextensive exclusivity period exception commercialization agreement otsuka discussed may vary countrybycountry basis companys significant current alliances arrangements currently marketed products investigational compounds noted current marketed products sanofi company agreements codevelopment cocommercialization avaproavalide angiotensin ii receptor antagonist indicated treatment hypertension diabetic nephropathy copromoted certain countries outside us tradename aprovelcoaprovel comarketed certain countries outside us company tradename karveakarvezide plavix platelet aggregation inhibitor copromoted certain countries outside us tradename plavix comarketed certain countries outside us company tradename iscover worldwide alliance operates framework two geographic regions one covering certain european asian countries defined territory one covering us puerto rico canada australia certain latin american countries defined territory b region covering us puerto rico canada australia certain latin american countries managed two separate territory agreements one us puerto rico avaproavalide second agreement us puerto rico plavix plus canada australia mexico brazil colombia argentina products within territories b territory partnership exists supply product countries within territory manage certain central expenses marketing research development royalties countries within territories b structured companys local affiliate sanofi either comarket separate brands eg affiliate operates independently sells competing brand copromote single brand within territory comarketing countries include germany spain italy irbesartan greece china clopidogrel bisulfate company sells iscover karveakarvezide sanofi sells plavix aprovelcoaprovel countries except china company retains right currently comarket iscover company sanofi copromote plavix aprovelcoaprovel france uk belgium netherlands switzerland portugal addition company sanofi copromote plavix austria italy ireland denmark finland norway sweden turkey taiwan korea singapore malaysia hong kong aprovelcoaprovel certain french export countries sanofi acts operating partner territory owns majority financial controlling interest territory companys ownership interest territory company accounts investment partnership entities territory equity method records share results equity net income affiliates consolidated statements earnings companys share net income partnership entities taxes million million million within territory b company sanofi copromote plavix us canada puerto rico avaproavalide canada territory b countries australia mexico brazil colombia clopidogrel bisulfate argentina comarketing countries company sanofi modified previous exclusive license company avaproavalide us puerto rico form copromotion joint venture part company contributed avaproavalide intellectual property sanofi agreed pay company million million company accounts payments sale interest license defers amortizes total amount million income expected useful life license approximately years date formation copromotion joint venture company acts operating partner territory b uspuerto rico table contents avaproavalide territory owns majority controlling interest territories company consolidates partnership results territories records sanofis share results minority interest net taxes million million million company recorded net sales territory b uspuerto rico avaproavalide territory territory comarketing countries billion billion billion territory partnerships governed series committees enumerated functions powers responsibilities territory two senior committees senior committees final decision making authority respect territory enumerated functions powers responsibilities within jurisdictions agreements sanofi expire later respect plavix respect avaproavalide americas australia europe asia ii expiration patents exclusivity rights applicable territory alliance arrangements may terminated company sanofi either whole affected country territory depending circumstances event voluntary involuntary bankruptcy insolvency case involuntary bankruptcy continues days order decree approving continues unstayed effect days ii material breach obligation major alliance agreement remains uncured days following notice breach except commencement diligent prosecution cure occurred within days notice iii deadlocks one senior committees render continued commercialization product impossible given country territory case avaproavalide us respect advertising promotion spending levels amount sales force commitment iv increase combined cost goods royalty exceeds specified percentage net selling price product v good faith determination terminating party commercialization product terminated reasons patient safety case termination rights agreements include provisions termination relevant alliance respect applicable product applicable country territory case termination due bankruptcy insolvency material breach products applicable territory termination procedures slightly different however events company could lose rights either products applicable relevant country territory even case bankruptcy insolvency material breach company defaulting party discussion companys strategic alliance sanofi see item financial statementsnote alliances collaborations otsuka company maintains worldwide commercialization agreement otsuka codevelop copromote abilify treatment schizophrenia related psychiatric disorders except japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt copromote product otsuka us puerto rico uk germany france spain us germany spain product invoiced thirdparty customers company behalf otsuka company records alliance revenue contractual share thirdparty net sales records expenses related product company recognizes alliance revenue abilify shipped risks rewards ownership transferred thirdparty customers uk france italy company presently exclusive distributor product company records net sales related cost products sold expenses company also exclusive right sell abilify countries europe americas number countries asia countries company records net sales related cost products sold terms agreement company purchases product otsuka performs finish manufacturing sale company otsuka third party customers agreement expires november us entire eu agreement expires june country company exclusive right sell abilify agreement expires later th anniversary first commercial sale country expiration applicable patent country early termination available based partys voluntary involuntary bankruptcy failure make minimum payments failure commence first commercial sale within three months receipt necessary approvals material breach early termination strategic alliance immediate upon notice case voluntary bankruptcy ii minimum payments made otsuka iii first commercial sale occurred within three months receipt necessary approvals days material breach occurred cured commencement cure occurred within days notice material breach days case involuntary bankruptcy petition filed dismissed addition termination available otsuka upon days notice event company challenge otsukas patent rights marketbymarket basis company market product direct competition abilify upon termination expiration alliance company retain rights abilify company recorded net sales abilify billion billion billion total milestone payments made otsuka agreement million table contents discussion companys strategic alliance otsuka see item financial statementsnote alliances collaborations imclone company commercialization agreement imclone wholly owned subsidiary lilly codevelopment copromotion erbitux us well codevelopment copromotion rights canada japan extent product commercialized countries erbitux indicated use treatment patients metastatic colorectal cancer use treatment squamous cell carcinoma head neck agreement covering north america imclone receives distribution fee based flat rate net sales north america company purchases commercial requirements bulk erbitux imclone price equal imclones manufacturing cost plus agreement expires erbitux north america september early termination available based material breach effective days notice material breach material breach cured commencement cure occurred upon six months notice company exists significant concern regarding regulatory patient safety issue would seriously impact longterm viability product upon termination expiration alliance company retain rights erbitux company sells erbitux intermediaries wholesalers specialty oncology distributors ships erbitux directly endusers product customers intermediaries beginning third quarter company began expanding distribution model include wholesalers distributors hold erbitux inventory company recognizes revenue upon shipment consistent revenue recognition policy july company imclone amended terms agreement codevelopment copromotion erbitux north america jointly agreed expand investment ongoing clinical development plan erbitux several hundred million dollars development costs threshold value sole responsibility company costs excess threshold shared companies according predetermined ratio company shares copromotion rights erbitux merck kgaa japan codevelopment cocommercialization agreement signed october expiring among bms bmkk er squibb sons llc imclone merck kgaa merck japan imclone ability terminate agreement determines commercially unreasonable imclone continue erbitux received marketing approval japan july use erbitux treating patients advanced recurrent colorectal cancer company recorded net sales erbitux million million million years ended december respectively upon initial execution commercialization agreement company acquired ownership interest imclone approximated time transaction noted accounting investment equity method company received approximately billion cash sale shares imclone lilly discussion companys strategic alliance imclone see item financial statementsnote alliances collaborations gilead company gilead joint venture develop commercialize atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oncedaily single tablet threedrug regimen combining companys sustiva efavirenz gileads truvada emtricitabine tenofovir disoproxil fumarate us canada europe july fda granted approval atripla first complete highly active antiretroviral therapy treatment product hiv available us fixeddose combination taken daily fixeddose combinations contain multiple medicines formulated together may help simplify hiv therapy patients providers guidelines issued us department health human services list combination emtricitabine tenofovir disoproxil fumarate efavirenz one preferred nonnnrtibased treatments use appropriate patients never taken antihiv medicines atripla approved health canada october european commission december commercialization countries eu well norway iceland company gilead share responsibility commercializing atripla us canada throughout eu certain european countries provide funding fieldbased sales representatives support promotional efforts atripla gilead records atripla revenues us canada countries europe company records revenue bulk efavirenz component atripla upon sales product joint venture gilead thirdparty customers companys revenue efavirenz component determined applying percentage atripla revenue approximates revenue sustiva brand limited number eu countries company records revenue atripla company agreed purchase product gilead distribute thirdparty customers company recorded efavirenz revenues million million million respectively related atripla sales table contents gilead consolidates results joint venture operating results company accounts participation us joint venture equity method accounting records share joint venture results equity net income affiliates consolidated statements earnings joint venture company gilead continue terminated mutual agreement parties otherwise described event material breach one party nonbreaching party may terminate joint venture parties agree desirable practicable withdraw combination product markets commercialized time one generic versions sustiva appear market us gilead right terminate joint venture thereby acquire rights combination product us canada however company continue three years receive percentage net sales based contribution bulk efavirenz atripla otherwise retains rights sustiva discussion companys strategic alliance gilead see item financial statementsnote alliances collaborations investigational compounds development medarex company maintains worldwide collaboration share purchase agreement medarex inc medarex codevelop copromote ipilimumab fully human antibody currently phase iii development treatment metastatic melanoma fda granted fast track status ipilimumab combination mdx gp vaccine developed combination ipilimumab treatment patients late stage unresectable metastatic melanoma failed intolerant firstline therapy future milestone payments expected made company medarex based upon successful achievement various regulatory salesrelated stages company medarex also share future development commercialization costs medarex could receive million regulatory milestones met million salesrelated milestones medarex option copromote receive profits company us company receive exclusive license outside us pay royalties medarex company maintains million equity investment medarex representing outstanding shares agreement medarex expire unless one following events occurs company voluntarily terminates agreement entirety countrybycountry basis providing medarex six months prior written notice company voluntarily terminates agreement productby product basis second product glp toxicology studies later countrybycountry basis providing medarex six months prior written notice depending circumstances company terminates medarexs copromotion option rights us days written notice end second calendar year event medarex provides less percent certain performance obligations two three consecutive calendar years termination right exercised respect indications medarex failed meet performance obligation upon termination company via scenarios medarex longer right share profits losses product terminated indications instead company pay medarex royalties net sales product medarex terminates agreement respect products days written notice company provides less percent certain performance obligations two three consecutive calendar years generally upon termination company assign rights product medarex receive royalty thereafter intellectual property licensed company medarex medarex may also elect copromote product one indications us event receive royalty sales product indication material breach manufacturing party party shall limited termination partys manufacturing rights astrazeneca january company entered two worldwide except japan codevelopment cocommercialization agreements astrazeneca one codevelopment cocommercialization saxagliptin dppiv inhibitor saxagliptin agreement one codevelopment cocommercialization dapagliflozin sglt inhibitor sglt agreement compounds studied treatment diabetes discovered company terms agreements company received astrazeneca upfront payment million january october company received astrazeneca milestone payment million june filing new drug application food drug administration fda onglyza companies proposed name onglyza approved fda european medicines evaluation agency serve trade name saxagliptin countries approved milestone payments expected received company upon successful achievement various development regulatory events well sales related milestones saxagliptin agreement company could receive million development regulatory milestones met additional million salesbased milestones met sglt agreement company could receive million development regulatory milestones table contents met additional million salesbased milestones met agreement company astrazeneca also share future development commercialization costs majority development costs initial development plans paid astrazeneca additional development costs generally shared equally company records research development expenses saxagliptin dapagliflozin development costs net alliance partners share agreement two companies jointly develop clinical marketing strategy share commercialization expenses profits losses equally global basis excluding japan case saxagliptin company manufacture products certain limited exceptions record net sales key markets december company astrazeneca executed amendment sglt agreement include development commercialization dapagliflozin japan astrazeneca operational cost responsibility development regulatory activities behalf collaboration two companies jointly market product japan sharing commercialization expenses activities splitting profits losses equally bristolmyers squibb manufacture dapagliflozin also record sales dapagliflozin currently studied phase ii clinical trials japan otsuka january company granted otsuka exclusive rights japan develop commercialize saxagliptin company receive milestone payments based certain regulatory events well salesbased payments following regulatory approval saxagliptin japan retained rights co promote saxagliptin otsuka japan otsuka responsible development costs japan pfizer april company pfizer entered worldwide codevelopment cocommercialization agreement apixaban anticoagulant discovered company studied prevention treatment broad range venous arterial thrombotic conditions accordance terms agreement pfizer made upfront payment million company may december company pfizer agreed include japan worldwide agreement pfizer made upfront payment million december pfizer fund development costs effective january going forward company fund company records expenses apixaban development costs net alliance partners share research development company may also receive additional payments million pfizer based development regulatory milestones companies jointly develop clinical marketing strategy apixaban share commercialization expenses profits losses equally global basis exelixis december company exelixis inc exelixis entered global codevelopment cocommercialization arrangement xl metvegret inhibitor oral anticancer compound license xl utility ras raf mutant tumors development exelixis terms arrangement company agreed pay exelixis million upon execution agreement additional million company expensed research development million upon execution agreement exelixis fund first million development xl exelixis elects continue sharing development costs elects copromote us exelixis fund future global development costs excluding japan share us profits losses equally failing elections exelixis receives milestones royalties company fund development costs japan addition doubledigit royalties exus sales company could pay million development regulatory milestones met additional million salesbased milestones met addition company exelixis history collaborations identify develop promote oncology targets december company exelixis entered oncology collaboration license agreement exelixis pursuing development three small molecule inds codevelopment copromotion terms agreement company paid exelixis million upfront fees company paid exelixis million ind acceptance milestones exelixis elects fund development costs copromote us parties equally share development costs profits exelixis opts codevelopment copromotion agreement bms take full development us commercial rights successful pay exelixis development regulatory milestones million additional million sales based milestones well double digit royalties since july company held equity interest exelixis december less additionally company licensing arrangements novartis reyataz hzi ixempra novel microtubulestabilizing agent treatment breast cancer based companys current expectations respect expiration market exclusivity companys significant markets licensing arrangements novartis reyataz expected expire us eu japan arrangements hzi ixempra expected expire us th anniversary first commercial sale eu japan discussion market exclusivity protection including chart showing net sales key products together year basic exclusivity loss occurred expected occur us eu japan see products intellectual property product exclusivity table contents information alliances relating products development drug discovery see research development nutritionals segment infant formulas toddlerchildrens nutritionals representing total nutritional net sales respectively follows net sales change dollars millions vs vs infant formulas enfamil toddlerchildrens nutritionals nutritionals segment mead johnson manufactures markets distributes sells infant formulas nutritional products including entire line enfamil products enfamil lipil product first infant formula us contain nutrients docosahexaenoic acid dha arachidonic acid ara also naturally found breast milk dha ara believed support infant brain eye development company obtains nutrients sole provider pursuant nonexclusive worldwide license supply agreement supply agreement force least provides firm guarantee supply pricing subject change pursuant pricing formula license expires beginning countrybycountry basis years company commenced sales country companys nutritionals products generally sold wholesalers retailers promoted primarily health care professionals company also promotes nutritionals products directly consumers worldwide advertising company manufactures products us five foreign countries nutritional net sales accounted companys net sales us nutritional net sales accounted total nutritional net sales respectively international nutritional net sales accounted total nutritional net sales respectively approximately onehalf us gross sales infant formula subject rebates issued women infants children wic program sales subject wic rebates much lower margins nonwic program sales information key nutritionals product lines sales see item managements discussion analysis financial condition results operationsresults operations productivity transformation initiative december july company announced productivity transformation initiatives pti designed fundamentally change way runs business meet challenges changing business environment take advantage diverse opportunities marketplace company transformed nextgeneration biopharmaceutical company create total billion annual productivity cost savings cost avoidance connection pti company aims achieve culture continuous improvement enhance efficiency effectiveness competitiveness substantially improve cost base key productivity initiatives include reducing general administrative operations simplifying standardizing outsourcing appropriate processes services rationalizing companys mature brands portfolio consolidating global manufacturing network eliminating complexity enhancing profitability simplifying geographic footprint implementing efficient gotomarket model charges associated previously announced pti estimated aggregate range billion billion includes million costs already incurred incurred costs net million gains related sale mature product lines business also included charges net termination benefits million million years ended december respectively exit costs million million years ended december respectively exact timing recognition pti charges predicted certainty affected existence triggering events expense recognition among factors sources availability raw materials general company purchases raw materials medical devices supplies required production companys products open market products company purchases raw materials medical devices supplies single source certain circumstances specified companys product registrations thereby requiring company obtain raw materials supplies particular source company attempts possible mitigate raw material supply risks company inventory management alternative sourcing strategies discussion sourcing see manufacturing quality assurance discussions particular products table contents manufacturing quality assurance meet expected product demand company operates manages manufacturing network including thirdparty contract manufacturers inventory related thereto manner permits company improve efficiency maintaining flexibility ability reallocate manufacturing capacity pharmaceutical production processes complex highly regulated vary widely product product given shifting adding manufacturing capacity lengthy process requiring significant capital outofpocket expenditures regulatory approvals company maintains operates flexible manufacturing network consisting internal external resources minimizes unnecessary product transfers inefficient uses manufacturing capacity discussion regulatory impact companys manufacturing see government regulation price constraints pharmaceutical manufacturing facilities require significant ongoing capital investment maintenance compliance increasing regulatory requirements addition company adds product line realigns focus next several years company expects modify existing manufacturing network meet complex processing standards may required newly introduced products including biologics biologics manufacturing involves complex processes traditional pharmaceutical operations board directors approved capital expenditures approximately million bulk biologics manufacturing facility us february company completed land purchase acre site locate large scale multiproduct bulk biologics manufacturing facility devens massachusetts construction devens massachusetts facility began early facility projected operationally complete end company expects submit site regulatory approval commercial production biologic compounds anticipated begin company relies third parties manufacture supply active ingredients necessary manufacture certain products including plavix baraclude avalide reyataz pravachol abilify erbitux sustiva franchise orencia maintain stable supply products company takes variety actions including inventory management maintenance additional quantities materials possible designed provide reasonable level ingredients held thirdparty supplier company companys manufacturing operations interrupted additional protection cases company takes steps maintain approved backup source available example company rely combined capacity devens massachusetts syracuse new york manati puerto rico facilities capacity available thirdparty contract manufacturers manufacture orencia commercial quantities companys investigational biologics compounds latestage development compounds receive regulatory approval company thirdparty manufacturer company relies existing future products unable maintain stable supply products operate sufficient capacity meet order requirements comply government regulations manufacturing pharmaceuticals meet heightened processing requirements biologics companys business performance prospects could negatively impacted additionally company thirdparty suppliers experience extended plant shutdowns substantial unplanned increases demand suspension manufacturing regulatory reasons company could experience interruption supply certain products product shortages production could resumed expanded connection divestitures licensing arrangements distribution agreements certain companys products certain circumstances company entered agreements company agreed supply products third parties addition liabilities could arise companys failure supply products agreements arrangements could require company invest facilities production non strategic products result additional regulatory filings obligations cause interruption manufacturing products companys success depends great measure upon customer confidence quality products integrity data support safety effectiveness product quality arises total commitment quality parts companys operations including research development purchasing facilities planning manufacturing distribution company maintains qualityassurance procedures relating quality integrity technical information production processes control production processes involves detailed specifications ingredients equipment facilities manufacturing methods processes packaging materials labeling company performs tests various stages production processes final product ensure product meets regulatory requirements companys standards tests may involve chemical table contents physical chemical analyses microbiological testing combination along analyses quality control provided business unitsite quality assurance groups monitor existing manufacturing procedures systems used company subsidiaries thirdparty suppliers intellectual property product exclusivity company owns licenses number patents us foreign countries primarily covering products company also developed many brand names trademarks products areas company considers overall protection patent trademark license intellectual property rights material value acts protect rights infringement pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity us countries market exclusivity expires generic versions product approved marketed often substantial rapid declines products sales rate decline varies country therapeutic category discussion generic versions product impact products sales see generic competition products market exclusivity generally determined two forms intellectual property patent rights held innovator company regulatory forms exclusivity innovative drug entitled patents key determinant market exclusivity branded pharmaceuticals patents provide innovator right exclude others practicing invention related medicine patents may cover among things active ingredients various uses drug product pharmaceutical formulations drug delivery mechanisms processes intermediates useful manufacture products protection individual products extends varying periods accordance expiration dates patents various countries protection afforded may also vary country country depends upon type patent scope coverage availability meaningful legal remedies country market exclusivity also sometimes influenced regulatory intellectual property rights many developed countries provide certain nonpatent incentives development medicines example us eu japan provide minimum period time approval new drug regulatory agency may rely upon innovators data approve competitors generic copy regulatory intellectual property rights also available certain markets incentives research new indications orphan drugs medicines useful treating pediatric patients regulatory intellectual property rights independent patent rights company may possess particularly important drug lacks broad patent protection however regulatory forms exclusivity prevent competitor gaining regulatory approval prior expiration regulatory data exclusivity basis competitors safety efficacy data drug even drug identical marketed innovator company estimates likely market exclusivity period products casebycase basis possible predict length market exclusivity companys products certainty complex interaction patent regulatory forms exclusivity inherent uncertainties concerning patent litigation assurance particular product enjoy market exclusivity full period time company currently estimates exclusivity limited estimate discussion market exclusivity see pharmaceuticals segment addition patents regulatory forms exclusivity company also holds intellectual property form trademarks products enfamil trademarks effect market exclusivity product considered marketing value worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely specific aspects law governing market exclusivity pharmaceuticals vary country country following summarizes key exclusivity rules markets representing significant company sales united states company seeking market innovative pharmaceutical us must file complete set safety efficacy data fda type application filed depends whether drug chemical small molecule biological product large molecule innovative pharmaceutical chemical company files new drug application nda medicine biological product biologic license application bla filed type application filed affects regulatory exclusivity rights table contents competitor seeking launch generic substitute chemical innovative drug us must file anda fda anda generic manufacturer needs demonstrate bioequivalence generic substitute approved nda drug anda relies upon safety efficacy data previously filed innovator nda medicines approved nda receive several types regulatory data protection innovative chemical pharmaceutical also known new chemical entity entitled five years regulatory data protection us anda filed fda innovators patent challenged described generic manufacturer may file anda fourth year fiveyear data protection period pharmaceutical drug product contains active ingredient previously approved nda approved new formulation new indication basis new clinical trials receives three years data protection finally nda designated orphan drug drug gains indication treatment condition occurs rarely us receive seven years exclusivity orphan indication time period neither ndas andas drug product approved orphan use significant portion patent life lost time takes obtain regulatory approval innovator extend one patent compensate innovator lost patent term least part specifically innovator may identify one patent claims product approved method use depending number factors may extend expiration date patent two limits extensions first maximum term patent extended five years second extension cause patent effect years date nda approval company may also earn six months additional exclusivity drug specific clinical trials conducted written request fda study use medicine treat pediatric patients submission fda made prior loss basic exclusivity sixmonth period extends forms exclusivity patent regulatory listed fda time studies completed submitted fda products already finally approved currently generic versions biological products approved us law however law could change future even absence new legislation fda taking steps toward allowing generic versions certain biologics competitors seeking approval biological products must file safety efficacy data address challenges biologics manufacturing involves complex processes costly traditional pharmaceutical operations many innovative drugs also covered patents held nda sponsor beyond minimum period regulatory exclusivity provided us law innovator company required list certain patents covering medicine fda commonly known orange book absent successful patent challenge fda approve anda innovators listed patents expire however innovator marketed product four years generic manufacturer may file anda allege one patents listed orange book innovators nda either invalid infringed allegation commonly known paragraph iv certification innovator must decide whether file patent infringement suit generic manufacturer one ndalisted patents successfully challenged innovator chooses sue first filer paragraph iv certification first filers one generic qualifies may entitled day period market exclusivity generic manufacturers time time andas including paragraph iv certifications filed respect certain companys products company evaluates andas casebycase basis warranted files suit generic manufacturer protect patent rights us increased likelihood generic challenges innovators intellectual property increased risk loss innovators market exclusivity first generic companies increasingly sought challenge innovators basic patents covering major pharmaceutical products discussion one litigation related patent challenges generic companies see item financial statementsnote legal proceedings contingenciesplavix litigation intellectual property litigation second statutory regulatory provisions us limit ability innovator company prevent generic drugs approved launched patent litigation ongoing third fda actively considering ways expand use regulatory mechanism allows regulatory approval drugs similar generic copies innovative drugs basis less extensive data required full nda result developments possible predict length market exclusivity particular company product certainty based solely expiration relevant patents current forms regulatory exclusivity information new legislation see government regulation price constraints european union recent pharmaceutical legislation eu impact procedures authorization pharmaceutical products eu centralized mutual recognition procedures particular legislation contains new data protection provisions products regardless whether approved centralized mutual recognition procedures subject regime eight years innovator received first community authorization medicinal product table contents generic company may file marketing authorization application product health authorities however generic company may commercialize product either years elapsed initial marketing authorization granted innovator possible oneyear extension available innovator first eight years marketing authorization obtains additional indication significant clinical benefit comparison existing treatments transitional provision new data protection requirements provisions apply new marketing authorization applications submitted new legislation products continue covered old law year period data protection centralized procedures period either six years mutual recognition procedure depending member state regardless procedure used obtain marketing authorization approval company must obtain pricing reimbursement pharmaceutical product typically subject member state law pricing reimbursement procedure take months sometimes years obtain patents pharmaceutical products generally enforceable eu however contrast us patents listed regulatory authorities generic copies approved data protection expires regardless whether innovator holds patents covering drug thus possible innovator may seeking enforce patents generic competitor already marketing product also european patent system opposition procedure generic manufacturers may challenge validity patents covering innovator products within nine months grant us patents eu may extended compensate patent term lost regulatory review process extensions granted countrybycountry basis general eu law treats chemicallysynthesized drugs biologicallyderived drugs respect intellectual property market exclusivity european medicines evaluation agency emea issued guideline outlines additional information provided biosimilar products also known generic biologics order emea review application marketing approval japan japan medicines new chemical entities generally afforded eight years data exclusivity approved indications dosage patents pharmaceutical products enforceable generic copies receive regulatory approval data exclusivity patent expirations us patents japan may extended compensate patent term lost regulatory review process general japanese law treats chemicallysynthesized biologicallyderived drugs respect intellectual property market exclusivity rest world countries outside us eu japan wide variety legal systems respect intellectual property market exclusivity pharmaceuticals developed countries utilize systems similar either us eg canada eu eg switzerland among developing countries adopted patent laws andor regulatory exclusivity laws others developing countries formally adopted laws order comply world trade organization wto commitments taken steps implement laws meaningful way enforcement wto actions long process governments assurance outcome thus assessing likely future market exclusivity companys innovative drugs developing countries company takes account formal legal rights political factors well marketing distribution customers company promotes products medical journals directly health care providers doctors nurse practitioners physician assistants pharmacists technologists hospitals pharmacy benefit managers pbms managed care organizations mcos government agencies company also markets directly consumers us directtoconsumer print radio television advertising addition company sponsors general advertising educate public innovative medical research discussion regulation promotion marketing pharmaceuticals see government regulation price constraints companys sales marketing organizations company explains approved uses advantages products medical professionals company works gain access health authority pbm mco formularies lists recommended approved medicines products including medicare part plans reimbursement lists demonstrating qualities treatment benefits products marketing prescription pharmaceuticals limited approved uses particular product company continues develop information products provides information response unsolicited inquiries doctors medical professionals drugs must complete clinical trials required regulatory authorities show safe effective treating one medical problems manufacturer may choose however table contents undertake additional studies including comparative clinical trials competitive products demonstrate additional advantages compound studies costly take years complete results uncertain balancing considerations makes difficult decide whether undertake additional studies successful studies major impact approved marketing claims strategies companys operations include several pharmaceutical marketing sales organizations organization markets distinct group products supported sales force typically based particular therapeutic areas physician groups sales forces often focus selling new products introduced promotion physicians increasingly targeted specialists high value primary care physicians companys prescription pharmaceutical products sold principally wholesalers company also sells directly distributors retailers hospitals clinics government agencies pharmacies gross sales three pharmaceutical wholesalers us mckesson cardinal health inc cardinal amerisourcebergen corporation amerisourcebergen accounted approximately respectively companys total gross sales gross sales mckesson cardinal amerisourcebergen accounted approximately respectively companys total gross sales gross sales mckesson cardinal amerisourcebergen accounted approximately respectively companys total gross sales gross sales us wholesalers concentrated pharmaceuticals segment companys us pharmaceuticals business inventory management agreements imas arrangements substantially direct wholesaler distributor customers allow company monitor us wholesaler inventory levels require wholesalers maintain inventory levels one month demand imas twoyear term december subject certain termination provisions company sells erbitux intermediaries wholesalers specialty oncology distributors ships erbitux directly end users product customers intermediaries company also sells erbitux us wholesalers distributors hold erbitux inventory company recognizes revenue upon shipment consistent revenue recognition policy information sales marketing nutritionals products see nutritionals segment competition markets company competes generally broadbased highly competitive principal means competition vary among product categories business groups companys pharmaceuticals segment competes worldwide researchbased drug companies many smaller research companies limited therapeutic focus generic drug manufacturers important competitive factors include product efficacy safety ease use price demonstrated cost effectiveness marketing effectiveness product labeling service research development new products processes sales companys products impacted new studies indicate competitors product greater efficacy treating disease particular form disease one companys products companys sales also impacted additional labeling requirements relating safety convenience may imposed products fda similar regulatory agencies different countries competitors introduce new products processes therapeutic cost advantages companys products subject progressive price reductions decreased volume sales successfully compete business mcos pbms company must often demonstrate products offer medical benefits also cost advantages compared forms care new products company introduces must compete products already market products later developed competitors manufacturers generic pharmaceuticals typically invest far less research development research based pharmaceutical companies therefore price products significantly lower branded products accordingly branded product loses market exclusivity normally faces intense price competition generic forms product certain countries outside us patent protection weak nonexistent company must compete generic versions shortly launches innovative product addition generic pharmaceutical companies may introduce generic product exclusivity expired resolution related patent litigation discussion generic launch clopidogrel bisulfate product competes plavix see item financial statementsnote legal proceedings contingenciesplavix litigation many companies large small manufacture sell one products similar marketed companys nutritionals segment sources competitive advantage include patents trademarks product quality efficacy brand identity advertising promotion product innovation broad distribution capabilities customer satisfaction price significant expenditures advertising promotion marketing generally required achieve consumer trade acceptance products table contents company believes longterm competitive position depends upon success discovering developing innovative costeffective products serve unmet medical need together ability manufacture products efficiently market effectively highly competitive environment assurance companys research development efforts result commercially successful products products processes become outmoded time time result products processes developed competitors managed care organizations growth mcos us major factor competitive makeup health care marketplace half us population participates version managed care size patient population covered mcos marketing prescription drugs pbms serve many organizations become important companys business mcos include medical insurance companies medical plan administrators health maintenance organizations medicare part formularies alliances hospitals physicians physician organizations organizations consolidating fewer even larger entities enhancing purchasing strength importance company major objective mcos contain possible reduce health care expenditures typically use formularies volume purchases longterm contracts negotiate discounts pharmaceutical providers mcos pbms typically develop formularies reduce cost medications formularies based prices therapeutic benefits available products due generally lower cost generic medicines often favored breadth products covered formularies vary considerably one mco another many formularies include alternative competitive products treatment particular medical problems mcos use variety means encourage patients use products listed formularies exclusion product formulary lead sharply reduced usage mco patient population consequently pharmaceutical companies compete aggressively products included possible companies compete inclusion based upon unique features products greater efficacy better patient ease use fewer side effects lower overall cost therapy also important factor products demonstrate fewer therapeutic advantages must compete inclusion based primarily price company generally although universally successful major products included mco formularies generic competition one biggest competitive challenges company faces us lesser extent internationally generic pharmaceutical manufacturers upon expiration loss market exclusivity product company lose major portion sales product short period time us fda approval process exempts generics costly timeconsuming clinical trials demonstrate safety efficacy allows generic manufacturers rely safety efficacy innovator product therefore generic competitors operate without companys large research development expenses costs conveying medical information product medical community information market exclusivity see intellectual property product exclusivity rate sales decline product expiration exclusivity varies country general decline us market rapid developed countries also declines developed countries tend rapid developing countries rate sales decline expiration exclusivity also historically influenced product characteristics example drugs used large patient population eg prescribed primary care physicians tend experience rapid declines drugs specialized areas medicine eg oncology drugs complex manufacture eg sterile injectable products usually experience slower decline simpler manufacture noted mcos focus primarily immediate cost drugs often favor generics brandname drugs many governments also encourage use generics alternatives brandname drugs health care programs laws us generally allow many cases require pharmacists substitute generic drugs rated government procedures therapeutically equivalent brandname drug substitution must made unless prescribing physician expressly forbids laws policies provide added incentive generic manufacturers seek marketing approval automatic substitution removes need generic manufacturers incur many sales marketing costs innovators must incur research development company invests heavily research development believes critical longterm competitiveness company major facilities princeton hopewell new brunswick new jersey wallingford connecticut pharmaceutical research development also carried various facilities us belgium canada uk india management continues emphasize leadership innovation productivity quality strategies success research development activities table contents company spent billion billion billion companysponsored research development activities company sponsored pharmaceutical research development spending includes certain payments thirdparty collaborations contracts end company employed approximately people research development throughout company including substantial number physicians scientists holding graduate postgraduate degrees higherskilled technical personnel company concentrates pharmaceutical research development efforts following disease areas significant unmet medical need affective psychiatric disorders alzheimersdementia atherosclerosisthrombosis diabetes hepatitis hivaids obesity oncology rheumatoid arthritis related diseases solid organ transplant however company continues analyze may selectively pursue promising leads areas addition discovering developing new molecular entities company looks ways expand value existing products new uses formulations provide additional benefits patients supplement companys internal efforts company collaborates independent research organizations including educational institutions research based pharmaceutical biotechnology companies contracts others performance research facilities companys drug discovery program includes many alliances collaborative agreements agreements bring new products pipeline help company remain cutting edge technology search novel medicines drug development company engages services physicians hospitals medical schools research organizations worldwide conduct clinical trials establish safety effectiveness new products drug development time consuming expensive risky development human health products industry practice government regulations us foreign countries provide determination effectiveness safety new molecular entities preclinical tests controlled clinical evaluation new drug may marketed us recorded data preclinical clinical experience included nda bla fda required approval assurance compound developed result program obtain regulatory approvals necessary marketed particular disease indication average one chemical compounds discovered pharmaceutical industry researchers proves medically effective safe enough become approved medicine process discovery regulatory approval typically takes years longer drug candidates fail stage process even latestage product candidates sometimes fail receive regulatory approval company believes investments research internally collaboration others rewarded number new pharmaceutical compounds indications stages development listed several investigational compounds company later stages development compounds phase iii clinical trials whether investigational compounds ultimately becomes one companys marketed products depends results preclinical clinical studies competitive landscape potential products market manufacturing processes necessary produce potential product commercial scale among factors however noted assurance company seek regulatory approval compounds approval sought obtained stage development company determine intellectual property issues patent protection may may available investigational compounds patent coverage highlighted include potential patent term extensions apixaban apixaban oral factor xa inhibitor discovered internally phase iii clinical trials prevention thromboembolic disorders april company entered worldwide agreement pfizer codevelopment cocommercialization apixaban company owns patent covering apixaban composition matter expires extended via patent term adjustment us saxagliptin saxagliptin oral compound potential treatment diabetes discovered internally currently regulatory review us europe january company entered agreement astrazeneca codevelopment cocommercialization saxagliptin company owns patent covering saxagliptin composition matter expires us dapagliflozin dapagliflozin oral compound potential treatment diabetes discovered internally currently phase iii clinical trials company entered agreement astrazeneca codevelopment cocommercialization dapagliflozin worldwide company owns patent covering dapagliflozin composition matter expires us table contents ipilimumab ipilimumab biologic product codeveloped medarex currently phase iii clinical trials monoclonal antibody investigated anticancer treatment novel class agents intended potentiate elements immunologic response company owns patent covering ipilimumab composition matter expires us rights method use patents licensed medarex expire us company also rights medarex patent covering ipilimumab composition matter expires extended via patent term adjustment us belatacept belatacept biological product developed internally phase iii clinical trials fusion protein novel immunosuppressive activity targeted prevention solid organ transplant rejection company owns patent covering belatacept composition matter expires us xl xl oral anticancer compound discovered licensed exelixis phase iii clinical testing xl targets three enzymes met encourages tumor cell survival movement vegf helps tumors develop new blood vessels ret also involved cell growth migration found many thyroid cancers compound currently phase iii clinical trials medullary thyroid cancer tanespimycin tanespimycin hsp inhibitor currently phase iii trials treatment multiple myeloma composition matter patent specifically covers tanespimycin tanespimycin granted approval filing orphan drug treatment chronic myelogenous leukemia obtain years exclusivity upon approval brivanib brivanib oral small molecule dual kinase inhibitor blocks vegf receptor fgf receptor currently phase iii trials anticancer treatment company owns patent covering brivanib composition matter expires us september company terminated collaboration agreement solvay pharmaceuticals bv included phase ii compound ibipinabant cannabinoid receptor antagonist phase ii clinical trials company sometimes enters agreements respect investigational compounds order share costs risks development cases facilitate commercialization agreements take many forms including codevelopment comarketing copromotion andor joint venture arrangements companys competitors also devote substantial funds resources research development addition consolidation occurred pharmaceutical industry created companies substantial research development resources extent companys competitors successful research could result erosion sales products unanticipated product obsolescence government regulation price constraints pharmaceutical industry subject extensive global regulation regional country state local agencies federal food drug cosmetic act fdc act federal statutes regulations various state statutes regulations laws regulations foreign governments govern varying degrees testing approval production labeling distribution postmarket surveillance advertising dissemination information promotion companys products lengthy process laboratory clinical testing data analysis manufacturing development regulatory review necessary required governmental approvals extremely costly significantly delay product introductions given market promotion marketing manufacturing distribution pharmaceutical products extensively regulated major world markets addition companys operations subject complex federal state local foreign environmental occupational safety laws regulations company anticipates laws regulations affecting manufacture sale current products introduction new products continue require substantial scientific technical effort time expense significant capital investment particular importance fda us jurisdiction virtually companys businesses imposes requirements covering testing safety effectiveness manufacturing labeling marketing advertising postmarketing surveillance companys pharmaceutical products fda also regulates companys nutritionals products many cases fdas requirements increased amount time money necessary develop new products bring market us companys pharmaceuticals products subject premarket approval requirements us new drugs approved subject fdc act related regulations biological drugs subject fdc act public health service act phs act related regulations biological drugs licensed phs act medical devices subject fdc act including medical device amendments companys nutritionals products regulated fda primarily infant formula act amendments table contents fda mandates drugs manufactured packaged labeled conformity current good manufacturing practices cgmp established fda complying cgmp regulations manufacturers must continue expend time money effort production record keeping quality control ensure product meets applicable specifications requirements ensure product safety efficacy fda periodically inspects drug manufacturing facilities ensure compliance applicable cgmp requirements failure comply statutory regulatory requirements subjects manufacturer possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experiences use products must reported fda could result imposition market restrictions labeling changes product removal product approvals may withdrawn compliance regulatory requirements maintained problems concerning safety efficacy product occur following approval federal government extensive enforcement powers activities pharmaceutical medical device manufacturers including authority withdraw product approvals commence actions seize prohibit sale unapproved noncomplying products halt manufacturing operations compliance cgmps impose seek injunctions voluntary recalls civil monetary criminal penalties restriction prohibition sales withdrawal approval products marketed company could materially adversely affect business financial condition results operations cash flows federal government similar powers respect manufacturing operations nutritionals business marketing authorization companys products subject revocation applicable governmental agencies addition modifications enhancements approved products changes manufacturing locations many circumstances subject additional fda approvals may may received may subject lengthy application process distribution pharmaceutical products subject prescription drug marketing act pdma part fdc act regulates activities federal state level pdma implementing regulations states permitted require registration manufacturers distributors provide pharmaceuticals even manufacturers distributors place business within state states also permitted adopt regulations limiting distribution product samples licensed practitioners pdma also imposes extensive licensing personnel recordkeeping packaging quantity labeling product handling facility storage security requirements intended prevent sale pharmaceutical product samples diversions discussion recent settlement certain investigations drug pricing sales marketing activities see item financial statementsnote legal proceedings contingencies fda amendments act imposed additional obligations pharmaceutical companies delegated enforcement authority fda area drug safety key elements legislation give fda new authority require companies conduct postmarketing safety studies drugs impose certain drug labeling changes relating safety mandate risk mitigation measures education healthcare providers restricted distribution medicines require companies publicly disclose data clinical trials prereview television advertisements marketing practices us pharmaceutical manufacturers subject federal state health care laws used protect integrity government health care programs office inspector general us department health human services oig oversees compliance applicable federal laws connection payment products government funded programs primarily medicaid medicare laws include federal antikickback statute criminalizes offering something value induce recommendation order purchase products services reimbursed government health care program oig issued series guidances segments health care industry including compliance program guidance pharmaceutical manufacturers oig guidance includes recommendation pharmaceutical manufacturers minimum adhere phrma code voluntary industry code marketing practices company subscribes phrma code implemented compliance program address requirements set forth oig guidance companys compliance health care laws failure comply health care laws could subject company administrative legal proceedings including actions state federal government agencies actions could result imposition civil criminal sanctions may include fines penalties injunctive remedies impact could materially adversely affect companys business financial condition results operations cash flows company also subject jurisdiction various federal state regulatory enforcement departments agencies federal trade commission department justice department health human services us company also licensed us drug enforcement agency procure produce controlled substances company therefore subject possible administrative legal proceedings actions organizations actions may result imposition civil criminal sanctions may include fines penalties injunctive administrative remedies companys activities outside us also subject regulatory requirements governing testing approval safety effectiveness manufacturing labeling marketing companys products regulatory requirements vary country country eu two ways company obtain marketing authorization pharmaceutical product first route centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds products second route obtain marketing authorization eu mutual recognition procedure applications made single member state table contents member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure member states set forth pricing reimbursement product continues subject member state law whether fda approval approval emea obtained product approval product comparable regulatory authorities countries outside us eu case may must obtained prior marketing product countries approval process may less rigorous country country time required approval may longer shorter required us approval one country assure product approved another country many markets outside us company operates environment governmentmandated costcontainment programs several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs andor enacted acrosstheboard price cuts methods cost control european countries provide market pricing new medicines except uk germany pricing freedom limited uk operation profit control plan germany operation reference price system companies also face significant delays mainly france spain italy belgium market access new products two years elapse new medicines become available national markets additionally member states eu regularly imposed new additional cost containment measures pharmaceuticals recent years italy example imposed mandatory price decreases existence price differentials within europe due different national pricing reimbursement laws leads significant parallel trade flows recent years congress state legislatures considered number proposals enacted laws could effect major changes health care system either nationally state level driven part budget concerns medicaid access reimbursement restrictions implemented states proposed many others similar cost containment issues exist many foreign countries company business federal state governments also pursued direct methods reduce cost drugs pay company participates state government managed medicaid programs well certain qualifying federal state government programs whereby discounts rebates provided participating state local government entities rebates medicaid related state programs reduced revenues million million million company also participates prime vendor programs government entities significant us department defense us department veterans affairs entities receive minimum discounts based defined nonfederal average manufacturer price purchases prime vendor programs company participates provide discounts outpatient medicines purchased certain public health service entities hospitals meeting certain criteria company recorded discounts related prime vendor programs million million million us governmental cost containment efforts extended federally funded special supplemental nutrition program wic states participate wic program sought obtained rebates manufacturers infant formula whose products used program states conducted competitive bidding infant formula contracts require use specific infant formula products state wic program unless physician requests noncontract formula wic customer states participating wic program required engage competitive bidding use cost containment measures yield savings equal greater savings generated competitive bidding system mead johnson participates program approximately half gross us sales subject rebates wic program rebates wic program reduced revenues million million million discussion rebates programs see item managements discussion analysis financial condition results operations results operations environmental regulation companys facilities operations subject extensive us foreign laws regulations relating environmental protection human health safety including governing discharges pollutants air water use management disposal hazardous radioactive biological materials wastes cleanup contamination pollution controls permits required many companys operations permits subject modification renewal revocation issuing authorities environment health safety group within company monitors operations around world providing company overview regulatory requirements overseeing implementation company standards compliance company also incurs operating capital costs matters ongoing basis company expended approximately million million million capital environmental projects undertaken specifically meet environmental requirements respectively expects spend approximately million although company believes substantial compliance applicable environmental health safety requirements permits required operations company nevertheless could incur additional costs including civil criminal fines penalties cleanup costs thirdparty claims property damage personal injury violations liabilities laws table contents many companys current former facilities operation many years time company operators facilities generated used stored disposed substances wastes considered hazardous federal state foreign environmental laws including us comprehensive environmental response compensation liability act cercla result soil groundwater certain facilities may contaminated company may required make significant expenditures investigate control remediate contamination cases provide compensation andor restoration damages natural resources currently company involved investigation remediation current former company facilities company also identified potentially responsible party prp applicable laws environmental conditions approximately former waste disposal reprocessing facilities operated third parties investigation andor remediation activities ongoing company may face liability cercla federal state foreign laws entire cost investigation remediation contaminated sites natural resource damages regardless fault ownership time disposal release addition certain sites company bears remediation responsibility pursuant contract obligations generally thirdparty operator sites involving multiple prps liability expected apportioned based nature amount hazardous substances disposed party site number financially viable prps additional information matters see item financial statementsnote legal proceedings contingencies employees december company employed approximately people company continued implement comprehensive cost reduction program included work force reduction areas rationalization facilities also company sold convatec medical imaging businesses employed approximately people discussion pti restructuring activities see productivity transformation initiative item financial statementsnote restructuring foreign operations company significant operations outside us conducted companys subsidiaries distributors involve business segments companys us operations pharmaceuticals nutritionals geographic breakdown net sales see table captioned geographic areas item financial statementsnote segment information discussion companys sales geographic area see item managements discussion analysis financial condition results operations geographic areas international operations subject certain risks inherent conducting business abroad including limited currency fluctuations possible nationalization expropriation price exchange controls counterfeit products limitations foreign participation local enterprises restrictive governmental actions companys international businesses also subject governmentimposed constraints including laws pricing reimbursement use products depending direction change relative us dollar foreign currency values increase reduce reported dollar value companys net assets results operations change foreign exchange rates net favorable impact growth rate revenues however trend changed latter half year company predict certainty future changes foreign exchange rates effect company attempts mitigate impact operational means using various financial instruments see discussions item quantitative qualitative disclosures market risk item financial statementsnote financial instruments bristolmyers squibb website companys internet website address wwwbmscom website company makes available free charge annual quarterly current reports including amendments reports soon reasonably practicable company electronically files material furnishes material sec information relating corporate governance bristolmyers squibb including companys standards business conduct ethics code ethics senior financial officers code business conduct ethics directors collectively codes corporate governance guidelines information concerning companys executive committee board directors including table contents board committees committee charters transactions bristolmyers squibb securities directors executive officers available companys website investorscorporate governance caption print stockholder upon request waivers codes directors executive officers material amendment code business conduct ethics directors code ethics senior financial officers posted promptly companys website information relating stockholder services including companys dividend reinvestment plan direct deposit dividends available companys website investorsstockholder services caption company incorporates reference certain information parts proxy statement annual meeting stockholders sec allows company disclose important information referring manner please refer information companys proxy statement annual meeting stockholders annual report available companys website investorssec filings caption march table contents item risk factors factors described could significantly negatively affect companys business prospects financial condition operating results credit ratings could cause trading price companys common stock decline additional risks uncertainties presently known company risks company currently considers immaterial may also impair companys operations company faces intense competition pharmaceutical manufacturers including lowerpriced generic products competition manufacturers competing products including lowerpriced generic versions companys products major challenge within united states us internationally pharmaceuticals segment confronted record level industry patent expirations increasingly aggressive generic competition competition may include new products developed competitors lower prices superior performance features otherwise competitive companys current products ii technological advances patents attained competitors iii results clinical studies related companys products competitors products iv business combinations among companys competitors major customers company depends key products net sales cash flows earnings company derives majority revenue key products net sales plavix contributed billion representing total net sales net sales abilify contributed approximately billion representing approximately total net sales three products avaproavalide reyataz sustiva franchise contributed billion net sales reduction sales products could significantly negatively impact companys net sales cash flows earnings possible company may lose market exclusivity product earlier expected pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity us countries market exclusivity expires generic versions product approved marketed often substantial rapid declines products sales rate decline varies country therapeutic category market exclusivity companys products based upon patent rights andor certain regulatory forms exclusivity scope companys patent rights may vary country country countries including certain european union member states basic patent protection companys products may exist historically certain countries offer right obtain certain types patents andor company licensors file markets absent relevant patent protection product data exclusivity period expires generic versions product approved marketed generic clopidogrel bisulfate certain eu markets addition prior expiration data exclusivity competitor could seek regulatory approval submitting clinical trial data obtain marketing approval manufacturers generic products also increasingly seeking challenge patents expire may cases launch generic product expiration applicable patents andor final resolution related patent litigation length market exclusivity companys products impossible predict certainty assurance particular product enjoy market exclusivity full period time appears estimates disclosed data protection plavix expired eu plavix faces competition european markets data protection plavix expired july european union eu major markets within europe product benefits national patents expiring specifically claim bisulfate form clopidogrel remainder eu member states however composition matter patent covering clopidogrel bisulfate competitors seeking regulatory authority enter markets generic clopidogrel bisulfate addition least one group competitor companies received marketing authorization started market alternate salt form clopidogrel germany company aware alternate salt applications filed eu time company estimate reliably impact competition companys financial results us foreign laws regulations may negatively affect companys sales profit margins company could become subject new government laws regulations health care reform initiatives us state federal level countries ii changes us food drug administration fda foreign table contents regulatory approval processes may cause delays approving preventing approval new products iii tax changes phasing tax benefits heretofore available us certain foreign countries iv new laws regulations judicial governmental decisions affecting pricing reimbursement marketing within across jurisdictions v changes intellectual property law vi matters compulsory licenses could alter protections afforded one products company faces increased pricing pressure us abroad managed care organizations institutional purchasers government agencies programs could negatively affect companys sales profit margins pharmaceutical products subject increasing price pressures restrictions us worldwide including rules practices managed care groups institutional governmental purchasers ii judicial decisions governmental laws regulations related medicare medicaid healthcare reform including medicare prescription drug improvement modernization act iii potential impact importation restrictions legislative andor regulatory changes pharmaceutical reimbursement medicare part formularies product pricing general iv developments technology andor industry practices could directly indirectly impact reimbursement policies practices thirdparty payers company may experience difficulties delays manufacturing sale products company may experience difficulties delays inherent manufacturing sale seizure recalls pharmaceutical products forced closings manufacturing plants ii failure obtain imposition limitations use loss patent intellectual property rights iii supply chain continuity including failure company vendors suppliers comply current good manufacturing practices applicable regulations quality assurance guidelines could lead temporary manufacturing shutdowns product shortages delays product manufacturing iv construction delays related construction new facilities expansion existing facilities including intended support future demand companys biologics products v manufacturing distribution problems including changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced biologics physical limitations could impact continuous supply company may experience difficulties delays development commercialization new products company may experience difficulties delays development commercialization new products including inherent risks uncertainties associated product development compounds products may appear promising development fail reach market within expected optimal timeframe fail ever reach market approved additional indications number reasons including efficacy safety concerns delay denial necessary regulatory approvals difficulty excessive cost manufacture ii failure enter successfully implement optimal alliances appropriate discovery andor commercialization products otherwise maintain consistent scope variety promising latestage products iii failure one companys products achieve maintain commercial viability legal matters adverse outcomes could negatively affect companys business company currently involved various lawsuits claims proceedings government investigations preclude delay commercialization products adversely affect operations profitability liquidity financial condition including intellectual property disputes ii sales marketing practices us internationally iii adverse decisions litigation including product liability commercial cases iv recalls withdrawals pharmaceutical products forced closings manufacturing plants v failure fulfill obligations supply contracts government customers may result liability vi product pricing promotion matters vii lawsuits claims asserting violations securities antitrust federal state pricing laws viii environmental health safety matters ix tax liabilities assurance increase scope matters additional lawsuits claims proceedings investigations future assurance matters material adverse impact company company relies third parties meet contractual regulatory obligations company relies vendors partners including alliances pharmaceutical companies development commercialization products third parties meet contractual regulatory obligations relation arrangements company failure parties meet obligations andor development significant disagreements factors materially disrupt ongoing commercial relationship prevent optimal alignment partners activities could material adverse impact company table contents failure execute companys business strategy could adversely impact growth profitability part strategy company currently implementing comprehensive cost reduction program includes workforce reductions areas rationalization facilities company expects incur restructuring charges connection program aggregate range billion billion pretax basis million charges incurred company may able fully execute strategic transformation business attain new period sustainable revenue earnings growth company continues invest key products pipeline part focus addressing areas significant unmet medical need failure realize expected cost savings achieve maintain competitive cost base successfully transition product portfolio however could materially adversely affect companys results operations addition companys failure hire retain personnel right expertise experience operations critical business functions could adversely impact execution business strategy changes companys structure operations revenues costs efficiency resulting acquisitions divestitures mergers alliances restructurings strategic initiatives could result greater expected costs difficulties including need regulatory approvals appropriate company increasingly dependent information technology outsourcing arrangements company increasingly dependent information technology systems significant breakdown invasion destruction interruption systems could negatively impact operations company also increasing dependence thirdparty providers certain services including information technology systems certain financial outsourcing arrangements certain human resource functions failure service providers meet obligations andor development significant disagreements factors materially disrupt companys ongoing relationship providers could negatively affect operations recent adverse changes us global regional economic conditions could continuing adverse effect profitability businesses recent turmoil financial markets adversely affected economic activity united states regions world business although believe based current cash cash equivalents marketable securities balances expected operating cash flows current lack liquidity credit markets material impact liquidity cash flow financial flexibility continued deterioration credit capital markets could cause additional impairments investment portfolio could negatively impact financial condition reported earnings continued decline economic activity could adversely affect demand products thus reducing revenue earnings well adverse impact customers distributors alliance partners suppliers service providers counterparties certain financial instruments marketable securities derivatives severe decline equity markets resulted decline pension plan assets increase future funding requirements changes foreign currency exchange rates interest rates could material adverse effect results operations significant operations outside us revenues operations outside us accounted companys revenues exposed changes fluctuation foreign currency exchange rates also significant borrowings exposed changes interest rates december company shortterm borrowings longterm debt billion company also exposed economic factors company control illegal distribution sale third parties counterfeit versions companys products could negative impact reputation third parties may illegally distribute sell counterfeit versions products meet rigorous manufacturing testing standards products undergo patient receives counterfeit drug may risk number dangerous health consequences reputation could suffer harm result counterfeit drugs sold name one products table contents item b unresolved staff comments none item properties companys world headquarters located park avenue new york ny leases approximately square feet floor space approximately square feet sublet others company manufactures products major worldwide locations aggregate floor space approximately million square feet facilities owned company following table illustrates geographic location companys significant manufacturing facilities business segment total pharmaceuticals nutritionals company united states europe middle east africa western hemisphere pacific total portions facilities facilities owned leased company us elsewhere used research administration storage distribution information companys facilities see item businessmanufacturing quality assurance part companys pti reduced expects continue reduce number manufacturing facilities item legal proceedings information pertaining legal proceedings found item financial statementsnote legal proceedings contingencies incorporated reference herein item submission matters vote security holders matters submitted vote security holders fourth quarter year ended december table contents part ia executive officers registrant listed information executive officers company february executive officers elected board directors initial term continues first board meeting following next annual meeting stockholders thereafter elected oneyear term successors elected executive officers serve pleasure board directors name current position age employment history past years james cornelius chief executive officer chairman board guidant chairman board chief executive officer corporation member management council interim chief executive officer chairman board guidant corporation interim chief executive officer director company chief executive officer director company present chairman board chief executive officer company lamberto andreotti senior vice president president international worldwide executive vice president chief operating officer medicines group division company worldwide pharmaceuticals executive vice president president worldwide member management council pharmaceuticals division company present executive vice president chief operating officer worldwide pharmaceuticals division company joseph c caldarella vice president finance pharmaceutical research institute vice president corporate controller division company corporate staff present vice president corporate controller corporate staff company john e celentano president latin america canada worldwide medicines senior vice president strategy productivity group division company transformation president health care group division company member management council present senior vice president strategy productivity transformation corporate staff company brian daniels md senior vice president global clinical development research senior vice president global development development division company medical affairs research development present senior vice president global development medical member management council affairs research development division company carlo de notaristefani senior vice president international finishing operations president technical operations worldwide worldwide medicines group division company pharmaceuticals present president technical operations worldwide member management council pharmaceuticals division company anthony c hooper present president us pharmaceuticals worldwide president us pharmaceuticals pharmaceuticals group division company member management council table contents jeanmarc huet chief financial officer royal numico nv present senior vice president chief financial officer chief financial officer corporate staff company corporate staff member management council sandra leung vice president corporate secretary corporate staff senior vice president general counsel company corporate staff vice president corporate secretary acting general member management council counsel corporate staff company present senior vice president general counsel corporate staff company anthony mcbride vice president human resources international global senior vice president human resources marketing division company corporate staff vice president human resources pharmaceutical commercial member management council operations division company present senior vice president human resources corporate staff company elliott sigal md phd senior vice president global clinical pharmaceutical executive vice president chief scientific officer development research institute division company president research development present chief scientific officer president research member management council development division company robert zito executive vice president communications new york stock senior vice president corporate business exchange communications chief communications officer present senior vice president corporate affairs corporate staff member management council company table contents part ii item market registrants common stock stockholder matters market prices bristolmyers squibb common preferred stocks traded new york stock exchange nyse traded nyse arca inc formerly pacific exchange inc symbols bmy bmypr quarterly summary high low market prices presented common high low high low first quarter second quarter third quarter fourth quarter preferred high low high low first quarter second quarter third quarter fourth quarter second third fourth quarters trades companys preferred stock preferred stock pays quarterly dividend per share holders common stock number record holders common stock december number record holders based upon actual number holders registered books company date include holders shares street names persons partnerships associations corporations entities identified security position listings maintained depository trust companies voting securities principal holders reference made proxy statement filed march respect voting securities principal holders incorporated herein reference made part hereof response information required item table contents dividends board directors company declared following dividends per share paid quarters indicated common preferred first quarter second quarter third quarter fourth quarter december board directors company declared quarterly dividend per share common stock company paid february shareholders record january board directors also declared quarterly dividend per share preferred stock company payable march shareholders record february unregistered sales equity securities use proceeds following table summarizes surrenders companys equity securities connection stock option restricted stock programs month period ended december total number approximate dollar total number shares purchased value shares average price part publicly may yet shares paid per announced plans purchased period purchaseda sharea programsb plans programsb dollars millions except per share data january february march three months ended march april may june three months ended june july august september three months ended september october november december three months ended december twelve months ended december reflects transaction months ended december surrender company shares common stock satisfy tax withholding obligations connection vesting restricted stock issued employees b june company announced board directors authorized purchase billion companys common stock months ended december shares repurchased pursuant program table contents performance graph following performance graph compares performance bristolmyers squibb periods indicated performance standard poors stock index sp average performance group consisting peer corporations lineofbusiness basis corporations making peer companies group abbott laboratories astrazeneca plc eli lilly company glaxosmithkline plc johnson johnson merck co inc novartis ag pfizer inc sanofiaventis including performance aventis prior merger sanofi scheringplough corporation wyeth total return indices reflect reinvested dividends weighted using beginningperiod market capitalization reported time periods measured performance group proxy statement comparison five year cumulative total return december bristolmyers squibb sp index peer group assumes invested december bristolmyers squibb common stock sp index peer group values december specified year assuming dividends reinvested table contents item selected financial data five year financial summary amounts millions except per share data income statement data net sales earning continuing operations income taxes minority interest net earnings continuing operations net earnings continuing operations per common share basic diluted average common shares outstanding basic diluted dividends paid common preferred stock dividends declared per common share financial position data december total assets cash cash equivalents marketable securities longterm debt stockholders equity company recorded items affected comparability results discussion items years see item managements discussion analysis financial condition results operationsexpensesgains table contents item managements discussion analysis financial condition results operations executive summary company bristolmyers squibb company may referred bristolmyers squibb bms company global biopharmaceutical nutritional products company whose mission extend enhance human life providing highest quality pharmaceutical nutritional products company engaged discovery development licensing manufacturing marketing distribution sale pharmaceuticals nutritional products company two reportable segmentspharmaceuticals nutritionals pharmaceuticals segment consists global pharmaceuticalbiotechnology international consumer medicines business accounted approximately companys net sales nutritionals segment consists mead johnson nutrition company mead johnson primarily infant formula childrens nutritionals business accounted approximately companys net sales financial highlights following table summary operating activity year ended december dollars millions net sales net earnings continuing operations net earnings discontinued operations net earnings net cashdebt net sales companys net sales continuing operations increased plavix clopidogrel bisulfate abilify continue drive worldwide sales growth sales increases respectively significant contributions sales growth also provided key products including orencia sprycel hiv hepatitis portfolio net earnings continued operations increases net earnings continuing operations attributed increased sales growth favorability gross margins portion attributed favorable product mix well cost savings avoidances resulting companys productivity transformation initiative pti million aftertax gain related tendering companys shares imclone also significant impact net earnings continuing operations amongst specified items discussed expensesgains net earnings discontinued operations company completed divestitures medical imaging business gross purchase price million resulting aftertax loss million well convatec business gross purchase price approximately billion resulting aftertax gain billion results medical imaging convatec businesses related gains losses included discontinued operations years presented net cashdebt net cashdebt position december improved due proceeds billion divestiture convatec medical imaging businesses proceeds billion sale imclone shares cash generated operating activities billion adequate fund dividend payments billion well capital expenditure payments million business environment company conducts business primarily within pharmaceuticalbiotechnology industry highly competitive subject numerous government regulations many competitive factors may significantly affect companys sales products including product efficacy safety price costeffectiveness marketing effectiveness product labeling quality control quality assurance manufacturing operations research development new products successfully compete business table contents health care industry company must demonstrate products offer medical benefits well cost advantages currently companys new product introductions compete products already market therapeutic category addition potential competition new products competitors may introduce future company manufactures branded products priced higher generic products generic competition one companys leading challenges globally pharmaceuticalbiotechnology industry majority innovative products commercial value usually realized period product market exclusivity product loses exclusivity longer protected patent subject new competing products form generic brands upon exclusivity loss company lose major portion products sales short period time currently generic versions biological products approved united states us law however law could change future even absence new legislation us food drug administration fda taking steps toward allowing generic versions certain biologics competitors seeking approval biological products must file safety efficacy data address challenges biologics manufacturing involves complex processes costly traditional pharmaceutical operations us internationally health care industry subject various governmentimposed regulations authorizing prices price controls continue impact companys sales us congress state legislatures considered number proposals enacted laws could result major changes current health care system either nationally state level driven part budget concerns medicaid access reimbursement restrictions implemented states proposed many others addition medicare prescription drug improvement modernization act provides outpatient prescription drug coverage senior citizens us legislation modest favorable impact company result increase number seniors drug coverage time continues potential negative impact us pharmaceutical business could result pricing pressures controls many markets outside us company operates environments governmentmandated costcontainment programs regulatory bodies groups exert downward pressure pricing pricing freedom limited united kingdom uk instance operation profit control plan germany operation reference price system companies also face significant delays market access new products two years elapse drug approval new medicines become available countries growth managed care organizations mcos us played large role competition surrounds health care industry mcos seek reduce health care expenditures participants making volume purchases entering longterm contracts negotiate discounts various pharmaceutical providers market potential created large pool participants marketing prescription drugs mcos become important part companys strategy companies compete inclusion mco formularies company generally successful major products included company believes developments managed care industry including continued consolidation continue generally downward pressure prices pharmaceuticalbiotechnology production processes complex highly regulated vary widely product product shifting adding manufacturing capacity lengthy process requiring significant capital expenditures regulatory approvals biologics manufacturing involves complex processes traditional pharmaceutical operations biologics become important companys product portfolio company continue make arrangements thirdparty manufacturers make substantial investments increase internal capacity produce biologics commercial scale one investment new stateoftheart manufacturing facility production biologics devens massachusetts construction began may company maintained competitive position market strives uphold position dependent success discovering developing innovative costeffective products serve unmet medical need company expanded pti activities order achieve additional savings order reduce costs streamline operations rationalize global manufacturing become productive competitive biopharmaceutical company company subsidiaries subject number significant pending lawsuits claims proceedings investigations possible time reasonably assess final outcome investigations litigations additional discussion legal matters see item financial statementsnote legal proceedings contingencies strategy companys multiyear strategy transformation nextgeneration biopharmaceutical company strategy encompasses aspects geographies business yield substantial cost savings cost avoidance increase companys financial flexibility take advantage attractive market opportunities may arise table contents managing costs one part companys overall strategy transitions nextgeneration biopharmaceutical company focused delivering present commitments maximizing nearterm growth opportunities improving earnings base company announced pti designed create total billion annual productivity savings cost avoidance first wave announced december targets billion savings cost avoidance second wave announced july targets additional billion savings cost avoidance company continue focus development biopharmaceutical business maintain growth investing research development new product pipeline company continue invest key growth products including specialty biologic medicines cardiovascular metabolic drugs company seeking reallocate resources continue string pearls strategy enable strategic transactions acquisition kosan biosciences inc kosan strategic alliances global codevelopment cocommercialization agreement exelixis inc exelixis global collaboration agreement zymogenetics entered company continue pursuing partnerships expanding collaborative arrangements biopharmaceutical companies continue entering strategic alliances third parties order obtain rights develop manufacture market andor sell pharmaceutical products rights owned third parties company continue maximize value noncore businesses company completed divestiture convatec medical imaging businesses company also sold mature brands business located egypt new product pipeline developments sprycel january company announced approval sprycel japan ixempra december company announced new data studies ixempra ixabepilone plus capecitabine compared capecitabine alone including prespecified sub set analysis demonstrating significant increase progression free survival patients triple negative breast cancer november committee medicinal products human use chmp europe issued negative opinion marketing authorization application ixempra treatment patients metastatic breast cancer company requested reexamination case currently consideration chmp exelixis december company announced global collaboration exelixis covering two novel molecules cancer associated development programs exelixis xl small molecule inhibitor met vegfr ret currently phase iii development medullary thyroid cancer exelixis xl small molecule inhibitor raf kinase currently phase development treatment patients advanced solid tumor malignancies agreement company receives development commercialization rights programs dapagliflozin december company astrazeneca announced expansion worldwide collaboration include development commercialization dapagliflozin japan dapagliflozin one two investigational drugs joint development companies currently studied phase iii clinical trials several countries including us assess efficacy safety oncedaily treatment type diabetes erbitux january company marketing partner imclone systems inc imclone whollyowned subsidiary eli lilly company lilly announced companies withdraw eventually resubmit application fda broaden use erbitux include first line treatment patients advanced nonsmall cell lung cancer combination platinumbased chemotherapy cisplatinvinorelbine october fda accepted filing priority review supplemental biologics license application sbla broaden indication erbitux include use combination platinumbased chemotherapy firstline treatment patients recurrent metastatic squamous cell carcinoma head neck october publication study results showing metastatic colorectal cancer mcrc patients wildtype normal kras tumors treated erbitux plus best supportive care bsc statistically significant increase overall survival progressionfree survival compared treated bsc alone specifically patients whose tumors normal mutant negative kras gene achieved near twofold improvement overall survival progressionfree survival patients treated bsc alone patients mutated kras tumors significant difference overall progressionfree survival treated erbitux plus bsc treated bsc alone company fda discussions regarding possible label changes related study table contents september announcement five year data showing significant improvements overall survival patients locally regionally advanced head neck cancer extreme study published new england journal medicine showing erbitux improved survival firstline recurrent andor metastatic head neck cancer july erbitux received marketing approval japan treatment patients advanced recurrent colorectal cancer may annual meeting american society clinical oncology asco landmark phase iii study flex showed addition erbitux platinumbased chemotherapy significantly increased overall survival firstline treatment patients advanced nonsmall cell lung cancer compared platinumbased chemotherapy alone abilify supplemental new drug application abilify approved fda february acute treatment manic mixed episodes associated certain pediatric patients age bipolar disorder fda approval received may new abilify indications pediatric bipolar ages maintenance therapy pediatric schizophrenia ages maintenance therapy addon treatment lithium valproate acute treatment bipolar disorder pediatric age adult patients european commission authorized marketing abilify march treatment moderate severe manic episodes bipolar disorder prevention new manic episode patients experienced predominantly manic episodes whose manic episodes responded abilify treatment orencia october company announced results month study showed orencia compared placebo pbo significantly improved multiple aspects healthrelated quality life physical psychosocial well pain sleep quality juvenile idiopathic arthritis jia patients ages years results part study looking safety efficacy orencia children jia failed previous treatments methotrexate mtx biologics october company announced results phase iiib study adult patients early moderatetosevere erosive rheumatoid arthritis ra never received previous mtx treatment study showed orencia combination mtx significantly patients achieve disease activity score using creactive proteindefined remission compared mtx plus pbo safety profile orencia combination mtx similar mtx plus pbo also quarter company filed sbla fda use orencia patients early ra june new phase ii data presented european league rheumatism demonstrated orencia may delay development ra people undifferentiated inflammatory arthritis april orencia approved fda treatment juvenile ra additionally us label orencia revised indication means orencia appropriate option patients moderatetosevere ra regardless prior treatment received reyataz october company announced week data castle study patients reyatazr arm achieved undetectable viral load defined human immunodeficiency virus hiv rna less copiesml compared patients lopinavirr arm difference treatment arms may related discontinuation rate reyatazr arm discontinuation rate lopinavirr arm october fda approved use reyataz atazanavir sulfate milligram oncedaily boosted ritonavir milligram part combination therapy previously untreated treatmentnave hiv infected patients use oncedaily reyatazritonavir hiv infected treatmentnave adult patients based upon week results castle study demonstrated similar antiviral efficacy reyatazritonavir twicedaily lopinavirritonavir part hiv combination therapy treatmentnave hiv infected adult patients data castle study published august issue lancet june european approval received expanded indication reyataz mg oncedaily boosted ritonavir mg part combination therapy treatmentnave hiv infected patients february first data comparing boosted reyataz reyataz plus ritonavir lopinavirritonavir presented congress retroviruses opportunistic infections table contents baraclude company announced november data two separate cohort evaluations longterm treatment baraclude associated improved liver histology including improvement fibrosis chronic hepatitis b patients histology data presented th annual meeting american association study liver diseases new data march asian pacific association study liver meeting demonstrated continued low incidence resistance baraclude nucleosidenaive patients five years treatment important many chronic hepatitis b patients requiring longterm treatment apixaban september company development partner pfizer announced phase ii study appraise apixaban novel anticoagulant provided encouraging trends suggesting anticoagulation apixaban top current standards care continued beyond initial hospitalization may reduce risk second heart attack stroke death primary endpoint met phase iii study apixaban prevention venous thromboembolism vte patients undergoing total knee replacement results trial necessitate changes protocols ongoing apixaban studies companies considering studies preventing vte knee surgery submit us regulatory filing vte prevention second half previously communicated programs directed toward prevention vte including european medicines evaluation agency registration studies treatment vte acute coronary systems prevention stroke atrial fibrillation continue planned ipilimumab favorable updated survival data announced september three phase ii studies ipilimumab saxagliptin favorable results announced september phase iii studies onglyza saxagliptin regulatory submissions onglyza made us europe june july respectively annual scientific sessions american diabetes association phase iii study demonstrated saxagliptin produced significant reductions key measures glucose control treatmentnave people type diabetes compared placebo elotuzumab company entered agreement pdl biopharma inc august global development commercialization elotuzumab antics antibody currently phase development multiple myeloma kai may company entered agreement kai develop commercialize kais novel acute heart attack medicine kai kosan june bristolmyers squibb completed acquisition kosan cancer therapeutics company library novel compounds including hsp inhibitors cancer microtubule stabilizers may additional potential neurodegenerative diseases zymogenetics january company zymogenetics announced global collaboration peginterferon lambda novel type interferon currently phase ib development treatment hepatitis c related development program plavix european committee medicinal products human use march issued positive opinion recommending approval milligram loading dose tablet plavix positive opinion ratified european commission table contents results operations following discussions companys results continuing operations exclude results related medical imaging business prior divestiture january convatec business prior divestiture august medical imaging convatec previously presented component former health care operating segment renamed convatec operating segment subsequent medical imaging divestiture businesses segregated continuing operations included discontinued operations periods presented companys results operations follows change dollars millions vs vs net sales earnings continuing operations income taxes minority interest net sales provision income taxes effective tax rate net earnings continuing operations net sales net sales composition changes net sales follows vs vs net sales analysis change analysis change foreign foreign dollars millions total change volume price exchange total change volume price exchange us nonus total increase us net sales primarily driven growth key us pharmaceutical products described detail increases international net sales aided weakened us dollar relative certain foreign currencies especially euro uk pound general companys business seasonal information us pharmaceutical prescriber demand reference made table within pharmaceuticals sets forth comparison changes net sales estimated total prescription growth retail mail order customers certain companys key pharmaceuticals products new products sold us pharmaceuticals business us nonus net sales based upon location customer table contents companys net sales segment follows net sales change total net sales dollars millions vs vs pharmaceuticals nutritionals total company recognizes revenue net various sales adjustments arrive net sales reported consolidated statements earnings adjustments referred grosstonet sales adjustments described critical accounting policies reconciliations companys gross sales net sales significant category grosstonet sales adjustments follows year ended december dollars millions gross sales grosstonet sales adjustments prime vendor chargebacks women infants children wic rebates managed health care rebates contract discounts medicaid rebates cash discounts sales returns adjustments total grosstonet sales adjustments net sales grosstonet adjustments primarily function gross sales activity typically correlated current sales trends case managed health care rebates contract discounts medicaid rebates cash discounts adjustments managed health care rebates contract discounts medicaid rebates also affected changes sales mix contractual legislative discount rates increases managed health care rebates contract discounts also impacted reduction reserves related tricare retail pharmacy refund program prime vendor chargebacks decreased throughout result lower sales taxol attributed loss exclusivity women infant children wic rebates decrease related net impact several wic contract transactions increase sales returns primarily attributed increased provisions pravachol driven higher retail sales returns previously assumed loss exclusivity zerit variance sales returns compared prior year attributed higher provisions cardiovascular non exclusive brands discontinued commercialization tequin gatifloxacin table contents activities ending balances significant category grosstonet sales adjustments follows managed health care women rebates infants prime vendor children contract medicaid cash sales dollars millions chargebacks wic rebates discounts rebates discounts returns adjustments total balance january provision related sales made current period provision related sales made prior periods returns payments impact foreign currency translation discontinued operations balance december provision related sales made current period provision related sales made prior periods returns payments impact foreign currency translation discontinued operations balance december company recorded grosstonet sales adjustments related sales made prior periods significant items included charges sales returns million million primarily resulting higher expected returns certain nonexclusive products significant revisions made estimates grosstonet sales adjustments pharmaceuticals composition changes pharmaceutical net sales follows vs vs net sales analysis change analysis change foreign foreign dollars millions total change volume price exchange total change volume price exchange us nonus total key us pharmaceutical products contributed growth sales plavix abilify represented approximately total us pharmaceuticals net sales represented approximately total growth pharmaceuticals sales compared prior year plavix abilify represented approximately total us pharmaceuticals net sales contributed approximately total growth us pharmaceuticals net sales growth offsets decreases us net sales attributed generic competition pravachol international pharmaceuticals sales aided weakened us dollar many foreign currencies compared previous period companys reported international net sales include copromotion sales reported alliance partner sanofiaventis sanofi plavix avaproavalide continued show growth net sales key pharmaceutical products represent total pharmaceutical net sales respectively following table details us international pharmaceuticals net sales key products percentage change prior year well foreign exchange impact compared prior year commentary detailing reasons significant variances key product provided table contents change attributable foreign net sales change exchange dollars millions vs vs vs vs cardiovascular plavix us nonus total avaproavalide us nonus total pravachol us nonus total virology reyataz us nonus total sustiva franchise total revenue us nonus total baraclude us nonus na total na oncology erbitux us nonus total taxol us nonus total sprycel us nonus na total na ixempra us na nonus total na affective psychiatric disorders abilify us nonus total immunoscience orencia us nonus na na total negative pravachol us sales reflect higher retail sales returns previously assumed change excess plavix platelet aggregation inhibitor part companys alliance sanofi us sales increases primarily attributed increased prescription demand higher average selling prices demand negatively affected beginning third quarter second quarter launch generic clopidogrel bisulfate generic distribution channel substantially depleted june estimated total us prescription demand clopidogrel bisulfate branded generic increased approximately respectively whereas estimated us prescription demand branded plavix increased respectively table contents international net sales negatively impacted august launch clopidogrel alternative salt clopidogrel beyslate launched germany see item financial statementsnote legal proceedings contingenciesplavix litigation discussion plavix exclusivity litigation us eu avapro avalide known eu aprovelkarvea angiotensin ii receptor blocker treatment hypertension diabetic nephropathy also part sanofi alliance worldwide sales increases primarily attributed higher average selling prices offset declines overall demand total us prescription demand avaproavalide decreased approximately approximately pravachol hmg coa reductase inhibitor treatment hypercholesterolemia reducing risk heart attack worldwide sales decreases attributed continued generic competition us key european markets market exclusivity ended us april eu countries us sales negatively impacted higher retail sales returns previously assumed reyataz protease inhibitor treatment hiv us sales increases primarily due higher prescription demand respectively international sales increase primarily due higher demand across markets europe key driver due june approval frontline treatment growth international revenue attributed increased demand europe latin america sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv includes sustiva antiretroviral drug bulk efavirenz also included combination therapy atripla efavirenez mg emtricitabine mgtenofovir disoproxil fumarate mg product sold joint venture gilead sciences inc worldwide sales increases primarily due higher demand attributed successful launch atripla us july eu december canada october us prescription demand sustiva franchise increased approximately lesser extent higher average selling prices contributed increase net revenues baraclude oral antiviral agent treatment chronic hepatitis b worldwide sales increases primarily due continued growth across markets particularly international markets due successful launch various countries including china february uk germany july france japan september us april continues increased awareness acceptance longterm efficacy safety resistance data evidenced american association study liver disease treatment guidelines recommended baraclude first line treatment option erbitux monoclonal antibody designed exclusively target block epidermal growth factor receptor expressed surface certain cancer cells multiple tumor types well normal cells currently indicated use colorectal cancer head neck cancer erbitux part companys strategic alliance imclone sold company almost exclusively us sales increases primarily due increased demand recent indication usage treatment head neck cancer sales also positively impacted transition broader distribution model resulting higher sales associated initial shipments inventory distributors taxol anticancer agent currently sold almost exclusively nonus markets sales decreases due primarily generic competition japan table contents sprycel oral inhibitor multiple tyrosine kinases treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy including gleevec imatinib meslylate worldwide sales increases primarily due higher demand associated successful launch us july european markets beginning fourth quarter higher us selling prices continued launches russia turkey ixempra microtubule inhibitor treatment patients metastatic locally advanced breast cancer sales increase reflects launch product us october abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder part companys strategic alliance otsuka pharmaceutical co ltd otsuka us sales increases primarily attributed increased demand higher average selling prices prescription demand increased approximately approximately contributing prescription growth new indications certain patients bipolar disorder major depressive disorder international sales increases also primarily attributed increased prescription demand sales growth aided new bipolar indication second quarter eu orencia fusion protein indicated adult patients moderate severe ra inadequate response one currently available treatments mtx antitumor necrosis factor therapy us sales increases primarily due continued growth since launch biologic product us february international sales increase reflects european launch may estimated us prescription change data provided throughout includes information retail mail order channels reflect information channels hospitals institutions longterm care among others estimated prescription data based next generation prescription service ngps version national prescription audit provided ims health ims supplier market research pharmaceutical industry described data provided ims product ims recordkeeping process estimate based ims sampling procedures data subject inherent limitations estimates based sampling may include margin error company calculated estimated total us prescription change based ngps data weightedaverage basis reflect fact mail order prescriptions include greater volume product supplied compared retail prescriptions mail order prescriptions typically reflect day prescription whereas retail prescriptions typically reflect day prescription calculation derived multiplying ngps mail order prescription data factor approximates three adding ngps retail prescriptions company believes calculation estimated total us prescription change based weightedaverage approach respect retail mail order channels provides superior estimate total prescription demand company uses methodology internal demand forecasts company continuously seeks improve quality estimates prescription change amounts ultimate patientconsumer demand review methodologies processes calculation estimates review analysis third parties data used calculations company expects continue review refine methodologies processes calculation estimates continue review analyze third parties data used calculations table contents estimated enduser demand following tables set forth companys key pharmaceutical products sold us pharmaceuticals business years ended december total us net sales period ii change reported us net sales period iii estimated total us prescription change retail mail order channels calculated company based ngps data weightedaverage basis iv months inventory hand wholesale distribution channel year ended december december change us change us months total us net sales net salesa total prescriptions b hand dollars millions plavix avaproavalide pravacholh reyataz sustiva franchise c baraclude erbitux na na na sprycel e ixemprad f na na na abilify orencia g na na na reflects percentage change net sales dollar terms b derived multiplying ngps mail order prescription data factor approximates three adding ngps retail prescriptions c beginning third quarter sustiva franchise total revenue includes sales sustiva well revenue bulk efavirenz included combination therapy atripla change us total prescriptions growth sustiva franchise includes branded sustiva atripla prescription units erbitux orencia ixempra parenterally administered products prescriptionlevel data physicians write prescriptions products e sprycel launched us july f ixempra launched us october g orencia launched us february h negative net sales attributed higher retail returns previously assumed change excess pursuant us securities exchange commission sec consent order described sec consent order company monitors level inventory hand us wholesaler distribution channel outside us direct customer distribution channel company obligated disclose products levels inventory excess one month hand expected demand subject de minimis exception following products estimated levels inventory distribution channel excess one month hand case companys us pharmaceuticals products december case companys international pharmaceuticals nutritionals products september september bufferin salicylatate drug approximately months inventory hand direct customers compared approximately months inventory hand december increased level inventory hand due primarily increased inventory levels china caused distributors preparations national holidays september dafalgan analgesic product sold principally europe approximately months inventory hand compared months inventory hand december previously stated level inventory hand september due primarily private pharmacists purchasing dafalgan approximately every eight weeks seasonality product september videxvidex ec antiviral product approximately months inventory hand direct customers compared months inventory hand december previously stated level inventory hand due primarily government purchasing patterns brazil company contractually obligated provide videxvidex ec brazilian government upon placement order product government terms contract company control inventory levels relating orders table contents us products sold exclusively wholesalers distributors company determines months hand estimates using information respect inventory levels product hand amount outmovement products provided companys three largest wholesalers accounted approximately total gross sales us pharmaceuticals products provided companys distributors factors may influence companys estimates include generic competition seasonality products wholesaler purchases light increases wholesaler list prices new product launches new warehouse openings wholesalers new customer stockings wholesalers addition estimates calculated using thirdparty data represent recordkeeping processes may also reflect estimates pharmaceutical products us sold exclusively wholesalers distributors companys pharmaceuticals business outside us nutritionals business units around world company significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely cases direct customer product level inventory ultimate patientconsumer demand outmovement data exist otherwise available company developed variety methodologies calculate estimates data including using factors historical sales made direct customers thirdparty market research data related prescription trends enduser demand accordingly company relies variety methods estimate direct customer product level inventory calculate months hand business units factors may affect companys estimates include generic competition seasonality products direct customer purchases light price increases new product product presentation launches new warehouse openings direct customers new customer stockings direct customers expected direct customer purchases governmental bidding situations nutritionals composition change nutritional net sales follows vs vs net sales analysis change analysis change total foreign total foreign dollars millions change volume price exchange change volume price exchange us nonus total infant formulas toddlerchildrens nutritionals representing total nutritional net sales respectively follows net sales change dollars millions vs vs infant formulas enfamil toddlerchildrens nutritionals decrease us nutritional net sales primarily due decreased sales infant formulas increase international nutritionals net sales primarily due growth infant formulas childrens nutritionals increase us nutritional net sales primarily due increased sales infant formulas international nutritional net sales increased primarily due growth infant formulas childrens nutritionals table contents geographic areas general companys products available countries world largest markets us france spain canada china japan italy mexico germany companys sales geographic areas based location entity selling product follows net sales change total net sales vs vs dollars millions united states europe middle east africa western hemisphere pacific total see items previously discussed item pharmaceuticals items impacting increase us net sales europe middle east africa sales increases primarily due sales growth major european markets abilify sprycel hiv hepatitis portfolio addition favorable foreign exchange impact sales essentially flat sales growth major european markets sprycel abilify hiv hepatitis portfolio favorable foreign exchange impact offset generic competition pravachol taxol western hemisphere countries sales essentially flat minimum foreign exchange impact sales increases primarily due increased sales plavix canada mexico key nutritional products avaproavalide canada favorable foreign exchange impact increases partially offset discontinued commercialization tequin pacific region sales increases primarily due sales growth baraclude china japan korea key nutritional products throughout region addition favorable foreign exchange impacts respectively addition sales negatively impacted increased generic competition taxol pravachol single country outside us contributed companys total revenues net sales france canada spain japan exceeded million net sales china italy exceeded million mexico million sales table contents expensesgains change net sales vs vs dollars millions costs products sold marketing selling administrative advertising product promotion research development acquired inprocess research development provision restructuring net litigation expense net gain sale product lines businesses equity net income affiliates gain sale imclone shares expense net total expenses net change excess costs products sold improvement costs products sold percentage net sales primarily attributed favorable worldwide pharmaceuticals product sales mix higher us pharmaceuticals average selling prices realized manufacturing savings pti factors partially offset product material price increases costs include manufacturing rationalization charges million related implementation pti net sales compared million rationalization charges recorded net sales improvement costs products sold percentage sales primarily due sales growth higher margin products including plavix marketing selling administrative increase primarily related million increased process standardization costs incurred part pti compared prior period million costs incurred part initial public offering mead johnson higher selling expenses support key products unfavorable foreign exchange impact increase primarily due unfavorable impact foreign exchange higher marketing expenses partially offset lower sales force expenses decrease marketing selling administrative expenses percentage net sales result increased sales growth outpacing expenses managed pti advertising product promotion increase primarily related increased promotions new indications abilify us increased promotion orencia increased expenses international nutritionals business unfavorable foreign exchange impact increase primarily related increased spending directtocustomer advertising plavix abilify orencia expenses support launch ixempra higher spending newer products europe unfavorable foreign exchange impact research development increase primarily related increased licensing upfront milestone payments increased spending pipeline compounds unfavorable foreign exchange impact increase partially offset sharing codevelopment costs alliance partners astrazeneca pfizer table contents increase primarily attributed continued investment latestage compounds developing pipeline disease areas address significant unmet medical needs well increased upfront milestone payments compared detailed increase partially offset sharing codevelopment costs alliance partners astrazeneca pfizer upfront milestone payments made expensed research development totaled million paid primarily exelixis pdl biopharma inc kai charges totaled million paid exelixis pfizer adnexus isis charges totaled million paid exelixis solvay global research development expenses dedicated pharmaceutical products pharmaceutical net sales respectively acquired inprocess research development acquired inprocess research development costs iprd consisted estimated fair value research development acquired part acquisition december immediately expensed acquisition date charge related iprd acquisition kosan whereas charge related iprd obtained acquisition adnexus therapeutics inc adnexus provision restructuring net increase provision restructuring net attributed timing implementation pti announced december expanded july increase attributed charges primarily severance related associated announcement pti december see item financial statementsnote restructuring litigation expense net litigation expenses related reserves settlement principle certain pricing sales investigations partially offset insurance recoveries unrelated matter positive settlement litigation matter additional information litigation matters see item financial statementsnote legal proceedings contingencies gain sale product lines businesses gain primarily attributable sale mature brands businesses egypt gain attributed sale bufferin excedrin brands japan asia excluding china taiwan certain oceanic countries well certain assets related us dermatology products gain attributed sale inventory patent intellectual property rights related dovonex additional information transactions see item financial statementsnote acquisitions divestitures equity net income affiliates equity net income affiliates principally related companys international joint venture sanofi increases correlated increases international plavix sales additional information equity net income affiliates see item financial statementsnote alliances collaborations gain sale imclone shares gain sale imclone shares attributed companys receipt approximately billion cash tendering investment imclone see item financial statementsnote alliances collaborations detail table contents expense net components expense net follows year ended december dollars millions interest expense interest income ars impairment charge gainloss debt buyback termination interest rate swap agreements foreign exchange transaction gainslosses net expense net interest expense decreases primarily due decreases interest rates interest income relates primarily interest earned cash cash equivalents investments marketable securities decrease interest income primarily due change mix companys shortterm investment portfolio well decrease rate return shortterm investments including us treasury bills compared prior year ars impairment charge attributed companys auction rate securities ars addition million loss sale ars recognized included net see item financial statementsnote cash cash equivalents marketable securities detail gain debt buyback attributed repurchase certain debt monetization certain interest rate swaps due recent appreciation value see item financial statements note shortterm borrowing longterm debt information foreign exchange transaction gains attributed strengthening us dollar impact nonqualifying foreign exchange hedges remeasurement nonfunctional currency denominated transactions compared prior year net includes income thirdparty contract manufacturing certain royalty income expense debt retirement costs gains losses sale property plant equipment gains losses sale marketable securities insurance recoveries deferred income recognized certain litigation matters convatec medical imaging net transitional service fees amortization certain upfront payments related companys alliances proceeds swap terminations pension curtailments see item financial statements note expense net information table contents years ended december company recorded following specified expenseincome items affected comparability results periods presented herein discussion items see item financial statementsnote alliances collaborations note restructuring note acquisitions divestitures note income taxes note cash cash equivalents marketable securities note shortterm borrowings longterm debt note legal proceedings contingencies acquired gain marketing inprocess provision sale gain dollars millions cost selling research research litigation product sale products restructuring expense lines imclone expense year ended december sold administrative development development net net businesses shares net total productivity transformation initiative downsizing streamlining worldwide operations accelerated depreciation asset impairment shutdown costs pension settlementscurtailments process standardization implementation costs gain sale leaseback properties termination lease contracts gain sale product lines businesses litigation settlement insurance recovery mead johnson charges product liability upfront milestone payments acquired inprocess research development asset impairment ars impairment charges loss sale debt buyback swap terminations gain sale imclone shares income taxes items decrease net earnings continuing operations table contents dollars millions gain marketing acquired provision sale cost selling research inprocess litigation product products research restructuring expense lines expense year ended december sold administrative development development net net businesses net total productivity transformation initiative downsizing streamlining worldwide operations accelerated depreciation asset impairment process standardization implementation costs litigation settlement insurance recovery product liability upfront milestone payments acquired inprocess research development ars impairment charges downsizing streamlining worldwide operations accelerated depreciation asset impairment contract termination gain sale properties product lines businesses income taxes items change estimate taxes prior year specified item decrease net earnings continuing operations dollars millions gain sale cost marketing research provision litigation product products selling restructuring expense lines expense year ended december sold administrative development net net businesses net total litigation matters pharmaceutical pricing sales litigation product liability claim damages commercial litigations insurance recovery debt retirement costs accelerated depreciation asset impairment contract termination upfront milestone payments downsizing streamlining worldwide operations gain sale product lines businesses income taxes items change estimate taxes prior year specified items decrease net earnings continuing operations specified items presented reflected segment results follows dollars millions pharmaceuticals nutritionals total segments corporateother total includes million gain sale imclone shares table contents earnings continuing operations income taxes minority interest earnings continuing operations income taxes minority interest change segment net sales vs vs dollars millions pharmaceuticals nutritionals total segments corporateother total pharmaceuticals earnings increased primarily due increased sales plavix abilify hiv hepatitis portfolio orencia increase segment income percentage segment net sales primarily due similar factors discussed analysis consolidated expenses favorable product sales mix higher average selling prices realized manufacturing savings pti contributed reduction costs products sold percentage net sales results pti also contributed reduction marketing selling administrative expense percentage net sales earnings increased primarily due increased plavix sales strong sales growth key products increase segment income percentage segment net sales similar reasons discussed although lesser extent pti beginning nutritionals earnings increased primarily due increased international net sales increase segment income percentage segment net sales primarily due growth rate net sales exceeding growth rate marketing selling administrative expenses research development well bad debt charge distributor insolvency factors partially offset higher dairy prices advertising promotion expenses additional legal accounting consulting expenses incurred preparation initial public offering earnings increased primarily due growth key products decrease segment income percentage segment net sales primarily due higher dairy prices unfavorable product mix bad debt charge distributor insolvency corporateother earnings continuing operations income taxes minority interest reported corporateother consists dollars millions corporate administrative expense stockbased compensation expense provision restructuring net litigation expense net interest expense interest income ars impairment charge gain sale imclone shares gain sale product lines businesses gainloss debt buyback termination interest rate swap agreements total corporateother earnings continuing operations income taxes minority interest table contents income taxes effective income tax rate earnings continuing operations income taxes minority interest compared increase effective tax rate primarily due higher pretax income us including gain sale imclone earnings mix high tax jurisdictions partially offsetting impacts lower nondeductible charges acquired inprocess research development expenses lower ars impairment charges little tax benefit tax rate favorably impacted benefit million tax related final settlement audit internal revenue service tax rate unfavorably impacted impairment companys investment certain ars little tax benefit nondeductible writeoff acquired inprocess research development expenses related acquisition adnexus partially offset tax benefit million first quarter due favorable resolution certain tax matters internal revenue service related deductibility litigation settlement expenses us foreign tax credits claimed effective tax rate unfavorably impacted elimination tax benefits section internal revenue code treatment provisions portion certain litigation reserves nondeductible partially offset favorable us tax legislation enacted related tax treatment certain intercompany transactions amongst companys foreign subsidiaries implementation tax planning strategies related utilization certain charitable contributions company recognized significant deferred tax assets december related us federal foreign tax credit carryforwards approximately million us federal research development tax credit carryforwards approximately million us federal charitable contribution carryforwards fully utilized due gains related convatec medical imaging divestitures foreign tax credit research development tax credit carryforwards expire varying amounts beginning foreign tax credit research development tax credit carryforwards reduced due derecognition fin convatec medical imaging divestitures resulted significant reduction foreign tax credit research development tax credit carryforwards realization foreign tax credit research development tax credit carryforwards dependent generating sufficient domesticsourced taxable income prior expiration although realization assured management believes likely deferred tax assets realized minority interest minority interest primarily related companys partnership sanofi territory covering americas related plavix sales increases minority interest correspond increased sales plavix dollars millions sanofi partnership others minority interest pretax income taxes minority interest net taxes financial position liquidity capital resources company continues maintain sufficient level working capital approximately billion december billion december future periods company expects cash generated us operations together existing cash cash equivalents marketable securities borrowings capital markets sufficient cover cash needs working capital capital expenditures company expects include investments facilities increase maintain companys capacity provide biologics commercial scale strategic alliances acquisitions milestone payments dividends paid us cash cash equivalents marketable securities conversion working capital items borrowings expected fund near term operations outside us december company obtained billion five year revolving credit facility syndicate lenders extendable anniversary date consent lenders facility contains customary terms conditions including financial covenant whereby ratio consolidated debt consolidated capital exceed end quarter company compliance covenant since inception new facility borrowings outstanding revolving credit facility december february mead johnson entered three year syndicated revolving credit facility agreement credit facility unsecured provides borrowings letters credit million table contents net financial assets net financial asset position december follows dollars millions financial assets cash cash equivalents marketable securitiescurrent total financial assets debt shortterm borrowings including current portion longterm debt longterm debt total debt net cashdebt net cashdebt net cashdebt position december improved due proceeds billion divestiture convatec medical imaging businesses proceeds billion sale imclone shares cash generated operating activities billion adequate fund dividend payments billion well capital expenditure payments million investments following table summarizes companys carrying value related unrealized lossgain position current noncurrent marketable securities include us dollardenominated floating rate securities frs ars accounted available sale debt securities see item financial statementsnote cash cash equivalents marketable securities discussion company frs ars portfolio including related cost basis fair value investment december december unrealized unrealized carrying lossgain carrying lossgain value accumulated oci value accumulated oci dollars millions current available sale floating rate securities us treasury bills total current noncurrent available sale auction rate securities floating rate securities total noncurrent company received million principal par primarily frs matured march temporarily reduced carrying value remaining frs million million unrealized loss accumulated comprehensive income oci addition company reclassified million remaining frs maturity dates beyond current assets noncurrent assets due liquidity concerns continued uncertainty capital markets company received million primarily connection sale ars carrying value million resulting loss million addition million otherthantemporary impairment charge recognized including million previously determined temporary december impairment charge required analysis otherthantemporary impairment factors including severity duration decline value future prospects issuer companys ability intent hold securities recovery ars sold securities generally backed subprime mortgages collateralized debt obligations structured credit ars remaining december represents interests insurance securitizations lesser extent structured credit table contents uncertainties credit capital markets continue markets deteriorate company experiences additional ratings downgrades investments portfolio including frs ars company may incur additional impairments investment portfolio could negatively affect companys financial condition reported earnings company believes based companys current level cash cash equivalents marketable securities expected operating cash flows current lack liquidity credit capital markets material impact companys liquidity cash flow financial flexibility ability fund operations including dividend credit ratings moodys investors service moodys longterm shortterm credit ratings company currently prime respectively moodys revised longterm credit rating outlook negative stable standard poors sp longterm shortterm credit ratings company currently respectively sps longterm credit rating remains stable outlook fitch ratings fitch longterm shortterm credit ratings company currently f respectively fitchs longterm credit rating remains stable outlook working capital following discussion working capital december dollars millions working capital increase working capital billion december december impacted proceeds sale convatec business billion proceeds sale imclone shares billion proceeds issuance notes due billion notes due million cash flows following discussion cash flow activities year ended december dollars millions cash flow provided byused operating activities investing activities financing activities operating activities cash flow operating activities represents cash receipts cash disbursements related activities company investing activities financing activities operating cash flow derived adjusting net earnings noncash operating items depreciation amortization impairment charges stockbased compensation charges gains losses attributed investing financing activities gains losses sale product lines businesses changes operating assets liabilities reflect timing differences receipt payment cash associated transactions recognized results operations companys operating cash flow grown consistently throughout three years ended december increases net income attributed reasons noted throughout mda continue directly impact operating cash flows evident net income adjusted noncash operating items well gains losses attributed investing financing activities amounted billion billion billion amounts exclude changes operating assets liabilities discussed net impact changes operating assets liabilities discussed detail include impact changes receivables inventories deferred income accounts payable income taxes receivablepayable operating assets liabilities company continues maximize operating cash flows recently announced working capital initiative designed continue improve working capital items directly affected changes sales volume accounts receivable inventories accounts payable table contents changes operating assets resulted net cash inflow million impacted cash inflows income tax payablereceivable million includes impact receipt million tax refund including interest related prior year foreign tax credit carryback claim cash inflows accounts payables million primarily attributed timing vendor alliance payments cash inflows inventory million primarily attributed utilization inventories built prior year new product launches strategic builds existing products launches including new indications abilify cash inflows deferred income million primarily due receipt upfront milestone payments alliance partners cash outflows operating assets liabilities million primarily due net litigation related payments made current period million attributed settlement certain pricing sales litigation accrued prior periods pension funding excess current year expense million increase noncurrent inventory million cash outflows accounts receivables million attributed increased sales changes operating assets resulted net cash outflow million impacted cash outflows accounts receivable million primarily attributed increased sales cash outflows us foreign income taxes payable million primarily attributed tax payments included settlement payments associated various tax issues irs audit cash inflows deferred income million primarily due receipt upfront milestone payments alliance partners including pfizer astrazeneca cash inflows operating assets liabilities million primarily due increases accrued royalties attributed increased plavix sales increases accrued salaries bonuses due timing payments partially offset cash outflows primarily related litigation related payments million settlement pricing sales litigation accrued prior periods cash inflows accounts payables million include impact increased purchases raw materials planned inventory buildup changes operating assets resulted net cash outflow million impacted cash outflows operating assets liabilities million primarily due pay accrued rebates returns primarily resulting exclusivity loss pravachol volume erosion highly rebated paraplatin taxol lower plavix volumes reduced royalties lower plavix sales additions litigation settlement accrual related pricing sales litigation settlements primarily offset net litigation related payments related matters accrued prior years million cash outflows accounts payable million primarily due lower purchases pravachol raw materials due loss pravachol exclusivity significant reduction payables early resulting lower payment invoices december cash inflows accounts receivables million primarily due lower plavix sales loss exclusivity pravachol table contents investing activities net cash provided investing activities billion included proceeds divestiture convatec billion medical imaging million mature brands business egypt million proceeds tendering companys shares imclone billion proceeds sale leaseback paris france facility million capital expenditures million included expenditures associated construction companys biologic facility devens massachusetts acquisition kosan million net cash used investing activities million included capital expenditures million acquisition adnexus million net proceeds sale marketable securities million proceeds sales bufferin excedrin brands japan asia excluding china taiwan certain oceanic countries us dermatology products million net cash provided investing activities million included net proceeds sale marketable securities million proceeds disposal properties connection sale lease back administrative facilities new jersey million proceeds sale various product assets primarily sale several assets related dovonex million capital expenditures million milestone payments primarily related imclone million financing activities net cash used financing activities billion included dividend payments billion redemption floating rate convertible senior debentures due billion repayment notes due august million yen notes due million repurchase companys notes million net proceeds issuance notes due million notes due billion net proceeds termination interest rate swap agreements million net proceeds stock option exercises million reflects exercise fewer stock options due decrease average stock price compared prior periods net cash used financing activities billion included dividend payments billion repayment floating rate bank facility billion proceeds exercise stock options million net cash used financing activities billion included debt payments associated early retirement notes due billion floating rate bank facility billion dividend payments billion proceeds issuance notes due billion euro notes billion table contents dividends declared per common share december company declared quarterly dividend per common share indicated dividend full year per share dividend decisions made quarterly basis companys board directors contractual obligations payments due period companys contractual obligations december follows obligations expiring period dollars millions total later years shortterm borrowings longterm debt interest longterm debt operating leases purchase obligations standby letters creditperformance guarantees uncertain tax positions longterm liabilities total current portion longterm debt obligations included shortterm borrowings companys consolidated balance sheet december balances approximate outstanding nominal longterm debt values includes estimated future interest payments shortterm longterm debt also includes accrued interest payable recorded consolidated balance sheets consists primarily accrual interest shortterm longterm debt well accrual periodic cash settlements derivatives netted counterparty due uncertainty related timing reversal uncertain tax positions shortterm uncertain tax benefits provided table include minority interest million table excludes future contributions company pension postretirement postemployment benefit plans required contributions contingent upon numerous factors including minimum regulatory funding requirements funded status plan due uncertainty future obligations excluded table contributions us international plans expected million see item financial statementsnote pension postretirement postemployment benefits detail addition company committed make approximately billion potential future research development milestone payments third parties part inlicensing development programs payments agreements generally become due payable upon achievement certain developmental regulatory milestones specific timing predicted achievement milestones neither probable reasonably estimable contingencies recorded companys consolidated balance sheets discussion contractual obligations see item financial statementsnote shortterm borrowings longterm debt note financial instruments note leases note pension postretirement postemployment liabilities sec consent order previously disclosed august company entered final settlement sec concluding investigation concerning certain wholesaler inventory accounting matters settlement reached consent copy attached exhibit companys quarterly report form q period ended september terms consent company agreed subject certain defined exceptions limit sales products sold direct customers including wholesalers distributors hospitals retail outlets pharmacies government purchasers based expected demand amounts exceed approximately one month inventory hand without making timely public disclosure change practice company also agreed consent certain measures implemented including establishing formal review certification process annual quarterly reports filed sec b establishing business risk disclosure group c retaining outside consultant comprehensively study help reengineer companys accounting financial reporting processes publicly disclosing sales incentives offered direct customers purpose inducing purchase products excess expected demand e ensuring companys budget process gives appropriate weight inputs come bottom top top bottom adequately documenting process table contents company established companywide policy limit sales direct customers purpose complying consent policy includes adoption various procedures monitor limit sales direct customers accordance terms consent procedures include governance process escalate appropriate management levels potential questions concerns regarding compliance policy timely resolution questions concerns addition compliance policy monitored regular basis company maintains inventory management agreements imas us pharmaceutical wholesalers account nearly total gross sales us pharmaceutical products current terms imas companys three largest wholesaler customers provide company weekly information respect months hand productlevel inventories amount outmovement products three wholesalers currently account approximately total gross sales us pharmaceuticals products inventory information received wholesalers together companys internal information used estimate months hand product level inventories wholesalers company estimates months hand product inventory levels us pharmaceutical businesss wholesaler customers three largest wholesalers extrapolating months hand calculated three largest wholesalers contrast companys pharmaceutical business outside us nutritionals business units around world company significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely accordingly company relies variety methods estimate months hand product level inventories business units company believes abovedescribed procedures provide reasonable basis ensure compliance consent recently issued accounting standards following new accounting pronouncements critical companys financial statements discussed item financial statementsnote accounting policiesrecently issued accounting standards considered evaluated required application impact eitf issue accounting nonrefundable advance payments goods services received use future research development activities sfas fair value option financial assets financial liabilities sfas fair value measurements sfas disclosures derivative instruments hedging activities eitf issue accounting collaborative arrangements related development commercialization intellectual property sfas noncontrolling interests consolidated financial statementsan amendment arb sfas r business combinations critical accounting policies company prepares financial statements conformity accounting principles generally accepted us preparation financial statements conformity us generally accepted accounting principles gaap requires use estimates assumptions affect reported amounts assets liabilities including disclosure contingent assets contingent liabilities date financial statements reported amounts revenue expenses reporting period companys critical accounting policies important companys financial condition results operations require difficult subjective complex judgments part management application often result need make estimates effect matters inherently uncertain uncertainty factors surrounding estimates judgments used preparation consolidated financial statements actual results may vary estimates company believes following discussion represents critical accounting policies management discussed companys critical accounting policies audit committee board directors revenue recognition company recognizes revenue accordance staff accounting bulletin sab revenue recognition financial statements amended sab revenue recognition companys accounting policy revenue recognition substantial impact reported results relies certain estimates require difficult subjective complex judgments part management company recognizes revenue net grosstonet sales adjustments discussed involve significant estimates judgments title substantially risks rewards ownership transferred customer generally occurs date shipment table contents case new products product introduction extension existing line product company determines products similar therapeutic category company determines new product dissimilar characteristics existing products company reliably estimate expected returns new product company defers recognition revenue right return longer exists company developed sufficient historical experience estimate sales returns discussions revenue recognition see item financial statementsnote accounting policiesrevenue recognition sales rebate return accruals grosstonet sales adjustments company following significant categories grosstonet sales adjustments prime vendor chargebacks wic rebates managed health care rebates contract discounts medicaid rebates cash discounts sales returns adjustments involve significant estimates judgments require company use information external sources company accounts grosstonet sales adjustments accordance eitf issue accounting consideration given vendor customer including reseller vendors products sfas revenue recognition right return exists applicable see net sales section reconciliation companys gross sales net sales significant category grosstonet sales adjustment prime vendor chargebacks companys us businesses participate prime vendor programs government entities significant us department defense us department veterans affairs parties whereby pricing products extended wholesaler list price participating entities entities purchase products wholesalers lower prime vendor price wholesalers charge difference acquisition cost lower prime vendor price back company company accounts prime vendor chargebacks reducing accounts receivable amount equal companys estimate chargeback claims attributable sale company determines estimate prime vendor chargebacks primarily based historical experience regarding prime vendor chargebacks current contract prices prime vendor programs company considers prime vendor payments levels inventory distribution channel companys claim processing time lag adjusts reduction accounts receivable periodically throughout quarter reflect actual experience wic rebates companys us nutritionals business participates competitive bidding basis nutrition programs sponsored states tribal governments commonwealth puerto rico us territories wic programs company reimburses entities difference wholesaler list price contract price eligible products company accounts wic rebates establishing accrual amount equal companys estimate wic rebate claims attributable sale company determines estimate wic rebate accrual primarily based historical experience regarding wic rebates current contract prices wic programs company considers levels inventory distribution channel new wic contracts terminated wic contracts changes existing wic contracts wic participation adjusts accrual periodically throughout quarter reflect actual experience managed health care rebates contract discounts company offers rebates discounts managed health care organizations us manage prescription drug programs medicare advantage prescription drug plans covering medicare part drug benefit addition commercial plans well globally contract counterparties hospitals group purchasing organizations addition company pays rebates us department defense tricare retail pharmacy refund program company accounts managed health care rebates contract discounts establishing accrual amount equal companys estimate managed health care rebates contract discounts attributable sale company determines estimate managed health care rebates contract discounts accrual primarily based historical experience regarding rebates discounts current contract prices company considers sales performance products subject managed health care rebates contract discounts levels inventory distribution channel adjusts accrual periodically throughout quarter reflect actual experience table contents medicaid rebates companys us businesses participate state governmentmanaged medicaid programs well certain qualifying federal state government programs whereby discounts rebates provided participating state local government entities discounts rebates provided latter programs included companys medicaid rebate accrual considered medicaid rebates purposes discussion company accounts medicaid rebates establishing accrual amount equal companys estimate medicaid rebate claims attributable sale company determines estimate medicaid rebates accrual primarily based historical experience regarding medicaid rebates well expansion prospective basis participation nonmandatory aspects qualifying federal state government programs legal interpretations applicable laws related medicaid qualifying federal state government programs new information regarding changes medicaid programs regulations guidelines would impact amount rebates company considers outstanding medicaid claims medicaid payments levels inventory distribution channel adjusts accrual periodically throughout quarter reflect actual experience cash discounts us certain countries company offers cash discounts approximating sales price incentive prompt payment company accounts cash discounts reducing accounts receivable full amount discounts company considers payment performance adjusts accrual reflect actual experience sales returns company accounts sales returns accordance sfas revenue recognition right return exists establishing accrual amount equal companys estimate sales recorded related products expected returned provision sales returns million million million approximates gross sales three years returns established products company determines estimate sales return accrual primarily based historical experience regarding sales returns also considers factors could impact sales returns factors include levels inventory distribution channel estimated shelf life product recalls product discontinuances price changes competitive products introductions generic products introductions competitive new products company considers factors adjusts accrual periodically throughout quarter reflect actual experience event product recall product discontinuance company considers reasons impact actions adjusts sales return accrual appropriate taking account historical experience estimated levels inventory distribution channel product discontinuances estimates continuing demand sales returns accruals new products estimated primarily based historical sales returns experience similar products within line product within similar therapeutic category limited circumstances new product extension existing line product company historical experience products similar therapeutic category company reliably estimate expected returns new product company defers recognition revenue right return longer exists company developed sufficient historical experience estimate sales returns company also considers shelf life new products determines whether believes adjustment sales return accrual appropriate shelf life connection new products tends shorter shelf life established products company may still developing optimal manufacturing process new product would lengthen shelf life addition higher launch quantities may manufactured advance launch date ensure sufficient supply exists satisfy market demand cases company assesses reduced shelf life together estimated levels inventory distribution channel projected demand determines whether believes adjustment sales return accrual appropriate adjustments addition grosstonet sales adjustments described company makes grosstonet sales adjustments example company offers sales discounts significantly nonus businesses also offers consumer coupons rebates significantly us nutritionals pharmaceuticals businesses addition number countries outside us including certain major european countries company provides rebates government entities company generally accounts grosstonet adjustments establishing accrual amount equal companys estimate adjustments attributable sale company generally determines estimates accruals grosstonet sales adjustments primarily based historical experience performance commitments government entities relevant factors including estimated levels inventory distribution channel adjusts accruals periodically throughout quarter reflect actual experience table contents use information external sources company uses information external sources estimate grosstonet sales adjustments companys estimates inventory wholesalers based projected prescription demandbased sales products historical inventory experience well companys analysis thirdparty information including written oral information obtained certain wholesalers respect inventory levels sellthrough customers third party market research data companys internal information inventory information received wholesalers product recordkeeping process excludes inventory held intermediaries sell retailers hospitals company receives information ims supplier market research pharmaceutical industry uses project prescription demandbased sales many us pharmaceutical products ims refined improved ngps projection methodology fully rolled ngps version national prescription audit subscribers resulted newly revised volume estimates historic time periods therefore since first quarter company used new ims standard ngps version projection methodology applied ngps version data reporting prescription growth market shares periods presented annual report company also continued practice combining retail mail prescription volume retailequivalent basis company uses methodology internal demand forecasts company also uses information external sources identify prescription trends patient demand average selling prices companys estimates subject inherent limitations estimates rely thirdparty information certain thirdparty information form estimates reflect limitations including lags date thirdparty information generated date company receives thirdparty information retirement benefits companys pension plans postretirement benefit plans accounted using actuarial valuations management required make significant subjective judgments number actuarial assumptions including discount rates salary growth longterm return plan assets retirement turnover health care cost trend rates mortality rates depending assumptions estimates used pension postretirement benefit expense could vary within range outcomes material effect reported earnings addition assumptions materially affect projected benefit obligations future cash funding company adopted sfas employers accounting defined benefit pension postretirement plansan amendment fasb statements r year ended december adoption accounting pronouncement resulted billion reduction accumulated comprehensive income stockholders equity million reduction total assets million increase total liabilities adoption sfas impact companys results operations cash flows companys key assumptions used calculating cost pension benefits discount rate rate compensation increase expected longterm rate return plan assets company consultation actuaries evaluates key actuarial assumptions assumptions used calculating cost pension benefits retirement turnover mortality rates based expectations actual experience appropriate determines assumptions december year calculate liability information date pension expense following year depending assumptions used pension expense could vary within range outcomes material effect reported earnings addition assumptions materially affect projected benefit obligations future cash funding actual results given year may differ estimated economic factors determining discount rate company uses yield high quality corporate bonds coincides cash flows plans estimated payouts citigroup median yield curve used determining discount rate us plans assumed rate compensation increase used company determining future pension obligations reflects estimate change actual future compensation levels due general price levels productivity seniority factors us plans pension expense determined using assumed discount rate assumed rate compensation increase present value benefit obligations december us plans determined using assumed discount rate assumed rate compensation increase assumed discount rate used determining us plans pension expense reduced expense would increased approximately million assumed rate compensation increase used determining us plans pension expense reduced expense would decreased approximately million assumed discount rate used determining projected benefit obligation december reduced projected benefit obligation would increased million table contents determining expected longterm rate return plan assets company estimates returns individual asset classes input external advisors company also considers longterm historical returns including actual performance compared benchmarks similar investments us plans pension expense determined using expected longterm rate return plan assets expected longterm rate return plan assets used determining us plans pension expense reduced expense would increased million detailed discussion retirement benefits see item financial statementsnote pension postretirement postemployment liabilities acquisitions companys consolidated financial statements results operations reflect acquired business completion acquisition acquired businesses accounted using purchase method accounting requires purchase price allocated net assets acquired respective fair values excess purchase price estimated fair values net assets acquired recorded goodwill amounts allocated acquired iprd expensed date acquisition judgments made determining estimated fair value assigned class assets acquired liabilities assumed well asset lives materially impact results operations several methods used determine fair value assets acquired liabilities assumed intangible assets including iprd typically use income method method starts forecast expected future net cash flows cash flows adjusted present value applying appropriate discount rate reflects risk factors associated cash flow streams significant estimates assumptions inherent income method methods include amount timing projected future cash flows amount timing projected costs develop iprd commercially viable products discount rate selected measure risks inherent future cash flows assessment assets life cycle competitive trends impacting asset including consideration technical legal regulatory economic barriers entry well expected changes standards practice indications addressed asset determining useful life intangible asset also requires judgment different types intangible assets different useful lives example useful life right associated pharmaceutical products exclusive patent finite result amortization expense recognized results operations determinable period detailed discussion acquired inprocess research development see item financial statementsnote accounting policiesacquired process research development impairment longlived assets company periodically evaluates whether current facts circumstances indicate carrying value depreciable assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows produced longlived asset appropriate grouping assets compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques including discounted value estimated future cash flows company reports asset disposed lower carrying value estimated net realizable value goodwill tested least annually impairment using twostep process first step identify potential impairment second step measures amount impairment loss goodwill deemed impaired carrying amount reporting units goodwill exceeds estimated fair value longlived assets tested impairment using onestep process consists comparison fair value carrying value asset assets deemed impaired net book value exceeds estimated fair value estimates future cash flows based reasonable supportable assumptions projections require managements judgment changes key assumptions companys businesses prospects changes market conditions could result impairment charge table contents impairment charges longlived assets million million million discussions impairment longlived assets see item financial statementsnote accounting policiesimpairment longlived assets goodwill intangible assets equity investments company reviews equity investments impairment based determination whether decline market value investment companys carrying value temporary making determination company considers apb opinion equity method accounting investments common stock related interpretations set forth factors evaluated determining whether loss value recognized including companys ability hold investment market price market price fluctuations investments publicly traded shares inability investee sustain earnings capacity would justify carrying amount investment companys previous investment imclone subject accounting discussion companys investment imclone see item financial statementsnote alliances collaborations discussions equity investments see item financial statementsnote accounting policiesinvestments note alliances collaborations marketable securities companys marketable securities december consisted us treasury bills frs ars due lack availability observable market quotes companys investment portfolio frs ars company utilizes valuation models including based expected cash flow streams collateral values including assessments counterparty credit quality default risk underlying security discount rates overall capital market liquidity valuation subject uncertainties difficult predict factors may impact companys valuation include changes credit ratings securities well underlying assets supporting securities rates default underlying assets underlying collateral value discount rates counterparty risk ongoing strength quality market credit liquidity considerable amount judgment estimation applied valuation frs ars addition company also applies judgment determining whether marketable securities otherthantemporarily impaired company typically considers severity duration decline future prospects issuer companys ability intent hold security recovery otherthantemporary impairment charges related ars million million respectively carrying value ars million december credit capital markets continued deteriorate uncertainties markets continue markets deteriorate company experiences additional ratings downgrades investments portfolio including ars company may incur additional impairment charges discussions marketable securities frs ars see item financial statementsnote fair value measurement note cash cash equivalents marketable securities restructuring streamline operations rationalize manufacturing facilities company periodically recorded restructuring charges result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place actual results could vary estimates adjustments reflect changes estimates restructuring actions taken prior periods resulted increase million reduction million million discussions restructuring see item financial statementsnote accounting policiesrestructuring note restructuring contingencies normal course business company subject contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability accordance sfas accounting contingencies company records table contents accruals contingencies probable liability incurred amount loss reasonably estimated estimates subject uncertainties difficult predict actual results could vary estimates discussions contingencies see item financial statementsnote accounting policiescontingencies note income taxes note legal proceedings contingencies income taxes provision income taxes determined using asset liability approach accounting income taxes approach deferred taxes represent future tax consequences expected occur reported amounts assets liabilities recovered paid provision income taxes represents income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax bases companys assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recorded reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made company net deferred tax assets billion billion december respectively net valuation allowances billion billion company recognized significant deferred tax assets december related us federal foreign tax credit carryforwards million us federal research development tax credit carryforwards million realization tax credit carryforwards dependent generating sufficient domestic sourced taxable income prior expiration although realization assured management believes likely deferred tax assets realized company establishes liabilities possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known discussions income taxes see item financial statementsnote accounting policiesincome taxes note income taxes special note regarding forwardlooking statements annual report written oral statements company makes time time contain certain forwardlooking statements within meaning section securities act section e securities exchange act identify forwardlooking statements fact use words expect anticipate estimate target may project guidance intend plan believe words terms similar meaning expression connection discussion future operating financial performance one also identify forwardlooking statements fact relate strictly historical current facts forwardlooking statements based current expectations involve inherent risks uncertainties including factors could delay divert change could cause actual outcomes differ materially current expectations statements likely relate among things companys goals plans projections regarding financial position results operations cash flows market position product development product approvals sales efforts expenses performance results current anticipated products outcome contingencies legal proceedings financial results based current expectations involve inherent risks uncertainties including internal external factors could delay divert change next several years company included important factors cautionary statements included annual report particularly item risk factors company believes could cause actual results differ materially forwardlooking statement although company believes prudent plans assumptions assurance given goal plan set forth forwardlooking statements achieved readers cautioned place undue reliance statements speak date made company undertakes obligation release publicly revisions forwardlooking statements result new information future events otherwise table contents item quantitative qualitative disclosures market risk company exposed market risk due changes currency exchange rates interest rates lesser extent natural gas pricing reduce risk company enters certain derivative financial instruments available costeffective basis hedge underlying economic exposure companys primary net foreign currency translation exposures euro japanese yen canadian dollar chinese renminbi mexican peso manage exposures company utilizes foreign currency contracts subject cash flow hedge accounting treatment instruments managed consolidated basis efficiently net exposures thus take advantage natural offsets company also uses derivative instruments part interest rate risk management strategy derivative instruments used comprised principally fixedtofloating rate interest swaps subject fairvalue hedge accounting treatment addition companys financial instruments including derivatives subject counterparty credit risk company considers part overall fair value measurement derivative financial instruments used speculative purposes foreign exchange risk significant portion companys revenues earnings exposed changes foreign currency rates addition company exposed foreign exchange transaction risk arises nonfunctional currency denominated assets liabilities order manage risk company uses foreign exchange forward contracts offset exposure certain assets liabilities earnings denominated certain foreign currencies foreign exchange forward contracts designated hedges therefore changes fair value derivatives recognized earnings expense net occur addition company utilizes foreign currency contracts manage foreign exchange risk primarily arises certain intercompany transactions designates derivative instruments foreign currency cash flow hedges appropriate notional amounts companys foreign exchange derivative contracts billion billion december respectively derivatives majority qualify hedges future anticipated cash flows effective portion changes fair value temporarily deferred accumulated oci recognized earnings hedged item affects earnings company estimates appreciation depreciation underlying currencies hedged levels us dollar december variables held constant would decrease million increase million respectively fair value foreign exchange forward contracts held december company also exposed translation risk nonus dollardenominated net assets order manage risk company uses nonus dollar borrowings primarily million notes due million notes due hedge foreign currency exposures companys net investment certain foreign affiliates nonus dollar borrowings designated hedges net investments effective portion foreign exchange gains losses hedges recorded part foreign currency translation component accumulated oci additional information see item financial statementsnote financial instruments interest rate risk company uses interest rate swaps part interest rate risk management strategy interest rate swaps used principally fixedtofloating rate swaps designated fairvalue hedges sfas accounting derivative instruments hedging activities requires interest rate swaps qualify fairvalue hedge accounting well underlying debt reported fair value swaps underlying debt revalued resulting million increase noncurrent assets longterm debt december swaps generally held maturity intended create appropriate balance fixed floating rate debt company company estimates increase decrease basis points shortterm long term interest rates would decrease increase fair value companys interest rate swaps million excluding effects counterparty credit risk additional information see item financial statementsnote fair value measurements note cash cash equivalents marketable securities note shortterm borrowings longterm debt note financial instruments table contents bristolmyers squibb company consolidated statements earnings dollars shares millions except per share data item financial statements supplementary data year ended december earnings net sales costs products sold marketing selling administrative advertising product promotion research development acquired inprocess research development provision restructuring net litigation expense net gain sale product lines businesses equity net income affiliates gain sale imclone shares expense net total expenses net earnings continuing operations income taxes minority interest provision income taxes minority interest net taxes net earnings continuing operations discontinued operations earnings net taxes gain disposal net taxes net earnings earnings per common share basic net earnings continuing operations discontinued operations earnings net taxes gain disposal net taxes net earnings per common share diluted net earnings continuing operations discontinued operations earnings net taxes gain disposal net taxes net earnings per common share average common shares outstanding basic diluted dividends declared per common share accompanying notes integral part financial statements table contents bristolmyers squibb company consolidated statements comprehensive income retained earnings dollars millions year ended december comprehensive income net earnings comprehensive incomeloss foreign currency translation foreign currency translation reclassified net earnings due business divestitures foreign currency translation hedge net investment derivatives qualifying cash flow hedges net tax derivatives qualifying cash flow hedges reclassified net earnings net tax minimum pension liability adjustment net tax pension postretirement benefits net tax pension postretirement benefits reclassified net earnings net tax available sale securities net tax available sale securities reclassified net earnings net tax total comprehensive lossincome comprehensive income retained earnings retained earnings january cumulative effect adoption fin net earnings cash dividends declared retained earnings december accompanying notes integral part financial statements table contents bristolmyers squibb company consolidated balance sheets dollars millions except share per share data december assets current assets cash cash equivalents marketable securities receivables net allowances inventories net deferred income taxes net valuation allowances prepaid expenses assets held sale total current assets property plant equipment net goodwill intangible assets net deferred income taxes net valuation allowances assets total assets liabilities current liabilities shortterm borrowings accounts payable accrued expenses deferred income accrued rebates returns us foreign income taxes payable dividends payable accrued litigation liabilities liabilities related assets held sale total current liabilities pension postretirement postemployment liabilities deferred income us foreign income taxes payable liabilities longterm debt total liabilities commitments contingencies note stockholders equity preferred stock convertible series par value per share authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares billion issued outstanding capital excess par value stock restricted stock accumulated comprehensive loss retained earnings less cost treasury stock million common shares total stockholders equity total liabilities stockholders equity accompanying notes integral part financial statements table contents bristolmyers squibb company consolidated statements cash flows dollars millions year ended december cash flows operating activities net earnings adjustments reconcile net earnings net cash provided operating activities depreciation amortization deferred income tax expensebenefits stockbased compensation expense acquired inprocess research development impairment charges gain sale product lines businesses gainloss debt buybackrestructuring interest rate swap termination loss sale property plant equipment gain sale imclone investments changes operating assets liabilities receivables inventories deferred income accounts payable us foreign income taxes receivablepayable changes operating assets liabilities net cash provided operating activities cash flows investing activities proceeds sale marketable securities purchases marketable securities additions property plant equipment capitalized software proceeds sale property plant equipment investment companies proceeds sale product lines businesses proceeds sale leaseback properties milestone payments intangible assets purchase businesses net cash acquired proceeds sale imclone shares net cash provided byused investing activities cash flows financing activities shortterm repaymentsborrowings longterm debt borrowings longterm debt repayments interest rate swap termination issuances common stock stock plans excess tax benefits sharebased payment arrangements dividends paid net cash used financing activities effect exchange rates cash cash equivalents increasedecrease cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period consolidated statements cash flows include activities discontinued operations accompanying notes integral part financial statements table contents note accounting policies basis consolidation consolidated financial statements prepared conformity united states us generally accepted accounting principles gaap include accounts bristolmyers squibb company may referred bristolmyers squibb bms company controlled majorityowned subsidiaries intercompany balances transactions eliminated company entered codevelopment cocommercialization license arrangements parties various therapeutic areas terms including upfront contingent payments arrangements parties determined variable interest entities requirements fin r consolidation variable interest entities primarily due company providing subordinated financial support result company consolidate financial results parties reclassifications certain prior year amounts reclassified conform current year presentation among changes company reclassified certain receivables sale products alliance partners new presentation also changed previously reported line items within consolidated statements cash flows however new presentation change net cash provided operating activities see note receivables net use estimates preparation financial statements requires use estimates assumptions based complex judgments considered reasonable affect reported amounts assets liabilities disclosure contingent assets contingent liabilities date financial statements reported amounts revenues expenses reporting period significant assumptions employed estimates used determining values intangible assets restructuring charges accruals sales rebate return accruals legal contingencies tax assets tax liabilities stockbased compensation expense retirement postretirement benefits including actuarial assumptions financial instruments observable market quotes well estimates used applying revenue recognition policy actual results may may differ estimated results revenue recognition company recognizes revenue title substantially risks rewards ownership transferred customer generally revenue recognized time shipment however case certain sales made nutritionals business certain nonus businesses within pharmaceuticals segment revenue recognized date receipt purchaser see note alliances collaborations discussion revenue recognition related alliances revenues reduced time recognition reflect expected returns estimated based historical experience business trends additionally provisions made time revenue recognition discounts rebates estimated sales allowances based historical experience updated changes facts circumstances appropriate provisions recorded reduction revenue case new products product introduction extension existing line product company determines products similar therapeutic category company determines new product dissimilar characteristics existing products company reliably estimate expected returns new product company defers recognition revenue right return longer exists company developed sufficient historical experience estimate sales returns table contents note accounting policies continued sales rebate return accruals sales rebate return accruals established period related revenue recognized resulting reduction sales establishment liability included accrued rebates returns accrual recorded based estimate proportion recorded revenue result rebate return prime vendor chargeback accruals cash discounts established similar manner recorded reduction accounts receivable accrued liabilities reductions trade receivables follows december dollars millions medicaid rebates women infants children wic rebates sales returns managed health care rebates contract discounts prime vendor chargebacks cash discounts adjustments income taxes provision income taxes determined using asset liability approach accounting income taxes approach deferred taxes represent future tax consequences expected occur reported amounts assets liabilities recovered paid provision income taxes represents income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax bases companys assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recorded reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made cash cash equivalents cash cash equivalents consist us treasury backed securities bank deposits time deposits money market funds cash equivalents primarily highly liquid investments original maturities three months less time purchase recorded cost approximates fair value company maintains cash cash equivalent balances us dollars foreign currencies subject currency rate risk marketable securities company determined appropriate classification marketable securities available sale time purchase companys investments marketable securities reported fair value december fair value determined based observable market quotes valuation models using assessments counterparty credit worthiness credit default risk underlying security overall capital market liquidity declines fair value considered temporary charged earnings considered temporary reported component accumulated comprehensive income oci stockholders equity company uses average cost method determining cost basis computing realized gains losses sale available sale securities realized gains losses included expense net inventory valuation inventories generally stated average cost excess market capital assets depreciation expenditures additions renewals improvements capitalized cost depreciation generally computed straightline method based estimated useful lives related assets estimated useful lives major classes depreciable assets years buildings years machinery equipment fixtures company periodically evaluates whether current events circumstances indicate carrying value depreciable assets may recoverable table contents note accounting policies continued impairment longlived assets company periodically evaluates whether current facts circumstances indicate carrying value depreciable assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows produced longlived asset appropriate grouping assets compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques including discounted value estimated future cash flows company reports asset disposed lower carrying value estimated net realizable value capitalized software certain costs obtain internal use software significant systems projects capitalized amortized estimated useful life software ranges three years costs obtain software projects significant expensed incurred capitalized software net accumulated amortization included intangible assets net million million december respectively amortization expense million million million investments company accounts lessowned companies ability exercise significant influence using equity method accounting otherwise cost method used companys share net income losses equity investments included equity net income affiliates consolidated statements earnings losses recognized expense net decline market value deemed temporary company reviews equity investments impairment based determination whether decline market value investment companys carrying value temporary making determination company considers factors evaluated determining whether loss value recognized including companys ability hold investment market price market price fluctuations investments publicly traded shares inability investee sustain earnings capacity would justify carrying amount investment acquisitions companys consolidated financial statements results operations reflect acquired business completion acquisition restated acquired businesses accounted using purchase method accounting requires assets acquired liabilities assumed recorded date acquisition respective fair values excess purchase price estimated fair values net assets acquired recorded goodwill amounts allocated acquired inprocess research development iprd expensed date acquisition goodwill recognized acquired net assets constitute business goodwill intangible assets goodwill tested impairment annually using twostep process first step identify potential impairment second step measures amount impairment loss goodwill deemed impaired carrying amount reporting units goodwill exceeds estimated fair value pharmaceutical segment includes four separate reporting units based geography nutritionals segment consists one reporting unit company completed annual goodwill impairment assessment first quarter monitored potential impairment remaining quarters none indicated impairment goodwill intangible assets net consisting patentstrademarks licenses technology capitalized software amortized straightline basis useful lives ranging two years intangible assets deemed impaired net carrying value exceeds estimated fair value restructuring company recognized restructuring charges connection activities streamline operations rationalize manufacturing facilities result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place actual results may vary estimates table contents note accounting policies continued product liability accruals product liability including associated legal costs recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information accruals adjusted periodically assessment efforts progress additional information becomes available receivables related insurance thirdparty recoveries product liabilities recorded undiscounted basis probable recovery realized classified reduction litigation expense net consolidated statements earnings contingencies normal course business company subject loss contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability company records accruals loss contingencies probable liability incurred amount loss reasonably estimated company recognize gain contingencies realized discussion contingencies see note legal proceedings contingencies derivative financial instruments derivative financial instruments used company principally management interest rate foreign currency exposures company hold issue derivative financial instruments speculative purposes company records derivative instruments balance sheet fair value changes derivatives fair value recognized earnings unless specific hedge criteria met derivative designated fair value hedge changes fair value derivative hedged item attributable hedged risk recognized consolidated statements earnings derivative designated cash flow hedge effective portions changes fair value derivative recorded oci subsequently recognized consolidated statements earnings hedged item affects earnings cash flows classified consistent underlying hedged item purchased foreign currency options entire change fair value included measurement hedge effectiveness cash flow hedges ineffective portions changes fair value cash flow hedges recognized charge credit earnings company designates assigns derivatives hedges forecasted transactions specific assets specific liabilities hedged assets liabilities sold extinguished forecasted transactions hedged longer expected occur company immediately recognizes gain loss designated hedging financial instruments consolidated statements earnings shipping handling costs company typically charge customers shipping handling costs therefore shipping handling costs included marketing selling administrative expenses million million million advertising costs advertising costs expensed incurred advertising expense million million million research development research development costs expensed incurred company time time enter strategic alliances third parties give company rights develop manufacture market andor sell pharmaceutical products rights owned third parties result alliances company may obligated make payments alliance partners connection research development contingent upon achievement certain predetermined criteria milestones achieved prior regulatory approval product payments expensed research development milestone payments made connection regulatory approvals including nonus regulatory approvals additional indications capitalized amortized cost products sold remaining useful life asset capitalized milestone payments tested recoverability periodically whenever events changes circumstances indicate carrying amounts may recoverable company records research development net reimbursements connection collaboration agreements table contents note accounting policies continued acquired inprocess research development fair value inprocess research development acquired business combination determined based present value research projects projected cash flows income approach utilized consistent guidance practice aid issued american institute certified public accountants assets acquired business combinations used research development activities focus software electronic devices pharmaceutical industries future cash flows predominately based net income forecast project consistent historical pricing margins expense levels similar products revenues estimated based relevant market size growth factors expected industry trends individual project life cycles life research projects underlying patent determining fair value research project expected revenues first adjusted technical risk completion resulting cash flows discounted rate approximating companys weightedaverage cost capital acquired inprocess research development expensed incurred underlying product received regulatory approval future alternative use addition costs nonrefundable related acquisition licensing products yet received regulatory approval marketed alternative future use charged earnings incurred earnings per share basic earnings per common share computed using weightedaverage number shares outstanding year diluted earnings per common share computed using weightedaverage number shares outstanding year plus incremental shares outstanding assuming exercise dilutive stock options restricted stock convertible instruments foreign currency translation statements earnings companys foreign subsidiaries translated us dollars using average exchange rates net assets companys foreign subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation adjustment account included accumulated oci recently issued accounting standards effective january company adopted emerging issues task force eitf issue accounting nonrefundable advance payments goods services received use future research development activities nonrefundable advance payments goods services used rendered future research development activities deferred capitalized amounts recognized expense related goods delivered services performed goods services longer expected provided companys adoption eitf material effect companys consolidated financial statements effective january company adopted statement financial accounting sfas fair value option financial assets financial liabilities including amendment sfas accounting certain investments debt equity securities permits entity measure certain financial assets financial liabilities fair value objective sfas improve financial reporting allowing entities mitigate volatility reported earnings caused measurement related assets liabilities using different attributes without apply complex hedge accounting provisions sfas entities elect fair value option instrument report unrealized gains losses earnings subsequent reporting date fair value option election irrevocable unless new election date occurs sfas establishes presentation disclosure requirements help financial statement users understand effect entitys election earnings eliminate disclosure requirements accounting standards assets liabilities measured fair value must displayed face balance sheet company chose elect fair value option financial assets liabilities existing january elect fair value option financial assets liabilities assets liabilities previously carried fair value therefore adoption sfas impact companys consolidated financial statements effective january company adopted provisions sfas fair value measurements financial assets liabilities assets liabilities carried fair value pronouncement defines fair value establishes framework measuring fair value expands disclosures fair value measurements implementation sfas nonfinancial assets liabilities effective january companys adoption sfas relating financial assets liabilities material effect companys consolidated financial statements adoption sfas respect nonfinancial assets liabilities future expected material impact companys consolidated financial statements march fasb issued sfas disclosures derivative instruments hedging activities amendment sfas accounting derivative instruments hedging activities sfas requires objectives using table contents note accounting policies continued derivative instruments disclosed terms underlying risk accounting designation fair value derivative instruments gains losses need presented tabular format order present complete picture effects using derivative instruments sfas effective financial statements issued fiscal years beginning november company provided required disclosures december consolidated financial statements december meeting fasb ratified consensus reached eitf issue accounting collaborative arrangements related development commercialization intellectual property eitf concluded collaborative arrangement one participants actively involved exposed significant risks rewards depend ultimate commercial success endeavor revenues costs incurred third parties connection collaborative arrangements would presented gross net based criteria eitf reporting revenue gross principal versus net agent accounting literature payments collaborators would evaluated presented based nature arrangement terms nature entitys business whether payments within scope accounting literature nature purpose collaborative arrangements disclosed along accounting policies classification amounts significant financial statement amounts related arrangements activities arrangement conducted separate legal entity accounted accounting literature however required disclosure eitf applies entire collaborative agreement eitf effective fiscal years beginning december applied retrospectively periods presented collaborative arrangements existing effective date accounting pronouncement material effect companys consolidated financial statements december fasb issued sfas noncontrolling interests consolidated financial statementsan amendment arb sfas establishes accounting reporting standards require ownership interests subsidiaries held parties parent clearly identified labeled presented consolidated balance sheets within equity separate parents equity fasb also requires amount consolidated net income attributable parent noncontrolling interest clearly identified presented face consolidated statements income changes parents ownership interest parent retains controlling financial interest subsidiary must accounted consistently subsidiary deconsolidated retained noncontrolling equity investment former subsidiary must initially measured fair value fasb also requires entities provide sufficient disclosures clearly identify distinguish interests parent interests noncontrolling owners fasb effective company january also change companys consolidated financial statements presentation december fasb issued sfas r business combinations replaces sfas business combinations requires recognition assets acquired liabilities assumed noncontrolling interest acquiree acquisition date measured fair values date business combination achieved stages fasb requires recognition identifiable assets liabilities well noncontrolling interest acquiree full amounts fair values fasb also requires fair value acquired inprocess research development recorded indefinite lived intangibles contingent consideration recorded acquisition date restructuring acquisitionrelated deal costs expensed incurred addition excess fair value net assets acquired purchase price subsequent changes estimated contingencies recorded earnings fasb applies companys business combinations acquisition date january july fasb issued fasb interpretation fin accounting uncertainty income taxes interpretation fasb statement case company effective january fin clarifies accounting uncertainty income taxes recognized enterprises financial statements accordance sfas accounting income taxes fin requires tax positions evaluated using recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return differences tax positions taken tax return amounts recognized financial statements recorded adjustments income taxes payable receivable adjustments deferred taxes fin also requires expanded disclosure end reporting period including tabular reconciliation unrecognized tax benefits company adopted fin january result adoption accounting pronouncement company recognized million previously unrecognized tax benefits accounted increase opening balance retained earnings may fasb issued fasb staff position fsp fin definition settlement fasb interpretation effective retroactively january fsp fin provides guidance determine whether tax position effectively settled purpose recognizing previously unrecognized tax benefits adoption fsp fin effect companys consolidated financial statements table contents note alliances collaborations sanofi company agreements sanofiaventis sanofi codevelopment cocommercialization avaproavalide irbesartanirbesartan hydrochlorothiazide angiotensin ii receptor antagonist indicated treatment hypertension diabetic nephropathy plavix clopidogrel platelet aggregation inhibitor worldwide alliance operates framework two geographic territories one americas principally us canada puerto rico latin american countries australia europe asia accordingly two territory partnerships formed manage central expenses marketing research development royalties supply finished product individual countries general country level agreements either copromote whereby partnership formed parties sell brand comarket whereby parties operate sell brands independently place agreements expire later respect plavix respect avaproavalide americas australia europe asia ii expiration patents exclusivity rights applicable territory company acts operating partner territory covering americas australia owns majority controlling interest territory sanofis ownership interest territory company consolidates country partnership results territory records sanofis share results minority interest net taxes million million million company recorded net sales territory comarketing countries outside territory germany italy spain greece million million million cash flows operating activities partnerships territory covering americas australia recorded operating activities within companys consolidated statements cash flows distributions partnership profits sanofi sanofis funding ongoing partnership operations occur routine basis also recorded within operating activities companys consolidated statements cash flows sanofi acts operating partner territory covering europe asia owns majority financial controlling interest within territory companys ownership interest partnerships within territory company accounts investment partnership entities territory equity method records share results equity net income affiliates consolidated statements earnings companys share income partnership entities taxes million million million company routinely receives distributions profits provides funding ongoing operations partnerships territory covering europe asia transactions recorded operating activities within companys consolidated statements cash flows company sanofi alliance copromotion irbesartan company recognized income million million million related amortization deferred income associated sanofis million payment company acquisition interest irbesartan license us upon formation alliance unrecognized portion deferred income amounted million million december respectively continue amortize expected expiration license following summarized financial information companys interests partnerships sanofi territory covering europe asia year ended december dollars millions net sales gross profit net income current assets current liabilities otsuka company worldwide commercialization agreement otsuka pharmaceutical co ltd otsuka codevelop copromote otsuka abilify aripiprazole treatment schizophrenia bipolar mania disorder major depressive disorder except japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt terms agreement company purchases product otsuka performs finish manufacturing sale company otsuka thirdparty customers product currently copromoted otsuka us united kingdom uk germany france spain us germany spain product invoiced thirdparty customers company table contents note alliances collaborations continued behalf otsuka company records alliance revenue contractual share thirdparty net sales records expenses related product company recognizes alliance revenue abilify shipped risks rewards ownership transferred thirdparty customers uk france italy company presently exclusive distributor product company records net sales related cost products sold expenses company also exclusive right sell abilify countries europe americas number countries asia countries company records net sales related cost products sold agreement expires november us entire european union eu agreement expires june country company exclusive right sell abilify agreement expires later th anniversary first commercial sale country expiration applicable patent country company recorded net sales abilify million million million total milestone payments made otsuka agreement december million million expensed acquired inprocess research development remaining million capitalized intangible assets net amortized cost products sold remaining life agreement us company amortized cost products sold million unamortized capitalized payment balance million million december respectively imclone company commercialization agreement expiring september imclone systems incorporated imclone codevelopment copromotion erbitux cetuximab us well codevelopment copromotion rights canada japan extent product commercialized countries erbitux indicated use treatment patients metastatic colorectal cancer use treatment squamous cell carcinoma head neck agreement covering north america imclone receives distribution fee based flat rate net sales north america october company imclone amended codevelopment agreement merck kgaa provide cocommercialization erbitux japan expires imclone ability terminate agreement determines commercially unreasonable imclone continue erbitux received marketing approval japan july use erbitux treating patients advanced recurrent colorectal cancer company recorded net sales erbitux million million million company amortized cost products sold million million million previously capitalized milestone payments accounted license acquisition unamortized portion approval payments recorded intangible assets net million million december respectively continue amortize remaining term agreement upon initial execution commercialization agreement company acquired ownership interest imclone approximated time transaction noted accounting investment equity method company recorded equity loss income affiliates adjusted revenue recognized imclone preapproved milestone payments made company prior million equity net income affiliates million million november eli lilly company lilly acquired imclone result company sold shares imclone billion recognized pretax gain million company continue marketing rights erbitux believes rights imclones investigational compound imcf gilead company gilead sciences inc gilead joint venture develop commercialize atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oncedaily single tablet threedrug regimen combining companys sustiva efavirenz gileads truvada emtricitabine tenofovir disoproxil fumarate us canada europe atripla approved fda july health canada october european commission december commercialization countries eu well norway iceland gilead records atripla revenues us canada countries europe consolidates results joint venture operating results company records revenue bulk efavirenz component atripla upon sales product joint venture thirdparty customers companys net sales efavirenz component determined applying percentage atripla revenue approximates revenue sustiva brand limited number eu countries company records revenue atripla company agreed purchase product gilead distribute thirdparty customers company recorded revenues million million million related atripla sales company accounts participation us joint venture equity method accounting records share joint venture results equity net income affiliates consolidated statements earnings company recorded equity loss us joint venture gilead million million table contents note alliances collaborations continued astrazeneca january company entered two worldwide except japan codevelopment cocommercialization agreements astrazeneca plc astrazeneca one codevelopment cocommercialization saxagliptin dppiv inhibitor saxagliptin agreement one codevelopment cocommercialization dapagliflozin sodiumglucose contransporter sglt inhibitor sglt agreement compounds studied treatment diabetes discovered company terms agreements company received astrazeneca upfront payment million january october company received astrazeneca milestone payment million june filing new drug application food drug administration fda onglyza companies proposed name onglyza approved fda european medicines evaluation agency serve trade name saxagliptin upfront milestone payments deferred recognized useful life products income company amortized income million upfront payments million unamortized portion upfront milestone payments million december million december additional milestone payments expected received company upon successful achievement various development regulatory events well salesrelated milestones saxagliptin agreement company could receive million development regulatory milestones met additional million salesbased milestones met sglt agreement company could receive million development regulatory milestones met additional million salesbased milestones met agreement company astrazeneca also share development commercialization costs majority development costs initial development plans paid astrazeneca additional development costs generally shared equally company records development costs related saxagliptin dapagliflozin net astrazenecas share research development expenses agreement two companies jointly develop clinical marketing strategy share commercialization expenses profitslosses equally global basis excluding japan company manufacture products pfizer april company pfizer inc pfizer entered worldwide codevelopment cocommercialization agreement apixaban anticoagulant discovered company studied prevention treatment broad range venous arterial thrombotic conditions accordance terms agreement pfizer made upfront payment million company may deferred recognized life agreement income december company pfizer agreed include japan worldwide agreement connection japan agreement pfizer made additional upfront payment million december deferred recognized useful life product income company amortized income million two upfront payments million unamortized portion upfront payments million december million december pfizer fund development costs effective january going forward company fund company records apixaban development costs net pfizers share research development expenses company may also receive additional payments million pfizer based development regulatory milestones companies jointly develop clinical marketing strategy share commercialization expenses profitslosses equally global basis manufacture product arrangement exelixis december company exelixis inc exelixis entered global codevelopment cocommercialization arrangement xl metvegret inhibitor oral anticancer compound license xl utility ras raf mutant tumors development exelixis terms arrangement company agreed pay exelixis million upon execution agreement additional million company expensed research development million upon execution agreement exelixis fund first million development xl exelixis elects continue sharing development costs elects copromote us exelixis fund future global development costs excluding japan share us profitslosses equally failing elections exelixis receives milestones royalties company fund development costs japan addition doubledigit royalties nonus sales company could pay million development regulatory milestones met additional million salesbased milestones met addition company exelixis history collaborations identify develop promote oncology targets december company exelixis entered oncology collaboration license agreement exelixis table contents note alliances collaborations continued pursuing development three small molecule inds codevelopment copromotion terms agreement company paid exelixis million upfront fees company paid exelixis million ind acceptance milestones exelixis elects fund development costs copromote us parties equally share development costs profits exelixis opts codevelopment copromotion agreement bms take full development us commercial rights successful pay exelixis development regulatory milestones million additional million salesbased milestones well doubledigit royalties note restructuring december july company announced productivity transformation initiatives pti designed fundamentally change way runs business meet challenges changing business environment take advantage diverse opportunities marketplace company transformed nextgeneration biopharmaceutical company create total billion annual productivity cost savings cost avoidance connection pti company aims achieve culture continuous improvement enhance efficiency effectiveness competitiveness substantially improve cost base charges associated previously announced pti estimated aggregate range billion billion includes million costs already incurred incurred costs net million gains related sale mature product lines businesses exact timing recognition pti charges predicted certainty affected existence triggering events expense recognition among factors also included charges net termination benefits million million exit costs million million net restructuring charges include termination benefits workforce reduction approximately manufacturing selling administrative research development personnel across geographic regions following table presents details expenses incurred segment corporateother connection restructuring activities termination exit termination exit termination exit benefits costs total benefits costs total benefits costs total dollars millions pharmaceuticals nutritionals corporateother subtotal changes estimates provision restructuring net table contents note restructuring continued following table represents reconciliation restructuring liabilities spending liabilities exit termination costs liability liability total dollars millions liability january charges spending changes estimates liability december charges spending changes estimates liability december charges spending change estimates convatec divestiture liability december addition termination charges company recognized accelerated depreciation fixed asset impairment charges shutdown costs million million million charges included cost products sold primarily relate rationalization companys manufacturing network pharmaceuticals segment assets continue depreciated facility closures complete remaining costs pti primarily attributed process standardization activities across company recognized incurred note acquisitions divestitures june company completed acquisition kosan biosciences inc kosan cancer therapeutics company library novel compounds including hsp inhibitors cancer microtubule stabilizers may additional potential neurodegenerative diseases net purchase price approximately million transaction accounted purchase method accounting purchase price preliminarily allocated acquired inprocess research development million net assets million goodwill million october company completed acquisition adnexus therapeutics inc adnexus developer new therapeutic class biologics called adnectins net purchase price million addition event certain future development regulatory milestones achieved company obligated terms agreement pay former stockholders adnexus additional million transaction accounted purchase method accounting purchase price allocated acquiredinprocess research development million identifiable intangible assets million existing process technology used future discovery net assets million goodwill million reflecting additional deferred tax assets million results operations two acquisitions included accompanying consolidated financial statements dates acquisition pro forma supplemental financial information included impact business combinations material december company completed sale mature brand business located egypt million cash glaxosmithkline result transaction company recognized pretax gain million million net tax fourth quarter august company completed divestiture convatec business january company completed divestiture bristolmyers squibb medical imaging see note discontinued operations assets held sale discussions divestitures table contents note acquisitions divestitures continued july company completed sale bufferin excedrin brands japan asia excluding china taiwan certain oceanic countries lion corporation japan million cash result transaction company recognized pretax gain million million net tax third quarter january company completed sale inventory trademark patent intellectual property rights us related dovonex treatment psoriasis warner chilcott company inc million cash addition company received royalty based net sales dovonex end result transaction company recognized pretax gain million million net tax first quarter note mead johnson nutrition company initial public offering february mead johnson nutrition company mead johnson completed initial public offering ipo sold million shares class common stock per share net proceeds received approximately million allocated minority interest net taxes capital excess par value stock within companys stockholders equity accordance sfas noncontrolling interests consolidated financial statements amendment arb upon completion ipo company held million shares mead johnson class common stock million shares mead johnson class b common stock rights holders shares class common stock class b common stock identical except regard voting conversion share class common stock entitled one vote per share share class b common stock entitled ten votes per share convertible time election holder one share class common stock class b common stock automatically convert shares class common stock certain circumstances upon completion ipo company holds interest mead johnson mead johnson continue consolidated financial reporting purposes company entered various agreements relating separation mead johnson including separation agreement transitional services agreement tax matters agreement registration rights agreement employee matters agreement february mead johnson entered three year syndicated revolving credit facility agreement credit facility unsecured provides borrowings letters credit million note discontinued operations assets held sale august company completed divestiture convatec business cidron healthcare limited affiliate nordic capital fund vii avista capital partners lp avista gross purchase price approximately billion resulting pretax gain billion billion net tax included discontinued operations gross purchase price includes estimated postclosing purchase price adjustment based companys estimate closing working capital convatec business therefore purchase price transaction gain subject future adjustment based actual closing working capital convatec business pursuant terms stock asset purchase agreement dated may addition company recorded discontinued operations curtailment loss million special termination benefits million associated remeasurement us japan pension plans obligations assets triggered decision sell convatec business results convatec business previously reported separate operating segment included earnings discontinued operations net taxes periods presented january company completed divestiture bristolmyers squibb medical imaging medical imaging avista gross purchase price approximately million excluding post closing adjustments resulting pretax gain million aftertax loss million included discontinued operations results medical imaging business previously included former health care operating segment included earnings discontinued operations net taxes periods presented net assets associated medical imaging business totaling approximately million reclassified assets liabilities held sale december period time company continue generate cash flows report income statement activity expense net associated convatec medical imaging businesses activities give rise cash flows income statement activities transitional nature generally result agreements intended facilitate orderly transfer business operations agreements include among others services accounting customer service distribution manufacturing activities convatec medical imaging businesses expected material companys results operations cash flows convatec agreements extend periods generally less months majority ranging six months transaction close date subject certain cases limited extensions medical imaging agreements extend periods generally less months majority ranging three six months transaction close date subject certain cases closing extensions transitional service fees net identifiable direct costs recognized expense net amounted million year ended december table contents note discontinued operations assets held sale continued following summarized financial information related convatec medical imaging businesses segregated continuing operations reported discontinued operations date disposition reflect costs certain services provided convatec medical imaging company costs allocated company convatec medical imaging services included without limitation legal counsel insurance external audit fees payroll processing certain human resource services information technology systems support year ended december convatec medical imaging dollars millions net sales earnings incomes taxes curtailment losses special termination benefits provision income taxes earnings net taxes gain disposal provision income taxes gainloss disposal net taxes consolidated statements cash flows includes convatec medical imaging businesses date disposition company uses centralized approach cash management financing operations accordingly debt allocated businesses following table includes medical imaging assets liabilities segregated classified assets held sale liabilities related assets held sale appropriate consolidated balance sheets december amounts presented adjusted exclude cash intercompany receivables payables business held sale company excluded divestiture addition goodwill december million excluded following summary net assets held sale considered determining pretax gain sale first quarter assets generating operating results cash flows included consolidated balance sheet assets held sale december dollars millions december medical imaging assets receivables net allowances inventories net assets property plant equipment net intangible assets net total assets held sale liabilities accounts payable accrued liabilities total liabilities related assets held sale net assets held sale table contents note earnings per share numerator basic earnings per share net earnings available common stockholders numerator diluted earnings per share net earnings available common stockholders interest expense added back assumed conversion convertible debt common stock denominator basic earnings per share weightedaverage number common stock outstanding period denominator diluted earnings per share weighted average shares outstanding adjusted effect dilutive stock options restricted shares assumed conversion convertible debt common stock computations basic diluted earnings per common share follows year ended december dollars millions except per share data basic net earnings continuing operations discontinued operations earnings net taxes gain disposal net taxes net earnings basic earnings per share average common shares outstanding basic net earnings continuing operations discontinued operations earnings net taxes gain disposal net taxes net earnings per common share diluted net earnings continuing operations interest expense conversion convertible debt net taxes net earnings continuing operations used diluted earnings per common share calculation discontinued operations earnings net taxes gain disposal net taxes net earnings diluted earnings per share average common shares outstanding basic conversion convertible debt incremental shares outstanding assuming exercisevesting dilutive stock optionsrestricted stock average common shares outstanding diluted net earnings continuing operations discontinued operations earnings net taxes gain disposal net taxes net earnings per common share weightedaverage shares issuable upon exercise stock options million million million included diluted earnings per share calculation antidilutive addition million shares assumed conversion convertible debt included diluted earnings per share calculation antidilutive table contents note expense net components expense net follows year ended december dollars millions interest expense interest income ars impairment charge gainloss debt buyback termination interest rate swap agreements foreign exchange transaction gainslosses net expense net interest expense includes million net interest rate swap gains net interest rate swap losses million million see note financial instruments additional discussion terminated swap contracts interest income relates primarily interest earned cash cash equivalents investments marketable securities detail auction rate securities ars impairment see note cash cash equivalents marketable securities net includes income thirdparty contract manufacturing certain royalty income expense gains losses sale property plant equipment gains losses sale marketable securities including million loss sale ars insurance recoveries certain litigation chargesrecoveries convatec medical imaging net transitional service fees amortization certain upfront payments related companys alliances see note alliances collaborations note income taxes components earningsloss continuing operations income taxes minority interest follows year ended december dollars millions us nonus amounts categorized based location taxing authorities provisionbenefit income taxes attributable continuing operations consisted year ended december dollars millions current us nonus deferred us nonus table contents note income taxes continued effective tax rate companys provision income taxes different amount computed applying statutory us federal income tax rate earnings continuing operations income taxes minority interest result following earnings income taxes minority interest dollars millions earnings continuing operations income taxes minority interest us statutory rate foreign tax effect operations ireland puerto rico switzerland state local taxes net valuation allowance us federal foreign contingent tax matters acquired inprocess research development expense us federal research development tax credit us federal foreign valuation allowance impairment financial instruments foreign increase effective tax rate primarily due higher pretax income us including gain sale imclone earnings mix high tax jurisdictions partially offsetting factors lower nondeductible charges acquired inprocess research development expenses lower ars impairment charges little tax benefit tax rate favorably impacted benefit million tax related final settlement audit internal revenue service tax rate unfavorably impacted impairment companys investment certain ars little tax benefit nondeductible writeoff acquired inprocess research development expenses related acquisition adnexus partially offset tax benefit million first quarter due favorable resolution certain tax matters internal revenue service related deductibility litigation settlement expenses us foreign tax credits claimed effective tax rate unfavorably impacted elimination tax benefits section internal revenue code treatment provisions portion certain litigation reserves nondeductible partially offset favorable us tax legislation enacted related tax treatment certain intercompany transactions amongst companys foreign subsidiaries implementation tax planning strategies related utilization certain charitable contributions table contents note income taxes continued deferred taxes valuation allowance components current noncurrent deferred income tax assetsliabilities follows december dollars millions acquired inprocess research development intercompany profit inventory items us federal foreign tax credit carryforwards deferred income us federal research development tax credit carryforwards us federal charitable contribution carryforwards state net operating loss carryforwards foreign net operating loss carryforwards foreign deferred tax assets pension postretirement benefits depreciation sharebased compensation repatriation foreign earnings legal settlements tax deductible goodwill milestone payments license fees net valuation allowance deferred tax assets net recognized deferred income taxes current deferred income taxes noncurrent us foreign income taxes payable liabilities noncurrent total company established valuation allowance deferred tax assets company determined likely deferred tax assets realized december valuation allowance million established following items million state deferred tax assets million foreign net operating loss tax credit carryforwards million state net operating loss tax credit carryforwards million related impaired financial instruments million us federal state deferred tax assets related adnexus kosan acquisitions offset goodwill company recognized significant deferred tax assets december related us federal foreign tax credit carryforwards million us federal research development tax credit carryforwards million us federal charitable contribution carryforwards fully utilized due gains related convatec medical imaging divestitures foreign tax credit research development tax credit carryforwards expire varying amounts beginning foreign tax credit research development tax credit carryforwards reduced due derecognition fin convatec medical imaging divestitures resulted significant reduction foreign tax credit research development tax credit carryforwards realization foreign tax credit research development tax credit carryforwards dependent generating sufficient domesticsourced taxable income prior expiration although realization assured management believes likely deferred tax assets realized income taxes paid year million million million discussed tax rate favorably impacted benefit million tax related final settlement audit internal revenue service final settlement related joint committee congress approval foreign tax credit carryback claim company received million cash refund including interest current tax benefit realized upon exercise stock options credited capital excess par value stock million million table contents note income taxes continued december company approximately billion undistributed earnings foreign subsidiaries taxes provided company invested expects invest undistributed earnings permanently offshore future earnings repatriated us company determines earnings remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes would provided company conducts business various countries throughout world subject tax numerous jurisdictions result business activities company files significant number tax returns subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported company may require several years resolve company establishes liabilities possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known effect changes estimates related contingent tax liabilities included effective tax rate reconciliation company adopted provisions fin january resulting recognition million previously unrecognized tax benefits accounted increase opening balance retained earnings fin requires expanded disclosure end annual reporting period including tabular reconciliation unrecognized tax benefits certain information regarding interest penalty amounts reflected part companys uncertain tax positions tabular reconciliation companys changes uncertain tax positions january december january december follows unrecognized income tax benefits unrecognized including income tax interest unrecognized benefits penalties federal state including deferred net deferred foreign interest income tax income dollars millions tax benefits interest penalties penalties benefits tax benefits total uncertain tax positions recognized would impact effective tax rate january add tax attributable deferred tax items january balance gross uncertain tax positions january gross additions tax positions related current year gross reductions tax positions related current year gross additions tax positions related prior years gross reductions tax positions related prior years settlements reductions tax positions related lapse statute cumulative translation adjustment balance gross uncertain tax positions december less tax attributable deferred tax items december total uncertain tax positions recognized would impact effective tax rate december total uncertain tax positions recognized would impact effective tax rate january add tax attributable deferred tax items january balance gross uncertain tax positions january gross additions tax positions related current year gross reductions tax positions related current year gross additions tax positions related prior years gross reductions tax positions related prior years settlements reductions tax positions related lapse statute cumulative translation adjustment balance gross uncertain tax positions december less tax attributable deferred tax items december total uncertain tax positions recognized would impact effective tax rate december annual tabular reconciliation required fin requires gross presentation unrecognized tax benefits gross basis reductions deferred tax assets companys total amount unrecognized tax benefits january excluding interest penalties million table contents note income taxes continued uncertain tax benefits december recorded companys deferred tax assets extent uncertainty directly related asset otherwise recorded either current noncurrent income taxes payable total amount gross uncertain tax benefits december excluding interest penalties decreased million reduction primarily due favorable resolution uncertain tax positions partially offset additional uncertain tax benefits accrued included gross reductions tax positions related prior years million uncertain tax positions longer included fin table result disposition businesses included balance unrecognized tax benefits million uncertain tax positions january million december ultimate deductibility highly certain uncertainty timing deductibility impact deferred tax accounting interest penalties applicable disallowance shorter deductibility period would affect annual effective tax rate would accelerate payment cash taxing authority utilization tax attributes earlier period amounts unrecognized tax benefits recognized would impact effective tax rate million january million december company classifies interest penalties related unrecognized tax benefits income tax expense amounts reflected separately reconciliation total amount interest penalties related uncertain tax positions recognized consolidated statements earnings net benefit million interest million penalties net benefit interest result million additional accrual million reduction interest net benefit penalties result million additional accrual million reduction penalties total amount interest penalties related uncertain tax positions recognized consolidated balance sheets december million interest million penalties company currently examination number tax authorities including major tax jurisdictions listed table proposed adjustments tax issues transfer pricing certain tax credits deductibility certain expenses company estimates reasonably possible total amount unrecognized tax benefits december decrease range approximately million million next twelve months result settlement certain tax audits settlements involve payment additional taxes adjustment certain deferred taxes andor recognition tax benefits company also anticipates reasonably possible new issues raised tax authorities may require increases balance unrecognized tax benefits however estimate increases reasonably made company believes adequately provided open tax years tax jurisdiction fin company files income tax returns us federal jurisdiction various state foreign jurisdictions exceptions company subject us federal state local nonus income tax examinations tax authorities following summary major tax jurisdictions tax authorities may assert additional taxes company based upon tax years currently audit subsequent years likely audited us canada france germany italy mexico table contents note fair value measurement stated note accounting policies january company adopted methods fair value described sfas value financial assets liabilities defined sfas fair value based price would received sell asset paid transfer liability orderly transaction market participants measurement date order increase consistency comparability fair value measurements sfas establishes fair value hierarchy prioritizes observable unobservable inputs used measure fair value three broad levels described level quoted prices unadjusted active markets accessible measurement date identical assets liabilities fair value hierarchy gives highest priority level inputs level observable prices based inputs quoted active markets corroborated market data level unobservable inputs used little market data available fair value hierarchy gives lowest priority level inputs determining fair value company utilizes valuation techniques maximize use observable inputs minimize use unobservable inputs extent possible well considers counterparty credit risk assessment fair value company chose elect fair value option prescribed sfas financial assets liabilities previously carried fair value therefore material financial assets liabilities carried fair value short longterm debt obligations trade accounts receivable payable still reported carrying values financial assets liabilities carried fair value december classified table one three categories described level level level total dollars millions available sale us treasury bills equity securities us treasurybacked securities floating rate securities auction rate securities total available sale assets derivatives interest rate swap derivatives foreign exchange derivatives total derivative assets total assets fair value level level level total dollars millions derivatives foreign exchange derivatives natural gas contracts total derivative liabilities total liabilities fair value companys assets utilize level inputs fair value measurement consist auction rate securities floating rate securities frs due lack observable market quotes companys ars investment portfolio company utilizes valuation models rely exclusively level inputs including based expected cash flow streams collateral values including assessments counterparty credit quality default risk underlying security discount rates overall capital market liquidity valuation companys ars investment portfolio subject uncertainties difficult predict factors may impact companys valuation include changes credit ratings securities well underlying assets supporting securities rates default underlying assets underlying collateral value discount rates counterparty risk ongoing strength quality market credit liquidity companys determination fair value ars investment portfolio december included indicative prices received external banks internally developed valuations based part indicative bids received underlying assets securities non observable evidence fair value although ars continue pay interest according stated terms due continued severity capital markets length time ars mature company believes full recovery longer probable discussion companys december fair value carrying value rollforward ars activity including sales otherthantemporary impairment charge recorded see note cash cash equivalents marketable securities table contents note fair value measurement continued companys frs primarily rated abaa better frs longterm debt securities coupons reset periodically benchmark interest rate underlying assets frs consist primarily consumer loans auto loans collateralized loan obligations monoline securities assetbacked securities corporate bonds loans since latter part general frs market became less liquid active due continuing credit liquidity concerns result availability observable market quotes active market level inputs market quotes similar identical assets liabilities inputs derived principally corroborated observable market data correlation means level inputs company markstomarket frs based indicative pricing indicative price quotes represent individual brokers assessments based similar assets well using valuation techniques analyzing underlying assets frs due current lack active market companys frs general lack transparency underlying assets company also relies qualitative analysis including discussions brokers fund managers default risk underlying security overall capital market liquidity level inputs value frs portfolio discussion companys december fair value carrying value rollforward activity occurred see note cash cash equivalents marketable securities financial assets liabilities utilize level level inputs company utilizes direct indirect observable price quotes including libor euribor yield curves foreign exchange forward prices nymex futures pricing common stock price quotes summary valuation techniques level level financial assets liabilities us treasury bills treasurybacked securities valued quoted market price broker dealer quotations transparent pricing sources reporting date equity securities valued using quoted stock prices new york stock exchange national association securities dealers automated quotation system reporting date interest rate swap derivative assets liabilities valued using libor euribor yield curves less credit valuation adjustments reporting date counterparties contracts financial institutions experienced downgrades valuations may fluctuate considerably periodtoperiod due volatility underlying interest rates driven market conditions duration swap addition credit valuation adjustment significant impact valuation companys interest rate swaps due changes counterparty credit ratings credit default swap spreads foreign exchange derivative assets liabilities valued using quoted forward foreign exchange prices reporting date counterparties contracts financial institutions experienced downgrades valuations may fluctuate considerably periodtoperiod due volatility underlying foreign currencies due shortterm maturities companys foreign exchange derivatives generally months less counterparty credit risk significant natural gas forward contracts valued using nymex futures prices natural gas reporting date counterparties contracts financial institutions experienced downgrades valuations may fluctuate considerably periodtoperiod due volatility underlying natural gas prices due shortterm maturities companys natural gas derivatives months less counterparty credit risk significant increases decreases aggregate fair value financial assets liabilities measured fair value would significant impact companys liquidity financial flexibility approximately fair value net financial assets us treasury bills us treasurybacked securities although company elected fair value option financial assets liabilities existing january transacted future transacted financial asset liability evaluated fair value election prescribed sfas fair valued provisions sfas company elect fair value option billion senior notes issued may table contents note cash cash equivalents marketable securities cash cash equivalents december million primarily consisted us treasurybacked securities cash cash equivalents december million primarily consisted bank deposits time deposits money market funds cash equivalents primarily highly liquid investments original maturities three months less time purchase recorded cost approximates fair value company maintains cash cash equivalent balances us dollars foreign currencies subject currency rate risk marketable securities december primarily consisted us treasury bills us dollardenominated frs companys frs holdings downgraded december ratings primarily aaaaaa ratings ranged aaaaaa abaa december frs longterm debt securities coupons reset periodically benchmark interest rate underlying assets companys frs consist primarily consumer loans auto loans collateralized loan obligations monoline securities assetbacked securities corporate bonds loans company accounts marketable securities accordance sfas accounting certain investments debt equity securities classifies available sale noncurrent frs classified noncurrent assets december following tables summarize companys current noncurrent marketable securities december include us dollardenominated frs ars accounted available sale debt securities unrealized lossgain accumulated december cost fair value carrying value oci dollars millions current available sale floating rate securities us treasury bills total current noncurrent available sale auction rate securities floating rate securities total noncurrent unrealized lossgain accumulated december cost fair value carrying value oci dollars millions current available sale floating rate securities total current noncurrent available sale auction rate securities total noncurrent company recognized pretax otherthantemporary impairment charge million respectively million loss sale certain securities table contents note cash cash equivalents marketable securities continued december companys principal value frs amounted million company received million principal par primarily frs matured march temporarily reduced fair value remaining frs million million unrealized loss accumulated oci addition company reclassified million remaining frs maturity dates beyond current assets noncurrent assets due liquidity concerns continued uncertainty capital markets company received million connection sale ars carrying value million resulting loss million addition million otherthantemporary impairment charge recognized including million previously determined temporary december impairment charge required analysis otherthantemporary impairment factors including severity duration decline value future prospects issuer companys ability intent hold security recovery ars sold securities generally backed subprime mortgages collateralized debt obligations structured credit ars remaining december primarily represents interests insurance securitizations lesser extent structured credits following table summarizes activity financial assets fair value measurements estimated utilizing level inputs ars frs noncurrent current frs frs ars total dollars millions carrying value january settlements transfers current noncurrent total losses included earnings included comprehensive income carrying value december discussion fair value financial instruments including ars frs see note fair value measurement contractual maturities carrying value available sale debt securities december follows dollars millions within year years years years total available sale floating rate securities auction rate securities us treasury bills total available sale table contents note receivables net major categories receivables follows december dollars millions trade receivables alliance partner receivables income tax refund claims miscellaneous receivables less allowances receivables net receivables netted deferred income sales product alliance partners recognition revenue result corresponding reclassification made reduced alliance partner receivables deferred income million million december respectively additional information companys alliance partners see note alliances collaborations aggregate receivables due three pharmaceutical wholesalers us represented total trade receivables december respectively note inventories net major categories inventories follows december dollars millions finished goods work process raw packaging materials inventories net inventories expected remain onhand beyond one year million million december respectively included non current assets note property plant equipment net major categories property plant equipment follows december dollars millions land buildings machinery equipment fixtures construction progress less accumulated depreciation property plant equipment net capitalized interest million million million table contents note goodwill changes carrying amount goodwill segment years ended december follows convatec pharmaceuticals nutritionals medical dollars millions segment segment imaging total balance january acquisition adnexus adjustments balance january sale medical imaging sale convatec sale mature brand business egypt acquisition kosan adnexus purchase price adjustment balance december see note acquisitions divestitures detail note intangible assets net december intangible assets consisted following total intangible patentstrademarks licenses technology capitalized software assets dollars millions gross carrying amount less accumulated amortization intangible assets net change carrying amount intangible assets years ended december follows total intangible assets dollars millions intangible assets net carrying amount january additions acquisition adnexus amortization medical imaging assets held sale sale convatec impairment charges intangible assets net carrying amount december impairment charges relate certain patent product rights acquired dupont results development programs abandoned license terminations amortization expense intangible assets million million million amortization expense intangible assets related convatec medical imaging reflected discontinued operations million million million expected amortization expense related current net carrying amount intangible assets follows years ending december dollars millions later years table contents note accrued expenses major categories accrued expenses follows december dollars millions employee compensation benefits royalties accrued research development restructuring current pension postretirement benefits note shortterm borrowings longterm debt shortterm borrowings million million december respectively september company repaid million principal amount million aggregate principal amount floating rate convertible senior debentures due result partial redemption note holders portion remaining balance million redeemed holders par september fundamental change ownership company occurs part remaining debt callable par time issuer debentures conversion price conversion rate shares subject certain antidilutive adjustments maximum conversion rate shares debentures pay interest quarterly annual rate equal three month libor reset quarterly minus yield never less zero august february company repaid million notes due million yen notes due respectively december company obtained billion five year revolving credit facility syndicate lenders extendable anniversary date consent lenders facility contains customary terms conditions including financial covenant whereby ratio consolidated debt consolidated capital exceed end quarter company compliance covenant since inception new facility borrowings outstanding revolving credit facility december components longterm debt follows december december dollars millions principal value notes due notes due euro notes due euro notes due notes due notes due debentures due debentures due debentures due floating rate convertible senior debentures due industrial revenue bonds due yen notes due variable rate industrial revenue bonds due subtotal adjustments principal value fair value interest rate swaps unamortized proceeds swap terminations unamortized bond discounts discussion companys interest rate swaps refer note financial instruments table contents note shortterm borrowings longterm debt continued november december company repurchased approximately million principal amount debt terminated million notional amount interest rate swaps resulting gain million reported expense net table summarizes debt repurchase related activity principal repurchase gain swap termination earnings dollars millions amount price repurchase proceeds impact notes due debentures due debentures due notes due total may company issued million aggregate principal amount notes due billion aggregate principal amount notes due collectively may issued notes registered public offering interest payments made may november year beginning november may issued notes senior unsecured obligations company rank equally right payment companys existing future senior unsecured indebtedness company may redeem may issued notes whole part time redemption price equal greater par value amount calculated based upon sum present values remaining scheduled payments set forth prospectus supplement dated april december company terminated million notional amount fixedtofloating interest rate swap agreements related notes due received proceeds million proceeds recognized interest expense remaining life underlying debt september company terminated million notional amount fixedtofloating interest rate swap agreements related million debentures due received proceeds million proceeds recognized interest expense remaining life underlying debt approximately million pretax recognized years discussion companys swap terminations refer note financial instruments including payments due interest rate swaps cash payments interest million million million cash receipts interest rate swaps million million million excluded cash payments interest companys principal value longterm debt obligations million december million due million due remaining million due later december company provided total million financial guarantees form standby letters credit performance bonds stand letters credit insurance companies support thirdparty liability programs performance bonds issued support range ongoing operating activities including sale company products hospitals foreign ministries health bonds customs duties value added tax guarantees related miscellaneous legal actions significant majority companys outstanding financial guarantees expire within year expected funded table contents note stockholders equity changes common shares treasury stock capital excess par value stock restricted stock follows cost capital excess common shares treasury treasury par value restricted dollars shares millions issued stock stock stock stock balance january employee stock compensation plans balance december employee stock compensation plans balance december employee stock compensation plans balance december share companys preferred stock convertible shares common stock callable companys option reductions number issued shares preferred stock due conversions shares common stock accumulated balances related component oci net taxes follows pension accumulated foreign derivatives minimum currency qualifying pension postretirement available comprehensive dollars millions translation cash flow hedges liability benefits sale securities incomeloss balance january comprehensive incomeloss adjustments adoption sfas balance december comprehensive incomeloss balance december comprehensive incomeloss balance december note employee stock benefit plans employee stock plans may stockholders approved companys stock award incentive plan plan plan replaced stock incentive plan plan expired may plan provides million new shares common stock reserved delivery participants plus shares remaining available new grants plan shares recaptured outstanding awards plan number shares actually delivered participants connection award restrictions lapsed counted number shares reserved shares tendered prior year pay purchase price options number shares previously utilized satisfy withholding tax obligations upon exercise continue available reserved december million million shares common stock respectively reserved issuance pursuant stock plans options conversions preferred stock million million shares available granted active plans december respectively adjusted combination plans companys plan plan executive officers key employees may granted options purchase companys common stock less market price date option granted options generally become exercisable installments per year first fourth anniversaries grant date maximum term years generally company issues shares stock option exercise treasury stock additionally plan provides granting stock appreciation rights whereby grantee may surrender exercisable rights receive common stock andor cash measured excess market price common stock option exercise price december thousand stock appreciation rights outstanding treated liability awards plan plan provide granting common stock key employees subject restrictions continuous employment restrictions generally expire four year period date grant compensation expense recognized restricted period first quarter company began granting restricted stock units instead restricted stock stock unit right receive stock end specified vesting period stock unit voting rights table contents note employee stock benefit plans continued plan plan also incorporate companys longterm performance awards awards delivered form target number performance shares three year cycle awards annual goals set beginning performance period based earnings per share sales maximum performance result maximum payout award award addition onetime special performance award granted performance period special performance award annual goals set beginning performance period based pretax operating margin operating cash flow maximum performance result maximum payout goals awards set three year period based cumulative earnings per share cumulative sales ultimate payout modified companys total stockholder return versus companies proxy peer group maximum performance three measures result maximum payout target threshold targets met performance period payment made plan teamshare stock option plan terminated january fulltime employees excluding key executives granted options purchase companys common stock market price date options granted company authorized million shares issuance plan individual grants generally became exercisable evenly third fourth fifth anniversary grant date maximum term years options million shares exercised plan december companys results operations years ended december reflect impact sfas r sharebased payment includes impact expensing stock options company elected alternative method provided fsp r transition election related accounting tax effects sharebased payment awards determining companys pool excess tax benefits following tables summarize stockbased compensation expense related employee stock options restricted stock longterm performance awards years ended december years ended december dollars millions stock options restricted stock longterm performance shares total stockbased compensation expense stockbased compensation expense recognized consolidated statements earnings follows years ended december dollars millions cost products sold marketing selling administrative research development total stockbased compensation expense deferred tax benefit stockbased compensation expense net taxes stockbased compensation expense million million million included discontinued operations table contents note employee stock benefit plans continued stock options summary stock option activities follows shares common stock issued weightedaverage shares millions plan exercise price shares balance january granted exercised expired forfeited balance december granted exercised expired forfeited balance december granted exercised expired forfeited balance december information related stock option grants exercises plan plan summarized follows year ended december amounts millions except per share data stock options granted weightedaverage grantdate fair value per share total intrinsic value stock options exercised cash proceeds exercise stock options december million total unrecognized compensation cost related stock options expected recognized weighted average period years following tables summarize information concerning companys stock compensation plans currently outstanding exercisable options number securities issued upon exercise weightedaverage outstanding exercise options price outstanding shares millions rights options rights plan category equity compensation plans approved security holders equity compensation plans approved security holders shares plan longer issued table contents note employee stock benefit plans continued following table summarizes significant ranges outstanding exercisable options december amounts millions except per share data options outstanding options exercisable weighted weighted average weighted average weighted remaining average aggregate remaining average aggregate contractual exercise intrinsic contractual exercise intrinsic number life price per value number life price per value range exercise prices outstanding years share millions exercisable years share millions vested expected vest aggregate intrinsic value preceding table represents total pretax intrinsic value based companys closing stock price december would received option holders option holders exercised options date total number inthemoney options exercisable december million december million outstanding options exercisable weightedaverage exercise price fair value employee stock options granted estimated date grant using blackscholes option pricing model stock options service condition monte carlo simulation model options service market conditions following table presents weightedaverage assumptions used valuation year ended december expected volatility riskfree interest rate dividend yield expected life yrs yrs yrs company derived expected volatility assumption required blackscholes model calculating year historical volatility weighting equally derived implied volatility selection blended historical implied volatility approach based companys assessment calculation expected volatility representative future stock price trends using historical volatility riskfree interest rate assumption based upon us treasury yield curve effect time grant dividend yield assumption based companys history expectation dividend payouts expected life employee stock options represents weightedaverage period stock options expected remain outstanding derived output latticebinomial model expected life employee stock options impacted underlying assumptions calibration companys model latticebinomial model assumes employees exercise behavior function options remaining vested life extent option inthe money latticebinomial model estimates probability exercise function two variables based entire history exercises cancellations past option grants made company stockbased compensation expense based awards ultimately expected vest forfeitures estimated based historical experience time grant revised subsequent periods actual forfeitures differ estimates company acquired adnexus october part acquisition agreement company assumed million shares adnexus incentive stock options isos replaced million shares company isos converted options retain original vesting schedules including vesting commencement date well expiration date blackscholes model used determine expected term individual isos valuations result weightedaverage expected term years weightedaverage fair value october table contents note employee stock benefit plans continued restricted stock awards restricted stock units fair value nonvested shares companys common stock determined based average trading price companys common stock grant date restricted share activities follows weightedaverage shares thousands number shares grantdate fair value nonvested shares january granted vested forfeited nonvested shares december granted vested forfeited nonvested shares december granted vested forfeited nonvested shares december expected vest december million total unrecognized compensation cost related nonvested restricted stock cost expected recognized weightedaverage period years total fair value nonvested shares share units granted recognized compensation expense million million million total fair value shares share units vested million longterm performance awards since adoption sfas r fair value performance award estimated date grant using monte carlo simulation model due market condition monte carlo simulation model utilizes multiple input variables determine probability satisfying market condition stipulated award grant calculates fair market value longterm performance awards performance awards theses awards contain market condition fair value based closing trading price companys common stock grant date valuation model award used following assumptions weightedaverage expected riskfree grant year grant date expected volatility dividend yield interest rate weightedaverage expected volatility based three year historical volatility levels companys common stock expected dividend yield based historical dividend payments riskfree interest rate reflects yield five year zero coupon us treasury bonds based performance shares contractual term fair value performance awards amortized performance period award table contents note employee stock benefit plans continued information related performance awards plan plan summarized follows shares thousands performance shares outstanding performance cycle weightedaverage grant date measurement date shares granted grantdate fair value december december annually annually annually annually annually annually total outstanding unrecognized compensation cost related performance share plan million december expected recognized weighted average period years accuracy fair value estimates companys determination fair value stockbased payment awards date grant using optionpricing model affected companys stock price well assumptions regarding number highly complex subjective variables variables include limited companys expected stock price volatility term awards actual projected employee stock option exercise behaviors optionpricing models developed use estimating value traded options vesting hedging restrictions fully transferable companys employee stock options certain characteristics significantly different traded options changes subjective assumptions materially affect estimated value managements opinion existing valuation models may provide accurate measure fair value companys employee stock options although fair value employee stock options determined accordance sfas r staff accounting bulletin sab sharebased payment using optionpricing model value may indicative fair value observed willing buyerwilling seller market transaction note financial instruments company exposed market risk due changes currency exchange rates interest rates lesser extent natural gas pricing reduce risk company enters certain derivative financial instruments available costeffective basis hedge underlying economic exposure companys primary net foreign currency translation exposures euro japanese yen canadian dollar chinese renminbi mexican peso manage exposures company utilizes foreign currency contracts subject cash flow hedge accounting treatment instruments managed consolidated basis efficiently net exposures thus take advantage natural offsets company also uses derivative instruments part interest rate risk management strategy derivative instruments used comprised principally fixedtofloating rate interest rate swaps subject fairvalue hedge accounting treatment derivative financial instruments used speculative purposes cash flow hedges foreign exchange contracts company utilizes foreign currency contracts hedge anticipated transactions primarily intercompany transactions certain foreign currencies designates derivative instruments foreign currency cash flow hedges appropriate notional amounts companys foreign exchange derivative contracts december million million respectively derivatives majority qualify hedges future anticipated cash flows effective portion changes fair value temporarily deferred accumulated oci recognized earnings hedged item affects earnings table summarizes companys outstanding foreign exchange forward contracts december fair value foreign exchange forward contracts based yearend currency rates fair value foreign exchange forward contracts viewed relation fair value underlying hedged transactions overall reduction exposure adverse fluctuations foreign currency exchange rates table contents note financial instruments continued weightedaverage fair value dollars millions except currency rates strike price notional amount assetliability maturity foreign exchange forwards cash flow hedges australian dollar brazilian real british pound canadian dollar euro japanese yen japanese yen mexican peso polish zloty swedish krona swiss franc total cash flow hedges december total notional fair market value contracts buy japanese yen million million respectively fully offset total notional fair market value sell contracts million million respectively december company hold foreign exchange option contracts buy sell japanese yen december balance deferred gains foreign exchange forward contracts qualified cash flow hedge accounting included accumulated oci pretax basis million million net tax expected reclassified earnings within next months sfas accounting derivative instruments hedging activities requires company perform periodic assessments hedge effectiveness company assesses effectiveness inception hedge quarterly basis assessments determine whether derivatives designated qualifying hedges continue highly effective offsetting changes cash flows hedged items ineffective portion fair value longer deferred accumulated oci included current period earnings years ended december impact hedge ineffectiveness earnings significant additionally years ended december impact discontinued hedges pretax gain million pre tax loss million million respectively natural gas contracts company utilizes forward contracts hedge anticipated purchase natural gas designates derivative instruments cash flow hedges appropriate derivatives majority qualify hedges future anticipated cash flows effective portion changes fair value temporarily deferred accumulated oci recognized earnings hedged item affects earnings year ended december impact discontinued natural gas hedges pretax loss million material year ended december nonqualifying foreign exchange contracts addition foreign exchange contracts noted company utilizes forward contracts hedge foreign currencydenominated monetary assets liabilities primary objective forward contracts protect us dollar value foreign currencydenominated monetary assets liabilities effects volatility foreign exchange rates might occur prior receipt settlement us dollars forward contracts designated hedges marktomarket expense net notional fair value amounts purchased sold foreign exchange forward contracts december material furthermore company uses foreign exchange forward contracts offset exposure certain assets liabilities earnings denominated certain foreign currencies foreign exchange forward contracts designated hedges therefore changes fair value derivatives recognized earnings expense net occur notional fair value amounts foreign exchange forward contracts december material hedge net investment company uses nonus dollar borrowings primarily million notes due million notes due hedge foreign currency exposures companys net investment certain foreign affiliates nonus dollar borrowings designated hedges net investments effective portion foreign exchange gains losses hedges recorded part foreign currency translation component accumulated oci table contents note financial instruments continued company unhedged exposures net foreign currencydenominated assets liabilities approximately million million december respectively primarily japan china mexico australia uk thailand fair value hedges interest rate contracts company uses derivative instruments part interest rate risk management strategy derivative instruments used comprised principally fixedto floating rate interest rate swaps subject fairvalue hedge accounting treatment november connection funding retirement fixed rate debt company executed several fixedtofloating interest rate swaps convert billion billion billion inception companys newlyissued fixed rate debt paid variable rate debt company executed additional fixedtofloating interest rate swaps convert billion companys newlyissued fixed rate debt paid variable rate total notional amounts outstanding interest rate swaps billion billion billion december billion billion billion december billion billion billion december company recognized net decrease interest expense million net increase million million respectively swaps well underlying debt hedged recorded fair value swaps generally held maturity intended create appropriate balance fixed floating rate debt company swaps qualify fair value hedges terminated prior maturity dates reported part carrying value underlying debt amortized earnings remaining life debt swaps qualify cash flow hedges terminated reported accumulated oci amortized earnings remaining life debt december balance deferred losses forward starting swaps included accumulated oci million reclassified earnings remaining life debt november december company repurchased approximately million principal amount debt terminated million notional amount interest rate swaps resulting gain million reported expense net also company terminated million notional amount fixedto floating interest rate swap agreements total proceeds million proceeds swap termination recognized interest expense remaining life underlying debt discussion companys debt buyback refer note shortterm borrowings longterm debt table contents note financial instruments continued following tables summarize interest rate swaps outstanding december earnings impact terminated interest rate swaps interest rate swaps outstanding notional amount underlying year fair interest rate swaps debt variable rate received transaction maturity value dollars millions swaps associated notes due month us libor notes due month us libor million notes due month eur euribor million notes due month eur euribor notes due month us libor notes due month us libor notes due month us libor notes due month us libor earnings impact terminated interest rate swaps pretax income unrecognized gainslosses expense recognized year longterm comprehensive interest rate swaps termination debt loss dollars millions interest rate swap lock associated notes due notes due swaps associated notes due notes due notes due notes due notes due notes due notes due notes due following table summarizes companys fair value outstanding derivatives december balance sheet location balance sheet location dollars millions derivatives designated hedging instruments interest rate contracts assets accrued expenses foreign exchange contracts assets accrued expenses hedge net investments shortterm borrowings hedge net investments longterm debt natural gas contracts accrued expenses derivatives designated hedging instruments foreign exchange contracts assets accrued expenses total derivatives table contents note financial instruments continued impact earnings interest rate swaps qualified fair value hedges years ended december follows dollars millions interest incomeexpense terminated gain recognized expense net total impact oci earnings foreign exchange natural gas forwards qualified cash flow hedges follows foreign forward exchange natural gas starting contracts contracts swap total impact dollars millions gainloss recognized oci december effective portion loss reclassified oci cost products sold effective portion gainloss recognized expense net discontinued ineffective portion impact oci earnings nonderivative debt designated hedge net investment years ended december follows net investment hedges dollars millions loss recognized oci effective portion gain recognized expense net ineffective portion amount excluded effectiveness testing impact earnings nonqualifying derivatives years ended december follows dollars millions gain recognized expense net discussion fair value financial instruments see note fair value measurement discussion cash cash equivalents marketable securities see note cash cash equivalents marketable securities longterm debt difference fair value carrying value material january company terminated fixedtofloating interest rate swaps notional amount million resulting million gain amortized remaining life debt note segment information segment information consistent management reviews businesses makes investing resource allocation decisions assesses operating performance company reports financial operating information two segmentspharmaceuticals nutritionals pharmaceuticals segment comprised global pharmaceutical international consumer medicines businesses nutritionals segment consists mead johnson primarily infant formula business childrens nutritional business january august company completed divestiture medical imaging convatec businesses respectively results medical imaging convatec businesses previously included former health care convatec operating segments respectively included discontinued operations additional information divestitures medical imaging convatec see note acquisitions divestitures note discontinued operations assets held sale companys products sold principally wholesale retail trade nationally internationally certain products also sold drug manufacturers hospitals clinics government agencies medical profession gross sales three pharmaceutical wholesalers us accounted approximately companys total gross sales companys total gross sales companys total gross sales table contents note segment information continued earnings continuing operations income taxes net sales minority interest yearend assets dollars millions pharmaceuticals nutritionals total segments corporateother total corporateother assets include cash cash equivalents marketable securities assets discontinued operations certain assets earnings continuing operations income taxes minority interest reported corporateother consists dollars millions corporate administrative expense stockbased compensation expense provision restructuring net litigation expense net interest expense interest income ars impairment charge gain sale imclone shares gain sale product lines businesses gainloss debt buyback termination interest rate swap agreements total corporateother earnings continuing operations income taxes minority interest net sales companys key products follows net sales products dollars millions pharmaceuticals plavix avaproavalide pravachol reyataz sustiva franchise total revenue baraclude erbitux taxol sprycel ixempra abilify orencia pharmaceuticals total pharmaceuticals nutritionals enfamil nutritionals total nutritionals total table contents note segment information continued capital expenditures depreciation dollars millions pharmaceuticals nutritionals total segments corporateother total corporateother amounts include activities convatec medical imaging businesses including capital expenditures million million million depreciation expense million million million companys selected geographic area information follows net sales yearend assets dollars millions united states europe middle east africa western hemisphere pacific total note leases minimum rental commitments noncancelable operating leases primarily real estate motor vehicles effect december follows years ending december dollars millions later years total minimum payments less total minimum sublease rentals net minimum rental commitments operating lease rental expense million million million net sublease rental income million million million february company completed sale leaseback administrative facility paris france million million resulting pretax gain transaction million million deferred reduce future lease rental costs lease period years december company completed sale leaseback several administrative facilities new jersey million resulting pretax gain transaction million million deferred reduce future lease rental costs lease periods ranging years table contents note pension postretirement postemployment liabilities company certain subsidiaries defined benefit pension plans defined contribution plans termination indemnity plans regular fulltime employees principal pension plan bristolmyers squibb retirement income plan us represents approximately companys total pension plan assets obligations funding policy contribute amounts provide current service fund past service liability plan benefits based primarily participants years credited service compensation plan assets consist principally equity fixedincome securities company also provides comprehensive medical group life benefits substantially us retirees elect participate comprehensive medical group life plans medical plan contributory contributions adjusted periodically vary date retirement original retiring company life insurance plan noncontributory plan assets consist principally equity fixedincome securities similar plans exist employees certain countries outside us net periodic benefit cost companys defined benefit pension postretirement benefit plans included following components pension benefits benefits dollars millions service cost benefits earned year interest cost projected benefit obligation expected return plan assets amortization prior service costbenefit amortization net actuarial loss amortization transitional obligation net periodic benefit cost curtailments settlements special termination benefits total net periodic benefit cost total net periodic benefit costs recognized follows pension benefits benefits dollars millions continuing operations discontinued operations total net periodic benefit cost estimated net actuarial loss prior service cost amortized accumulated oci net periodic benefit cost dollars millions pension benefits benefits amortization net actuarial loss amortization prior service costbenefit table contents note pension postretirement postemployment liabilities continued changes benefit obligations plan assets funded status amounts recognized balance sheet years ended december companys defined benefit postretirement benefit plans follows pension benefits benefits dollars millions benefit obligation beginning year service costbenefits earned year interest cost projected benefit obligation plan participants contributions curtailments settlements actuarial assumptions lossesgains plan amendments retiree drug subsidy received benefits paid special termination benefits exchange rate gainslosses benefit obligation end year fair value plan assets beginning year actual return plan assets employer contribution plan participants contributions settlements retiree drug subsidy received benefits paid exchange rate lossesgains fair value plan assets end year funded status amounts recognized consolidated balance sheets consist assets accrued expenses pension postretirement liabilities accrued benefit cost net amount recognized amounts recognized accumulated comprehensive loss net actuarial loss net obligation adoption prior service costbenefit net amount recognized impact medicare prescription drug improvement modernization act million million million reflected reduction accumulated postretirement benefit obligation accumulated benefit obligation defined benefit pension plans million million december respectively information related companys pension plans december follows dollars millions pension plans projected benefit obligations excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligations excess plan assets accumulated benefit obligation fair value plan assets table contents note pension postretirement postemployment liabilities continued actuarial assumptions weightedaverage assumptions used determine benefit obligations december follows pension benefits benefits discount rate rate compensation increase weightedaverage actuarial assumptions used determine net periodic benefit cost years ended december follows pension benefits benefits discount rate expected longterm return plan assets rate compensation increase company uses yield high quality corporate bonds matches duration benefit obligations determining discount rate citigroup median yield curve used developing discount rate us plans company considers several factors developing expected return plan assets longterm historical returns input external advisors individual asset class return forecasts developed based upon market conditions example priceearnings levels yields longterm growth expectations expected longterm rate return weightedaverage target asset allocation individual asset class longterm expected rate return plan assets us plans included active management premium approximately projected market returns received external advisors companys longterm expected annualized returns us pension plans follows years years years expected return plan assets determined using expected rate return calculated value assets referred marketrelated value marketrelated value exceeds fair value plan assets approximately billion december less fair value plan assets approximately million december change primarily driven significant losses incurred plan assets due current market conditions differences assumed actual returns amortized marketrelated value straightline basis three year period gains losses resulted changes actuarial assumptions changes discount rate differences assumed actual experience differences actual assumed returns plan assets gains losses except differences amortized market related value amortized extent exceed higher marketrelated value projected benefit obligation respective plan result approximately billion related pension benefits expected amortized remaining actuarial losses amortized expected remaining service periods active participants assumed health care cost trend rates december follows health care cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend rate year rate reaches ultimate trend rate assumed health care cost trend rates effect amounts reported health care plans onepercentagepoint change assumed health care cost trend rates would following effects percentage percentage dollars millions point increase point decrease effect total service interest cost effect postretirement benefit obligation table contents note pension postretirement postemployment liabilities continued plan assets companys asset allocation december follows pension benefits benefits publicly traded equity securities debt securities including cash private equity total companys investment strategy emphasizes equities order achieve high expected returns long run low expense low required cash contributions us pension plans target asset allocation public equity us international private equity fixed income maintained cash flow ie cash contributions benefit payments used rebalance back targets necessary investments well diversified within three major asset categories approximately us equity investments actively managed investment strategies international pension plans typically similar although asset allocations usually conservative private equity valued three month lag bristolmyers squibb company common stock represents less plan assets december contributions contributions us pension plans million million million contributions us pension plans expected approximately million million contributed january contributions international pension plans million million million contributions international plans expected range million million estimated future benefit payments following benefit payments mainly us pension plans reflect expected future service appropriate expected paid benefits pension medicare dollars millions benefits gross subsidy net years table contents note pension postretirement postemployment liabilities continued adoption sfas company adopted sfas employers accounting defined benefit pension postretirement plansan amendment fasb statements r year ended december resulting million reduction accumulated oci stockholders equity million reduction total assets million increase total liabilities impact adoption summarized follows sfas adjustments presfas postsfas dollars millions pretax tax net current assets deferred income taxes noncurrent assets deferred income taxes prepaid pension assets current liabilities accrued expenses us foreign income taxes payable noncurrent liabilities liabilities stockholders equity accumulated comprehensive loss savings plan principal defined contribution plan bristolmyers squibb savings investment program companys contribution based employee contributions level company match companys contributions plan million million million post employment benefit plan company offers longterm disability benefits certain employees post employment liabilities million million december respectively expense related benefits million million million termination indemnity plans company operates certain jurisdictions primarily europe require recording statutory termination obligations obligations recognized undiscounted basis assuming employee termination measurement date total pension liability recorded obligations million december million december note legal proceedings contingencies various lawsuits claims proceedings investigations pending involving company certain subsidiaries accordance sfas accounting contingencies company records accruals contingencies probable liability incurred amount loss reasonably estimated matters involve antitrust securities patent infringement pricing sales marketing practices environmental health safety matters consumer fraud employment matters product liability insurance coverage significant litigation charges million million million net revised estimates previously accrued amounts cash payments related significant litigation million million million significant matters described assurance increase scope pending matters future lawsuits claims proceedings investigations material table contents note legal proceedings contingencies continued intellectual property plavix litigation plavix currently companys largest product ranked net sales plavix patents subject number challenges us including litigation apotex inc apotex corp apotex described less significant markets product possible reasonably estimate impact lawsuits company however loss market exclusivity plavix sustained generic competition us would material companys sales plavix results operations cash flows could material companys financial condition liquidity company product partner sanofi companies intend vigorously pursue enforcement patent rights plavix plavix litigation us patent infringement litigation apotex related matters previously disclosed companys us territory partnership alliance sanofi plaintiff pending patent infringement lawsuit instituted united states district court southern district new york district court entitled sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v apotex suit based us patent patent composition matter patent discloses claims among things hydrogen sulfate salt clopidogrel medicine made available us companies plavix also previously reported district court upheld validity enforceability patent maintaining main patent protection plavix us november district court also ruled apotexs generic clopidogrel bisulfate product infringed patent permanently enjoined apotex engaging activity infringes patent including marketing generic product us patent expires apotex appealed district courts decision december united states court appeals federal circuit circuit court affirmed district courts ruling sustaining validity patent apotex filed petition circuit court rehearing en banc petition pending district court stayed certain antitrust counterclaims brought apotex pending final outcome appeal previously disclosed companys us territory partnership alliance sanofi also plaintiff five additional pending patent infringement lawsuits dr reddys laboratories inc dr reddys laboratories ltd dr reddys teva pharmaceuticals usa inc teva cobalt pharmaceuticals inc cobalt watson pharmaceuticals inc watson laboratories inc watson sun pharmaceuticals sun lawsuits dr reddys teva cobalt relate patent trial date action dr reddys set january court entered order requires dr reddys give company business days notice intent launch patent infringement actions teva cobalt stayed pending resolution apotex litigation parties actions agreed bound outcome litigation apotex although teva cobalt appeal outcome litigation consequently july district court entered judgments cobalt teva permanently enjoined cobalt teva engaging activity infringes patent patent expires cobalt teva filed appeal lawsuit watson filed october based us patent patent discloses claims particular crystalline polymorph form hydrogen sulfate salt clopidogrel marketed plavix december court permitted watson pursue declaratory judgment counterclaim respect us patent january court approved parties stipulation stay case pending outcome trial apotex matter april pharmastar filed request inter partes reexamination patent us patent trademark office granted request july thus patent currently reexamination lawsuit sun filed july based infringement patent patent respect patent sun agreed bound outcome apotex litigation although sun like teva cobalt appeal outcome litigation dr reddys teva cobalt watson sun filed anda fda exclusivity periods statutory stay periods hatchwaxman act expired accordingly final approval fda would provide company authorization distribute generic clopidogrel bisulfate product us subject various legal remedies companies may apply including injunctive relief damages previously disclosed march company served civil investigative demand ftc requesting documents information related proposed settlement company ftc currently discussions regarding potential resolution matter addition previously disclosed april company received subpoena new york state attorney generals office antitrust bureau nyag documents related proposed settlement december company entered settlement agreement nyag behalf states pursuant company agreed pay million resolve states claims table contents note legal proceedings contingencies continued possible time reasonably assess outcomes appeal apotex circuit courts decision plavix patent litigations timing renewed generic competition plavix apotex additional generic competition plavix thirdparty generic pharmaceutical companies however apotex prevail appeal patent litigation company would expect face renewed generic competition plavix promptly thereafter loss market exclusivity plavix andor sustained generic competition would material companys sales plavix results operations cash flows could material companys financial condition liquidity additionally possible time reasonably assess amount damages could recovered company apotexs ability pay damages event company prevails apotexs appeal district court decision additionally november apotex filed lawsuit new jersey superior court entitled apotex inc et al v sanofiaventis et al seeking payment million plus interest related breakup proposed settlement agreement december defendants removed case federal district court new jersey apotex moved remand case back state court plavix litigation international plavix canada apotex inc previously disclosed sanofisynthelabo sanofisynthelabo canada inc instituted prohibition action federal court canada apotex minister health response notice allegation noa apotex directed canadian patent patent covering clopidogrel bisulfate apotexs noa indicated filed abbreviated new drug submission ands clopidogrel bisulfate tablets sought approval notice compliance ands expiration patent scheduled august apotexs noa alleged patent invalid infringed march canadian federal court ottawa rejected apotexs challenge canadian plavix patent held asserted claims novel obvious infringed granted sanofis application order prohibition minister health apotex order prohibition precludes approval apotexs ands patent expires unless federal courts decision reversed appeal apotex filed appeal december federal court appeal dismissed apotexs appeal upheld federal courts issuance order prohibition february apotex filed leave appeal decision supreme court canada granted july biotecanada canadian generic pharmaceutical association canadas researchbased pharmaceutical companies granted leave intervene november supreme court canada dismissed apotexs appeal federal court appeal decision upheld validity patent order prohibition also previously disclosed april apotex filed lawsuit canada ontario superior court justice entitled apotex inc et al v sanofiaventis et al seeking payment million plus interest related breakup proposed settlement agreement january court granted defendants motions dismiss grounds forum non conveniens subject matter jurisdiction apotex appealed decision court appeal ontario october court appeal dismissed lawsuit apotex appeal supreme court canada instead november apotex filed lawsuit new jersey superior court described plavix canada cobalt previously disclosed sanofi sanofisynthelabo canada instituted prohibition action federal court canada cobalt minister health response noa cobalt directed patent canadian patent patent cobalts noa indicated filed ands clopidogrel bisulfate tablets sought notice compliance ands expiration patents cobalt alleged patent invalid patent invalid infringed following supreme court canada decision apotex inc v sanofisynthelabo canada inc scc dismissing apotexs appeal upholding validity patent described federal court canada granted sanofis application order prohibition minister health cobalt precluding approval cobalts ands patent expires sanofi pursue prohibition action respect patent plavix korea previously disclosed june korean intellectual property tribunal kipt invalidated claims sanofis korean patent including claims directed clopidogrel pharmaceutically acceptable salts clopidogrel bisulfate sanofi appealed january patent court affirmed kipt decision company sanofi filed appeal supreme court korea sanofi also commenced infringement actions generic pharmaceutical companies launched generic clopidogrel bisulfate received approval alternate salt forms clopidogrel korea possible time reasonably assess outcome lawsuits impact company table contents note legal proceedings contingencies continued plavix australia previously disclosed sanofi notified august genrx proprietary limited genrx obtained regulatory approval application clopidogrel bisulfate mg tablets australia genrx formerly subsidiary apotex since changed name apotex august apotex filed application federal court australia seeking revocation sanofis australian patent case nsd sanofi filed counterclaims infringement sought injunction september australian court granted sanofis injunction subsidiary company subsequently added party proceedings february second company spirit pharmaceuticals pty ltd also filed revocation suit patent case consolidated apotex case trial occurred april august federal court australia held claims patent covering clopidogrel bisulfate hydrochloride hydrobromide taurocholate salts valid federal court also held process claims pharmaceutical composition claims claim directed clopidogrel pharmaceutically acceptable salts invalid view decision possible generic company could develop seek registration australia alternate salt form clopidogrel bisulfate hydrochloride hydrobromide taurocholate company sanofi filed notices appeal full court federal court australia appealing holding invalidity claim covering clopidogrel pharmaceutically acceptable salts process claims pharmaceutical composition claims stayed federal courts ruling apotex filed notice appeal appealing holding validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claims hearing appeals occurred february decision pending plavix germany previously disclosed yes pharmaceutical development services gmbh yes pharmaceutical filed application marketing authorization germany alternate salt form clopidogrel application relied data studies originally conducted sanofi bms plavix may german health authority bfarm granted marketing authorization yes pharmaceutical product data protection plavix expire july sanofi bms filed objection grant marketing authorization grounds data exclusivity rights infringed yes pharmaceutical partners sought immediate enforcement marketing authorization denied bfarm yes pharmaceutical partners filed legal motion immediate enforcement administrative court granted yes pharmaceuticals partners hexal ratiopharm began continue market product germany sanofi bms appealed decision administrative court appeal rejected administrative appeal court third party objection bfarm dismissed bfarm sanofi bms appealed decision administrative court cologne matter currently pending yes pharmaceutical partners announced plan seek marketing authorization eu countries addition germany also company believes companies filed approvals eu clopidogrel containing product applications pending intellectual property litigation abilify previously disclosed otsuka filed patent infringement actions teva barr pharmaceuticals inc barr sandoz inc sandoz synthon laboratories inc synthon sun pharmaceuticals sun apotex relating us patent covers aripiprazole expires october aripiprazole comarketed company otsuka us abilify lawsuits currently pending us district court district new jersey possible time reasonably assess outcome lawsuits impact company erbitux previously disclosed february abbott laboratories abbott filed suit imclone us district court district massachusetts alleging imclones manufacture sale erbitux infringe us patent patent seeking damages alleged infringement pursuant settlement sublicensing agreements executed imclone repligen corporation repligen announced september repligen granted imclone royaltyfree irrevocable worldwide sublicense future use patented technology including patent owned abbott licensed repligen agreement abbott repligen september imclone abbott executed written settlement agreement ending litigation pending parties terms settlement agreement imclone paid abbott million full final settlement claims counterclaims companys commercial agreements imclone include provisions pursuant certain financial consequences company resulting settlement sublicensing agreements would responsibility imclone table contents note legal proceedings contingencies continued possible time assess outcome lawsuit potential impact company enfamil september company whollyowned subsidiary mead johnson co filed patent infringement lawsuit abbott laboratories abbott nutrition abbott us district court southern district indiana infringement us patent companies allege abbotts sale certain cans similac infant formula powder infringes patent february companies entered settlement agreement resolving matter general commercial litigation clayworth litigation previously disclosed company together number pharmaceutical manufacturers named defendant action filed california state superior court oakland james clayworth et al v bristolmyers squibb company et al alleging defendants conspired fix prices pharmaceuticals agreeing charge drugs us charge outside us particularly canada asserting claims californias cartwright act unfair competition law plaintiffs sought trebled monetary damages injunctive relief relief december court granted company manufacturers motion summary judgment based passon defense judgment entered favor defendants july judgment favor defendants affirmed california court appeals november california supreme court granted plaintiffs petition review possible time reasonably assess outcome lawsuit impact company event plaintiffs successful appeal rxusa wholesale litigation previously disclosed july complaint filed drug wholesaler rxusa wholesale inc us district court eastern district new york company drug manufacturers five drug wholesalers two officers defendant mckesson wholesale distribution industry trade group rxusa wholesale inc v alcon labs inc et al complaint alleges violations federal new york antitrust laws well various laws plaintiff claims defendants allegedly engaged anticompetitive acts resulted exclusion plaintiff relevant market seeks million damages trebling relief company together manufacturer defendants filed motion dismiss case november motion remains pending court possible time reasonably estimate outcome lawsuit impact company antitrust litigation previously disclosed lawsuits comprised individual suits purported class actions filed company us district court southern district ohio western division various plaintiffs including pharmacy chains individually assignees whole part certain wholesalers various health welfare benefit plansfunds individual residents various states lawsuits allege among things purported settlement apotex patent infringement litigation violated sherman act related laws plaintiffs seeking among things permanent injunctive relief barring apotex settlement andor monetary damages putative class actions filed behalf direct purchasers consolidated caption plavix direct purchaser antitrust litigation putative class actions filed behalf indirect purchasers consolidated caption plavix indirect purchaser antitrust litigation amended complaints filed october defendants filed consolidated motion dismiss december remains pending possible time reasonably assess outcome lawsuits impact company shareholder derivative actions previously disclosed july certain members board directors current former officers company named two derivative actions filed new york state supreme court john frank v peter dolan et al donald beebout v peter dolan et al one derivative action filed federal district court steven w sampson v james robinson iii et al cv complaints allege breaches fiduciary duties allegedly failing disclose material information relating efforts settle plavix patent infringement litigation apotex plaintiffs seek monetary damages behalf company contribution indemnification decision filed december state court granted motions dismiss complaints frank beebout relating certain members board directors table contents note legal proceedings contingencies continued dismiss complaints former officers decision dated august federal district court granted companys motion dismiss sampson action plaintiffs appealed district courts decision us circuit court appeals second circuit pending securities litigation bristolmyers squibb co securities litigation previously disclosed june july two putative class action complaints minneapolis firefighters relief assoc v bristolmyers squibb co et al cv jean lai v bristolmyers squibb company et al filed us district southern district new york company companys former chief executive officer peter dolan former chief financial officer andrew bonfield complaints allege violations securities laws allegedly failing disclose material information relating efforts settle plavix patent infringement litigation apotex september court dismissed lai case without prejudice changed caption case bristolmyers squibb co securities litigation appointed ontario teachers pension plan board lead plaintiff october ontario teachers pension plan board filed amended complaint making similar allegations earlier filed complaints naming additional former officer longer naming andrew bonfield defendant decision dated august federal district court denied defendants motions dismiss company intends defend vigorously litigation possible time reasonably assess outcome lawsuits potential impact company pricing sales promotional practices litigation investigations awp litigation previously disclosed company together number pharmaceutical manufacturers defendant number private class actions well suits brought attorneys general various states actions plaintiffs allege defendants caused average wholesale prices awps products inflated thereby injuring government programs entities persons reimbursed prescription drugs based awps company remains defendant five state attorneys general suits pending federal state courts around country previously reported one set class actions together suit arizona attorney general consolidated us district court district massachusetts awp mdl court awp mdl certified three classes persons entities paid reimbursed seven companys physicianadministered drugs june company settled principle claims class medicare part b beneficiaries nationwide million plus half costs class notice maximum payment million parties finalizing terms settlement hearing scheduled preliminary approval class settlement june nonjury trial awp mdl court found company liable violations massachusetts consumer protection laws respect certain oncology drugs certain years awarded damages amount thousand plus interest class private thirdparty payors instructed parties apply courts opinion determine damages class medigap insurers august court found damages thousand plus interest class company appealed june decision us court appeals first circuit oral arguments heard november september court awp mdl issued order certifying multistate classes class class possible time reasonably assess outcome litigation matters described potential impact company california b litigation previously disclosed august county santa clara filed purported class action company numerous pharmaceutical manufacturers behalf putative class cities counties california well covered entities purchased drugs pursuant b drug discount program july us district court northern district california dismissed lawsuit prejudice failure state claim plaintiff appealed us court appeals ninth circuit september ninth circuit reversed district courts dismissal reinstated lawsuit possible time reasonably assess outcome lawsuit potential impact company table contents note legal proceedings contingencies continued product liability litigation company party various product liability lawsuits addition lawsuits company also faces unfiled claims involving products time company believe ongoing lawsuits likely result material effect companys financial results operations however company also aware potential unfiled claims possible time reasonably assess outcome additional lawsuits might filed potential impact company company certain affiliates sanofi defendants number individual lawsuits claiming personal injury allegedly sustained using plavix appear united states district court district new jersey nj district court nj district court ordered administrative termination cases pending resolution potentially related issues united state supreme court cases involving prescription drugs preemption defendants executed tolling agreements respect unfiled claims potential additional plaintiffs possible time reasonably asses outcomes lawsuits impact company environmental proceedings previously reported company party several environmental proceedings matters responsible various state federal foreign laws including comprehensive environmental response compensation liability act cercla certain costs investigating andor remediating contamination resulting past industrial activity companys current former sites waste disposal reprocessing facilities operated third parties cercla matters respect cercla matters company responsible various state federal foreign laws company typically estimates potential costs based information obtained us environmental protection agency epa counterpart state agency andor studies prepared independent consultants including total estimated costs site expected costsharing potentially responsible parties company accrues liabilities probable reasonably estimable december company estimated share total future costs sites approximately million recorded liabilities represents sum best estimates simple estimate reasonably made estimates minimal probable amount among range costs without taking account potential recoveries parties currently expected passaic river nj remediation natural resource damages claims previously disclosed september new jersey department environmental protection njdep issued administrative enforcement directive requiring company companies perform assessment natural resource damages implement unspecified interim remedial measures restore conditions lower passaic river lpr directive named company due releases nearby bulk chemical reprocessing facility operated predecessor mckesson corp subsequently epa issued notice letters numerous parties company requesting performance remedial investigationfeasibility study rifs conditions lpr consent agreement epa group parties committed pay roughly half million estimated rifs epa time epa thereafter substantially increased estimate scope cost rifs result epa agreed allow group perform remaining rifs tasks groups estimate total costs complete rifs related tasks exceed million group negotiated amended consent agreement epa conduct remaining rifs work became effective may part process company mckesson bought remaining rifs tasks separately company agreed pay approximately thousand towards rifs tasks previously funded mckesson work cooperatively going forward subject later reallocation mid epa announced plans seek implementation earlyaction remedial measures address highly contaminated portions lpr rifs completed epa indicated expects select actions early also subgroup cooperating private parties commenced discussions federal natural resource trustee agencies concerning agreement assess natural resource damages lpr discussions expected continue mid remaining parties including company mckesson declined discuss proposal least scope cost earlyactions sought epa thoroughly understood extent liability company may face related requirements yet determined north brunswick township board education previously disclosed october company contacted counsel representing north brunswick nj board education boe regarding site waste materials er squibb sons may disposed fill material containing industrial waste heavy metals excess residential standards discovered table contents note legal proceedings contingencies continued expansion project north brunswick township high school well number neighboring residential properties adjacent public park areas january njdep sent company others information request letter possible waste disposal site company responded march boe township current owners school property park conducting jointly financing soil remediation work ground water investigation work work plan approved njdep asked company contribute cost company actively monitoring cleanup project including costs date neither school board township asserted claim company instead company local entities negotiated agreement attempt resolve matter informal means including mediation binding allocation necessary central component agreement provision company interim funding help defray cleanup costs assure work interrupted company transmitted initial interim funding payment december parties since commenced mediation activities expected conclude mid ods regulatory compliance previously disclosed epa investigating industrial commercial facilities throughout us use refrigeration equipment containing ozone depleting substances ods enforcing compliance regulations governing prevention service repair leaks ods requirements company performed voluntary corporatewide audit facilities us puerto rico use odscontaining refrigeration equipment company submitted audit report epa november identifying potential violations ods requirements several facilities addition matters covered companys audit report letter epa epa previously sent mead johnson request information regarding compliance ods requirements facility evansville indiana company responded request june result identified potential violations evansville facility company signed consent decree epa resolve potential violations discovered audit identified result epa request information evansville facility filed evansville division us district court southern district indiana july consent decree requires company pay civil penalty thousand retire retrofit replace odscontaining refrigeration units june located facilities new jersey indiana puerto rico consent decree also requires company spend least thousand supplemental environmental project consists removal two odscontaining comfort cooling devices new brunswick nj facility tie functions new centralized chiller system use ods refrigerant consent decree yet entered court new brunswick facility environmental personal injury lawsuits previously disclosed may approximately lawsuits filed company superior court middlesex county nj behalf current former residents new brunswick nj live adjacent companys new brunswick facility complaints allege various personal injuries property damage resulting soil groundwater contamination property stemming historical operations new brunswick facility complaints also allege bms failed remediate contamination new brunswick facility compliance state federal cleanup requirements new brunswick facility already undergoing environmental remediation part new jersey department environmental protection njdep approved cleanup plan addition lawsuits plaintiffs filed notice seeking relief nj environmental rights act october new jersey supreme court granted mass tort status cases transferred new jersey superior court atlantic county centralized case management purposes company filed motions dismiss lawsuits denied leave refile discovery taken others still pending court company intends defend vigorously litigation possible time reasonably assess outcome lawsuits potential impact company wage hour litigation previously disclosed putative class action complaint filed company former sales representatives beth amendola v bristolmyers squibb company et al docket cv filed june district court plaintiff alleges company violated federal fair labor standards act among things paying overtime compensation putative class similarly situated sales employees june court issued decision renders case nonclass action lawsuit company settled lawsuit individual plaintiffs settlement agreement material company concludes lawsuit table contents note legal proceedings contingencies continued proceedings sec germany investigation previously disclosed october sec notified company conducting informal inquiry activities certain companys german pharmaceutical subsidiaries employees andor agents october sec informed company inquiry formal secs inquiry encompasses matters currently investigation german prosecutor munich germany company understands inquiry investigation concern potential violations foreign corrupt practices act german law respectively company cooperating sec german authorities company established accrual respect investigation german prosecutor possible time reasonably assess outcome investigations impact company convatec italy investigation previously reported italian competition authorities investigated complaint lodged hospital ferrara region italy relating allegation four medical device companies including convatec boycotted tenders ferrara tenders may convatec received statement objections italian competition authorities whereby authorities alleged four medical device companies including convatec acted concerted manner regard ferrara tenders tenders pricing discussions three regions acted way prevent competition throughout italy august competition authorities issued decision found four medical device companies infringed italian antitrust law participating ferrara tenders imposed fine convatec amount material company convatec division bms italy prior divestiture fine imposed bms italy convatec appealed decision administrative court fine imposed convatec later reduced company appealed decision high court second instance consiglio di stato hearing occurred february table contents note selected quarterly financial data unaudited dollars millions except per share data first quarter second quarter third quarter fourth quarter year net sales gross margin net earnings continuing operations net earnings discontinued operations net net earnings earnings per common share basic net earnings continuing operations net earnings discontinued operations net net earnings per common share diluted net earnings continuing operations net earnings discontinued operations net net earnings per common share dividends declared per common share cash cash equivalents marketable securities dollars millions except per share data first quarter second quarter third quarter fourth quarter year net sales gross margin net earningsloss continuing operations net earnings discontinued operations net net earningsloss earnings per common share basic net earningsloss continuing operations net earnings discontinued operations net net earningsloss per common share diluted net earningsloss continuing operations net earnings discontinued operations net net earningsloss per common share dividends declared per common share cash cash equivalents marketable securities earnings per share quarters may add amounts year period computed discrete basisthe following table reconciles previously reported data current year quarterly data updated discontinued operations related convatec disposition see note discontinued operations assets held sale first quarter fourth quarter first quarter adjusted reported adjusted reported adjusted reported dollars millions except per previously convatec december previously convatec december previously convatec december share data reported disposition k reported disposition k reported disposition k net sales gross margin net earnings continuing operations net earnings discontinued operations net net earnings earnings per common share basic net earnings continuing operations net earnings discontinued operations net net earnings per common share diluted net earnings continuing operations net earnings discontinued operations net net earnings per common share table contents note selected quarterly financial data unaudited continued company recorded following specified expenseincome items affected comparability results dollars millions first quarter second quarter third quarter fourth quarter year productivity transformation initiative downsizing streamlining worldwide operations accelerated depreciation asset impairment shutdown costs pension settlementscurtailments process standardization implementation costs gain sale leaseback properties termination lease contracts gain sale product lines businesses litigation settlement insurance recovery mead johnson charges product liability upfront milestone payments acquired inprocess research development asset impairment ars impairment charges gainloss sale debt buyback swap terminations gain sale imclone shares income taxes items decreaseincrease net earnings continuing operations dollars millions first quarter second quarter third quarter fourth quarter year productivity transformation initiative downsizing streamlining worldwide operations accelerated depreciation asset impairment process standardization implementation costs litigation settlement insurance recovery product liability upfront milestone payments acquired inprocess research development ars impairment charges downsizing streamlining worldwide operations accelerated depreciation asset impairment contract termination gain sale properties product lines businesses income taxes items change estimate taxes prior year specified item decreaseincrease net earnings continuing operations table contents report independent registered public accounting firm board directors stockholders bristolmyers squibb company audited accompanying consolidated balance sheets bristolmyers squibb company subsidiaries company december related consolidated statements earnings comprehensive income retained earnings cash flows three years period ended december audits also included financial statement schedule listed index item financial statements financial statement schedule responsibility companys management responsibility express opinion financial statements financial statement schedule based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidated financial statements present fairly material respects financial position bristolmyers squibb company subsidiaries december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion financial statement schedule considered relation basic consolidated financial statements taken whole presents fairly material respects information set forth therein discussed notes consolidated financial statements company adopted financial accounting standards board interpretation fin accounting uncertainty income taxes interpretation fasb statement effective january statement financial accounting standards sfas employers accounting defined benefit pension postretirement plans amendment fasb statements r effective december also audited accordance standards public company accounting oversight board united states companys internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion companys internal control financial reporting deloitte touche llp parsippany new jersey february table contents item changes disagreements accountants accounting financial disclosure none item controls procedures evaluation disclosure controls procedures december management carried evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure controls procedures term defined exchange act rule ae based evaluation management concluded december disclosure controls procedures effective managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance united states generally accepted accounting principles due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp independent registered public accounting firm audited companys financial statements included report issued report effectiveness companys internal control financial reporting december included herein changes internal control financial reporting changes companys internal control financial reporting quarter ended december materially affected reasonably likely materially affect companys internal control financial reporting item b information february mead johnson company mjc borrower mead johnson nutrition company mead johnson guarantor indirect majorityowned subsidiaries company entered three year syndicated revolving credit facility agreement credit facility financial institutions lenders named therein including jpmorgan chase bank na jpmcb administrative agent credit facility unsecured repayable maturity february subject annual extensions sufficient lenders agree maximum amount outstanding borrowings letters credit permitted one time credit facility million amount may increased time time million request mjc subject customary conditions contained credit facility proceeds credit facility used working capital general corporate purposes mead johnson subsidiaries including commercial paper backup repurchase shares borrowings credit facility bear interest either libor rate specified interest periods plus margin determined reference companys consolidated leverage ratio b floating rate based upon jpmcbs prime rate federal funds rate libor rate plus case margin determined reference companys consolidated leverage ratio company also paying customary facility structuring syndication administration fees mead johnson guaranteed obligations mjc subsidiary borrowers credit facility additional subsidiaries mead johnson may become borrowers credit facility case mead johnson mjc guaranty obligations subsidiary credit facility credit facility contains customary covenants including covenants applicable mead johnson subsidiaries limiting liens substantial asset sales mergers restrictions subject certain minimum thresholds exceptions credit facility also contains following financial covenants mead johnson required maintain ratio consolidated total debt b consolidated ebitda greater compliance covenant tested last day fiscal quarter condition precedent credit extension credit facility mead johnson required maintain ratio consolidated ebitda ii consolidated interest expense least compliance covenant tested last day fiscal quarter preceding four consecutive fiscal quarters addition credit facility customary events default including subject certain materiality thresholds grace periods payment default failure comply covenants material inaccuracy representation warranty bankruptcy insolvency proceedings change control erisa matters cross default debt agreements table contents report independent registered public accounting firm board directors stockholders bristolmyers squibb company audited internal control financial reporting bristolmyers squibb company subsidiaries company december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion companys internal control financial reporting process designed supervision companys principal executive principal financial officers persons performing similar functions effected companys board directors management personnel provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting including possibility collusion improper management override controls material misstatements due error fraud may prevented detected timely basis also projections evaluation effectiveness internal control financial reporting future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission also audited accordance standards public company accounting oversight board united states consolidated financial statements financial statement schedule year ended december company report dated february expressed unqualified opinion financial statements financial statement schedule deloitte touche llp parsippany new jersey february table contents part iii item directors executive officers registrant reference made proxy statement filed march respect directors registrant incorporated herein reference made part hereof response information required item b information required item respect executive officers registrant included part ia reliance general instruction g instruction item b regulation sk item executive compensation reference made proxy statement filed march respect executive compensation incorporated herein reference made part hereof response information required item item security ownership certain beneficial owners management related stockholder matters reference made proxy statement filed march respect security ownership certain beneficial owners management incorporated herein reference made part hereof response information required item item certain relationships related transactions reference made proxy statement filed march respect certain relationships related transactions incorporated herein reference made part hereof response information required item item auditor fees reference made proxy statement filed march respect auditor fees incorporated herein reference made part hereof response information required item table contents part iv item